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ABSTRACT 
 
Parkinson’s disease (PD) pathology is characterised by distinct types of cellular defects: 
notably, oxidative damage and mitochondria dysfunction, leading to selective loss of 
dopaminergic neurons in the substantia nigra pars compacta. Exposure to heavy metals and 
some environmental toxicants have been associated for many years with this disease 
pathogenesis. Raised iron levels have been consistently observed in the nigrostriatal pathway 
in PD cases. This thesis focused on the effects of an endogenous heavy metal micronutrient 
(copper - Cu) and an exogenous environmental heavy metal (vanadium - Vd), and explored the 
interplay with iron (Fe), focusing for the first time on sub-toxic effects of these metals upon 
neuronal cell oxidative and ER stress, differentiation, calcium signalling, motor activity, 
oxidative stress and lifespan in an in vitro (Catecholaminergic a-differentiated (CAD) cells) 
and in vivo (Drosophila melanogaster) model of PD respectively.  
Undifferentiated CAD cells were more susceptible to vanadium exposure than differentiated 
cells and this susceptibility was modulated by iron. Both a natural (Aloysia citrodora) and 
synthetic iron chelator, Deferoxamine (DFO), significantly and efficiently protected against 
chronic sub-toxic Vd-induced mitochondrial oxidative stress in contrast, iron chelation 
exacerbated the oxidative stress elicited by Cu. 
Low dose Cu had no significant effect upon metabolic rate (in both differentiated and 
differentiating CAD cells) but significantly protected undifferentiated cells, decreased 
potassium chloride (KCl)-induced depolarisation and positively enhanced the expression of 
MAP2 in differentiated cells  
 In vivo exposure of Drosophila melanogaster (DM) to sub-toxic doses of Vd had a range of 
differential biochemical and behavioural effects upon wild-type (WT) and PD Pink-1B9 
drosophila fly models. In pink-1 flies, exposure to chronic low dose of vanadium exacerbated 
the existing motor deficits, reduced survival, increased the production of reactive oxygen 
species (ROS), as well as T-SH and a reduction in survival. In WT, it caused an enhancement 
in motor activity (like L-dopa), in parallel with a reduction in brain RONS generation and 
increased total thiol levels (T-SH), with a resulting lifespan extension. Both Aloysia citrodora 
L, and DFO significantly protected against the PD-like phenotypes in both models. The results 
accrued in this thesis favours the case for iron-chelation therapy as a viable option for the 
symptomatic treatment of PD. 
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Chapter 1:  Environmental Factors and PD 
 
1.1 Introduction   
1.2 The Burden of Neurodegenerative Diseases  
Neurodegenerative diseases constitute a global health challenge (World Health Organisation - 
WHO, 2006; Wichterle and Przedborski, 2010). They account for about 6% of the global 
burden of disease and it is projected that there will be a two-fold increase in the current number 
of persons with neurological disorders every 20 years. WHO also projected that by the year 
2040, as the populations in the developed world get older, neurodegenerative diseases (such as 
Alzheimer’s), and conditions that affect mainly the motor functions, like PD and Amyotrophic 
Lateral Sclerosis (ALS) will be the leading causes of death, after cardiovascular disease 
(Gammon, 2014). Furthermore, neurodegenerative diseases constitute a huge economic burden 
on individuals, families, caregivers, and society (Weintraub, et al., 2008, Skovronsky, et al., 
2006). 
 
Metal dysregulation associated with neurodegenerative disorders is increasingly recognised as 
a serious, worldwide public health concern (Montgomery, 1995; Caudle, et al., 2012; 
Shribman, et al., 2013; Benammi, et al., 2015; Bjorklund, et al., 2018). Metal dyshomeostasis 
has been associated with PD (Myhre, et al.,2013; Goldman, 2014; Dusek, et al., 2015). This 
has become critical as between 5-10% of reported cases of PD are of genetic origin, whilst 90-
95% cases are sporadic with significant linkage with environmental factors. Several PD genes 
are activated by xenobiotic exposure while the association between PD and exposure to 
environmental toxicant (such as metals and pesticides) has been demonstrated recently 
(Bjorklund, et al, 2018).   
 
The aetiology of most neurodegenerative diseases is multifactorial due to the interaction 
between multiple genes and environmental factors (Cicero, et al., 2017). A host of 
environmental risk factors have been associated with neurodegenerative disorders. For 
example, polychlorinated biphenyl (PCB) in the industry (Carpenter, 1998), phalates 
(Berlinger, 2008), lead (Jusko, et al., 2008), methyl mercury (Oken, et al., 2008), 
polychlorinated biphenyls (Winneke, 2011),  organophosphate pesticides (Eskenazi, et al.,  
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2007; London, et al., 2012) and organochlorine pesticides (Eskenazi, et al., 2008) endocrine 
disruptors (Braun, et al., 2011, Miodovnik, et al., 2011), automotive exhaust (Volk, et al., 
2011), polycyclic aromatic hydrocarbons (Perera, et al., 2009), brominated flame retardants 
(Herbstman, et al., 2010), Perfluorinated compounds (Stein and Savitz, 2011) and metals (Neal, 
et al., 2012) have all been implicated (directly or indirectly) in the pathogenesis of 
neurodegenerative diseases. Among these, metals are gaining increasing attention because of 
their intricate roles in biological processes and a growing presence of environmental pollutants 
by way of industrial and chemical pollution of food, air, and water (Kwok, 2010). 
 
The role of metals in the aetiology of PD is equally of great interest to the scientific world and 
is a notable public health concern. Several metals are vital to many physiological processes and 
their homeostasis is tightly regulated and the accumulation or deficiency may have 
pathophysiological and/or pathogenic consequences (Fraga, 2005). Whilst there is 
accumulating evidence to substantiate the essential functions of metals in the healthy brain, 
studies also abound that show that dysregulation or disruption of biometal homeostasis is a key 
process in the pathogenesis of several neurodegenerative diseases (Devi, et al., 2014; Jomova,  
et al.,  2010).  
 
Chen, et al (2016) observed that the accumulation of metals in the body may result in permanent 
injuries, including some neurological disorders. In their findings from both epidemiological 
and clinical studies, they found correlations exist between aberrant metal exposure and several 
neurological diseases, such as ALS, autism spectrum disorders, Guillain-Barrré disease, Gulf 
War Syndrome, Huntington’s Disease (HD), Multiple Sclerosis (MS) and Wilson’s Disease. 
Similarly, several studies have underscored the detrimental effects of a shift in the 
physiological balance of metals in biological systems, resulting in neurological disorders such 
as PD (Devi, et al., 2014; Jomova, et al., 2010; Moriarty, et al., 2014). 
 
The role biometals play in the pathogenesis of brain disorders is highlighted by evidence from 
a plethora of sources, including molecular genetics (Blum, et al., 2001; Lev, et al., 2003; 
Thomas, 2005; Gasser, 2009); biochemical studies (Cookson, 2005; Riederer, 1983) and 
biometal imaging (Wang, et al., 2017; Gotz, et al., 2004; White, et al., 2015). Results from 
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these studies have stimulated a growing interest in understanding the role of metals in brain 
functions and diseases, as well as interventions that could help restore altered balance in the 
brain/body.  
 
PD is the first form of chronic neurodegeneration found to be associated with the perturbation 
of metal homeostasis. This observation dates to about six decades ago (Aizenman, et al., 2015) 
when Hallgren and Sourander in 1958, in a seminal study, described the observed increase in 
iron levels in the substantia nigra (SN) of PD patients.  
 
1.3 The epidemiology of PD: influence of environmental factors.  
PD is associated with age. It has been noted that the prevalence increases with age and this 
correlation is astonishingly similar in most countries in Europe (De Rijk et al., 1997; De Rijk 
et al., 2000; von Campenhausen et al., 2005;). The possible explanation for this remarkable 
age-specific prevalence across Europe and the observed difference in other regions of the 
world have been adduced to variations in life expectancy and case ascertainment (Foltynie, et 
al., 2004). In the UK, age-adjusted prevalence rates are around 150 per 100,000 population 
per year, with several studies suggesting a mean age of 70 (Hindle, 2010).    
Across Europe, the prevalence rates range from between 65.6 per 100,000 to 12,500 per 
100,000 (von Campenhausen et al., 2005). The annual incidence rate of PD in Europe is 
estimated to range from 5 per 100,000 to 346 per 100,000 (von Campenhausen et al., 2005). 
These data give an indication of the relatively low rate of incidence of PD in some countries 
in Europe. Whilst investigating the prevalence rate by age and gender, De Rijk  (2000) and 
his colleagues reported a prevalence rate of 1.8 per 100 population in persons 65 years of age 
and older. This rate, however, increases with age. They noted an increase of 0.6 for those age 
65 to 69 years and 2.6 for those 85 to 89 years. They did not observe any sex difference in the 
prevalence of PD- this underscores the importance of ageing in the progression of this disease 
(Blin et al., 1991; Fearnely and Lees, 1991; Wüllner et al., 2007; Rajabally and Martey 
2013). 
In a population study in South-Western Finland, age-adjusted prevalence (with the Finnish 
general population) was 139 per 100,000 as at 1971 and 166 in 1992 - indicating a change in 
the epidemiology of PD in Finland (Kuopio et al., 1999). Unlike the findings of De Rijk et 
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al., (2000) where they reported no gender difference in the rate of prevalence, In an earlier 
study, Kuopio et al., reported an increase in prevalence from 1.2 in 1971 and 1.7 in 1992 for 
gender distribution showed.  They also reported age-specific prevalence which showed a 
male preponderance in all age groups (as at 1992) and rural preponderance in age groups over 
60 years.  
Ageing as a factor in the aetiology of PD and described as the product of a random and 
predictable process that leads to the accumulation of unrepaired cellular damage, weakening 
cellular repair and compensatory mechanism (Kirkwood, 2003). However, there are 
individual variations. These variations are accounted for with lifestyle, environmental factor, 
and the genes (Kirkwood, 2003). Brian cells are vulnerable to accumulated effects of ageing 
including mitochondria dysfunction, increased free radical production and oxidative stress. 
All these lead to genomic instability and DNA mutations (Tai and Schuman, 2008; Best and 
Coppedè, 2009). 
Besides age, exposure to environmental pollutant has been implicated in the pathogenesis of 
PD. For example, occupational exposure to a high concentration of manganese (Mn) can 
result in several neurodegenerative disorders similar to PD- such as manganism (Zayed, et al., 
1990; Keen and Zidenberg-Cherr, 1994). Populations studies dating back to the last two 
decades reported that general population living within a mining district displayed poor motor 
functions (Santos-Burgoa, et al., 2001). In an earlier study of a population in Southwest 
Quebec exposed to Mn from a variety of sources, a correlation was established between poor 
performance for coordinated upper limb movement and elevated blood Mn levels (Mergler, et 
al., 1999).  
In a multicentre large case-control study (with biomarker data) Weisskopf  et al., (2010) 
reported cumulative exposure to lead (Pb) in populations across four USA states they 
investigated and noted an increased odd of PD with increasing cortical bone Pb. Although, no 
strong association between bone Pb and PD in this study, however, considerable experimental 
evidence point to the association that Pb disrupts the dopaminergic system (as it acutely 
increases spontaneous dopamine release, inhibits depolarisation-evoked dopamine release, 
decrease dopamine neuron spontaneous activity in vivo as well as alters dopamine-dependent 
behaviours)- Minnema, et al., 1986; Cory-Slechta, 1997. 
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1.4 Importance of metals in the brain 
Several important biological functions in the brain require metal ions such as sodium, calcium, 
potassium, zinc, iron, and Cu (Crichton, et al., 2012). For example, sodium and potassium are 
involved in the fast transmission of electrical impulses between neurons and along their axons 
to muscles and endocrine tissues, the maintenance of ionic gradients, and the synthesis of 
neurotransmitters requires these metal ions. Besides, metals are involved in the regulation of 
gated sodium and potassium channels, to generate electrochemical gradients across the plasma 
membranes of neurons, for the transmission of nervous impulses in the central, and the 
peripheral nervous system.   
 
Furthermore, metals are vital to functional and physicochemical processes, such as electron 
transport, oxygen transportation, protein modification, neurotransmitter synthesis (Riordan, 
1977; Goldstein and Czapski, 1986; Foulkes, 1990; Montgomery, 1995; D’Souza, et al., 2003), 
redox reaction, immune responses, cell adhesion, and protein and carbohydrate metabolism 
(Chen, et al., 2014).  
 
Metals in association with proteins are involved in signal transduction. The physiological 
functions of proteins are dependent on their charge and shape. However, the binding of calcium 
ions (Ca 2+) to proteins (just as the phosphorylation of hydroxyl groups of Ser and Thru residues 
via a protein kinase) can elicit changes in both the shape and charge of the proteins. For 
instance, Ca 2+, like phosphoryl group, can alter the local electrostatic fields this makes it vital 
in signal transduction (Xia, et al., 2005) and synaptic plasticity (Hudmon, et al., 2002). 
In the nervous system, Ca 2+ plays a significant role in regulating the range of cellular processes 
through ligand-gated channels, such as the NMDA receptor; this is activated by N-methyl-D-
aspartate or voltage-gated Ca 2+ channels. Postsynaptically, Ca2+ /calmodulin-dependent protein 
kinase CaMKII is the most abundant protein in the postsynaptic density (Ward, et al.,  2015) 
and plays a central role in Ca 2+ signal transduction, in the region, where the postsynaptic 
membrane is in close contact with ion channel which mediates synaptic transmission. 
 
Another notable metal ion that has, to a large extent, been implicated in brain function is Zn2+ 
(Bitanihirwe, et al., 2009; Bitanihirwe, et al., 2009). Zn 2+ is sequestered by glutamatergic 
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neurons present in the mammalian forebrain in their synaptic vesicles and released into the 
synaptic cleft during synaptic transmission. Zinc may also act as a critical neural messenger 
through its ability to regulate NMDA receptor activity. However, excessive release of zinc into 
the synaptic cleft and its permissive entry into vulnerable neurons contributes to severe 
neuronal cell death (Ward, et al., 2015). 
 
Besides Zn, the redox-active metals, Cu, and Iron (Fe) are both essential for normal brain 
function. Cu is a vital co-factor for two key proteins involved in neurotransmitter synthesis; 
these are dopamine β-hydroxylase which transforms dopamine to noradrenaline, and peptidyl-
α-amidating monooxygenase involved in the amidation of neuropeptide (Lutsenko, et al., 
2010). Deficiency of Cu during the foetal and neonatal periods has an adverse effect on both 
myelin formation and maintenance. Also, excess “free” Cu is equally dangerous because of its 
capacity (like iron) to participate in redox reactions, thus, generating insidious reactive oxygen 
and nitrogen species (Cricton, 2009). 
 
Similarly, Fe is essential in several biological processes in the brain, including oxygen 
transport, DNA synthesis, nitric oxide metabolism, and mitochondrial respiration, as well as 
several specific neuronal functions in myelin synthesis and neurotransmitter synthesis and 
metabolism (Crichton, 2009). Iron deficiency has deleterious effects on pre- and postnatal brain 
development due to its involvement in several nervous system processes (Crichton, 2009). It 
was reported (Crichton, et al., 2006; Crichton, et al., 2014) that there is an elevation of brain 
iron in specific brain regions with ageing, such as frontal cortex, caudate nucleus, putamen, 
substantia nigra and Globus pallidus with no apparent adverse effect. However, aberrant 
increase in metals (an excessive amount) in the wrong place in specific intracellular 
compartments or specific regions of the brain could lead to neurodegenerative diseases 
(Crichton, et al., 2006; Crichton, et al., 2014).  
 
Manganese is another trace element that is necessary for biological processes (Kumar, et al., 
2014; Singh, et al., 2020). At low concentration, Mn serves as a co-factor in a variety of 
metalloproteins, inclusive of MnSOD and arginase. It has also been associated in the function 
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of a variety of enzymes, including glutamine synthetase, hydrolases and lyases (Chen, et al., 
2015).  
 
1.5 Metal-based neurodegeneration 
The pathogenetic basis of neurodegeneration due to heavy metals can be categorised into three 
types: firstly, those diseases resulting from excessive environmental exposure, such as lead 
poisoning (Erwin, et al., 1995); the second group are disorders associated with aberrant 
depositions of various metals without excessive environmental exposure. A good example 
being Wilson’s disease, associated with brain Cu. The third group are disorders in which the 
pathogenesis is due to an augmentation of the naturally occurring presence of metal ions, as 
seen in increased iron levels in PD. Erwin, et al (1995) suggested that abnormal metal 
deposition, in neurodegenerative disorders, is greatest in the basal ganglia in contrast to other 
regions of the brain. This aberrant increase of metals in the basal ganglia has been associated 
with the onset and progression of PD, and consequently, disruption of basal ganglia function 
and movement. However, it is unknown if neuronal cell death is a consequence of metal 
deposition or a secondary effect, arising from other mechanisms that indirectly lead to 
abnormal metal deposition. The latter is particularly true of Hallervorden-Spatz disease (Erwin, 
et al., 1995). 
 
Since the advent of neuroimaging techniques, such as magnetic resonance imaging (MRI), with 
a quantitative analytical method, positron emission tomography (PET), and 
metaiodobenzylguanidine (MIBG)-cardioscintigraphy among others, the diagnoses of 
neurodegenerative diseases has become more accurate (Orimo, et al., 1999; Hirata, et al.,  
2005).  Some metals have been associated with the onset and sometimes progression of 
neurodegenerative diseases such as Cu, Zn and Fe for AD, Fe for PD, Cu and Zn for familial 
ALS (Crichton, 2006). Table 1 gives a summary/overview of various neurodegenerative 
disorders and the implicated metal and metalloprotein or enzymes. 
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Table 1.1: Some neurodegenerative disorders with possible metal-associated pathology 
(Crichton, 2006) 
Disorder  Implicated Metal Implicated Metalloproteins or enzymes 
PD Iron  
α-synuclein, neuromelanin, lactoferrin, 
ferritin, melanotransferrin, ceruloplasmin, 
divalent cation transporter  
Alzheimer’s disease Cu, iron, zinc Aβ, APP 
Creutzfeldt-Jakob disease  Cu, Iron Prion protein 
Familial amyotrophic 
lateral sclerosis 
Cu, Zinc deficiency Superoxide dismutase I 
Friedreich’s ataxia Iron Frataxin, aconitase, mitochondrial proteins 
Multiple sclerosis Iron Not known 
Wilson’s disease Cu Ceruloplasmin deficiency, Wilson’s protein  
Hallervorden-Spatz 
syndrome 
Iron  Vitamin B5 metabolism 
Huntington’s disease  Iron, calcium Huntingtin  
 
There is regional variation in the distribution of metals in the brain. Functional and metabolic 
differences may account for some of these variations. For example, Fe has been noted to be 
higher in brain regions with higher motor activities (Gotz, et al., 2004). In pathological 
conditions, sometimes moderate to profound differences in regional metal distribution have 
been reported (Uitti, et al., 1989). Research from patients who had suffered from 
Parkinsonism (Uitti, et al., 1989) reported higher metal content (for some metals) in certain 
regions of the brain in PD patients and lower concentrations in PD patients compared to 
matched control for some metals (see Table 1.2).  
 
The brain regions that are primarily involved in the modulation of motor activity (substantia 
nigra, caudate nucleus, frontal cortex, and the cerebellum)  have been noted to have marked 
difference in metal content in patients with PD compared with a matched control. These brain 
regions are components of the extrapyramidal system and lesions therein are known to cause 
abnormalities in movement (Uitti, et al., 1989). For example, the pre-motor area of the 
cerebral cortex involved in the production of complex patterned movements and the caudate 
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nucleus involvement in the inhibition of spontaneous movement, have profuse connections 
with other areas of the brain concerned with motor control- lesions in the substantia nigra 
produce parkinsonism. While the cerebellum is in the coordination of voluntary movements 
required for normal motor action and gait. 
 
Table 1.2: Metals concentrations by brain regions in PD and control brains 
 Brain Region (µg/g dry weight.) 
Metal Substantia nigra 
 
Caudate nucleus 
 
Frontal Cortex 
 
Cerebellum 
 PD Control PD Control PD Control PD Control 
Cu  29.3 38.8 25.7 28.6 25.0 26.5 34.1 33.0 
Al 10.2 7.7 2.9 10.7 5.0 5.2 1.4 7.9 
As 0.2 0.2 0.1 0.1 0.1 0.2 0.1 0.1 
Ca 468 623 468 630 506 554 410 618 
Fe 653 613 610 651 280 295 268 325 
Mg 414 452 471 530 482 539 515 560 
Mn 6.8 3.0 6.6 3.6 2.6 1.9 3.0 3.1 
Zn 68.8 78.6 72.5 71.0 63.0 51.2 64.8 76.9 
-Adapted from Uitti, et al., 1989. 
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1.6 Metals implicated in the pathogenesis of PD 
Metals are crucial in ensuring many cellular processes. Their concentrations within cells must 
be finely tuned because any aberration may lead to cell death and several diseases. In the 
brain, some enzymes and chaperones tightly regulate the metal ion content. They do this by 
controlling metal uptake and delivery to specific domains and by preventing a passive of flux 
of metals from the circulation. Besides, the blood-brain barrier also regulates the flux of 
metal from the blood into the brain by constituting a physical/physiological barrier (Outten 
and O'Halloran, 2001).  In a healthy state, the concentrations of free metal ions are 
maintained at a very low level. Each physiological metal ion is selectively delivered to its site 
of action to tightly control redox activity. Table 1.3 gives an overview of the metals 
implicated in the pathogenesis of PD. 
 
Table 1.3: Metals implicated in the pathogenesis of PD 
Metals Levels in PD Brian 
regions 
Role in disease pathogenesis  Reference  
Fe  Elevated  Substantia 
nigra 
(SNpc), 
basal 
ganglia 
 
Oxidative stress (caused by free Fe), 
free radical formation and loss of 
dopaminergic neurons of the SN as 
well as the deposition of 
intracellular inclusion bodies (Lewy 
bodies). 
Dexter, et al (1989). 
Dexter, et al (1991). 
Montgomery 
(1995). 
Barrnham and Bush, 
(2008). 
Kozlowski, et al 
(2012). 
 Decrease  Globus 
pallidus 
 Dexter, et al (1989). 
Dexter, et al (1991). 
Cu  Decrease SNpc Decrease Cu level is accompanied 
by a loss of copper-dependent 
enzyme activities, for example, 
cytochrome c oxidase, superoxide 
dismutase 1, ceruloplasmin. 
Barnham and Bush 
(2008). 
Binolfi, et al (2012). 
Cu Accumulation 
(other 
scholars 
noted an 
association 
between Cu 
accumulation 
and PD)  
SNpc 
Basal 
ganglia 
nuclei 
Leads to dopaminergic 
neurodegeneration, reduced striatal 
dopamine, loss of tyrosine 
hydroxylase projections, loss of 
neurons in the striatum and 
substantia nigra respectively- due to 
generation of neurotoxic reactive 
species (caused by oxidative stress). 
It has been shown to accelerate the 
oligomerization of α-synuclein 
monomers into neurotoxic fibrils, 
Hitoshi, et al (1991). 
Oder, et al (1993). 
Gorell, et al (1997). 
Gorell, et al (1999). 
Uversky, et al 
(2001) 
Barthel, et al (2003). 
Rossi, et al (2004). 
Yu, et al (2008). 
Paris, et al (2009). 
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which can impair mitochondria 
function. 
Zn  Elevated Substantia 
nigra (SN), 
Caudate 
Nucleus 
Though an antioxidant, elevated 
level in PD patients contributes to 
neurodegeneration.  
Dexter, et al (1989). 
Forsleff, et al 
(1999). 
Barrnham and Bush 
(2008). 
Kozlowski, et al 
(2012). 
Mn Unchanged   Mn increases the rate of dopamine 
auto-oxidation in the SNpc leading 
to lipid peroxidation. 
In excess, it can inhibit 
mitochondria function, reduce 
glutathione levels, increase NMDA-
mediated neurotoxicity, and alters 
calcium homeostasis (which 
culminate in cellular dysfunction). It 
is a potent mediator of pro-oxidant 
activities, through the production of 
(ROS), superoxide, peroxide, and 
hydroxyl radical.  
Montgomery 
(1995). 
Caudle, et al (2012). 
Jenner (2003). 
 
Hg Not specific Nigrostriatal 
dopamine 
Dopamine 
Transporters 
(DAT) 
Impacts the normal functioning of 
the dopamine nigrostriatal 
dopamine system. Reduces DAT 
function in striatum. Reduces 
neurites and of dopaminergic 
neurons. 
Yin, et al (2008). 
Lin, et al (2011). 
 
Pb Accumulation   SNpc Causes a significant modification in 
the function of the nigrostriatal 
dopamine system, reduction in the 
number of dopamine neurons in the 
SNpc as well as a decrease in the 
firing rate of dopaminergic neurons. 
Disrupts Ca uptake through Ca 
channel. 
Coon, et al (2006). 
Weisskopf, et al 
(2010). 
Tavakoli-Nezhad, et 
al (2001). 
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1.7 Parkinson’s Disease 
PD is the second most common form of neurodegeneration, first described, in 1817, by the 
English surgeon James Parkinson as ‘The Shaking Palsy’ (Crichton, et al., 2006). It is 
characterized by a progressive loss of dopaminergic neurons in the substantia nigra pars 
compacta (SNpc), located in the ventral midbrain as well as Lewy body pathology (Crichton 
et al., 2006). Clinically, the disorder is characterised by motor symptoms, such as bradykinesia, 
muscular rigidity, resting tremor, and postural instability (Bonilla-Ramirez, et al., 2013). It is 
also characterised by non-motor symptoms, including disorders of mood that results in apathy, 
depression, cognitive dysfunction, hallucinations, as well as complex behavioural disorders 
(Chaudhuri and Schapira, 2009). Associated with these are common symptoms such as sensory 
dysfunction with hyposmia or pain (Shulma, et al., 2002; Fasano, et al., 2012; Pfeiffer, 2016).  
 
The Queen Square Brain Bank has developed two steps diagnostic criteria for PD. The first 
step focuses on the definition of Parkinsonism which requires the presence of bradykinesia 
(plus at least one of tremor at rest, extrapyramidal rigidity, or postural instability) and certain 
exclusion and supportive criteria. Table 1.4 describes the clinical classification of PD (Gibb, et 
al (1988).  Table 1.5 outlines the United Kingdom’s PD Society Brain Bank Clinical Diagnostic 
Criteria (Hughes, et al., 1992). 
  
Parkinsonian syndromes may be broadly classified into three categories: idiopathic PD; 
secondary Parkinsonism; Parkinsonism with neural system degeneration (Parkinson – plus 
syndromes) (Hughes, et al., 1992). 
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Table 1.4: Clinical classification of parkinsonian syndromes Gibb, et al., (1988) 
 
Step 1. Diagnosis of a parkinsonian syndrome  
Bradykinesia and at least one of the following:  
Muscular rigidity.  
Rest tremor (4-6 Hz).  
Postural instability unrelated to primary visual, cerebellar,  
vestibular or proprioceptive dysfunction. 
Step 2. Exclusion criteria 
History of:  
Cerebrovascular disease with a stepwise progression.  
Repeated head injury.  
Antipsychotic or dopamine-depleting drugs.  
Definite encephalitis and/or oculogyric crises on no drug treatment. 
More than one affected relative.  
Sustained remission.  
The negative response to large doses of levodopa (if malabsorption excluded).  
Unilateral features after three years.  
Other neurological features: supranuclear gaze palsy,  
cerebellar signs, early severe autonomic involvement.  
Babinski sign, early severe dementia with disturbances of: 
language, memory, or praxis.  
Exposure to a known neurotoxin. 
Step 3. Supportive criteria  
Unilateral onset.  
Excellent response to levodopa.  
Rest tremor present.  
Progressive disorder.  
Persistent asymmetry, affecting side of onset most.  
Severe levodopa-induced chorea.  
Levodopa response for five years plus. 
The clinical course of 10 years plus. 
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Table 1.5: United Kingdom PD Society Brain Bank clinical diagnostic criteria.75- 
Hughes, et al (1992) 
1. Idiopathic PD  
2. Secondary (symptomatic) parkinsonism  
Post encephalitic  
Drug-induced (e.g., antipsychotics, metoclopramide)  
Arteriosclerotic (small vessel disease of the brain)  
Toxic (e,g., manganese, carbon monoxide, MPTP)  
Wilsons disease  
Post-traumatic  
Neoplastic  
Normal-pressure hydrocephalus 
 
3. Parkinsonism in neural system degeneration  
Multiple system atrophy  
Striatonigral degeneration  
Shy-Drager syndrome  
Olivopontocerebellar atrophy  
Progressive supranuclear palsy (Steele-Richardson Olszewski)  
Alzheimer’s disease  
Pallidonigral and corticobasal degenerations  
Diffuse Lewy body disease 
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The observed motor deficits are consequences of the loss of dopaminergic neurons and 
decrease in the amount of the neurotransmitter (dopamine) content in the striatum (Bonilla-
Ramirez, et al., 2013), cytoplasmic inclusions of insoluble aggregated proteins (known as Lewy 
bodies) and elevated levels of iron (Cuervo, et al., 2010; Peng, et al., 2007; Fasano, et al., 2006; 
Rhodes and Ritz, 2008; Sian-Hulsmann, et al., 2011). 
 
Although the aetiology of the disease is unknown, possible multifactorial factors have been 
deduced; with input ranging from a variety of genetic (Christine, et al., 2012), exposure to 
environmental toxins (Goldman, 2014; Sirisha, et al., 2016), gene-environmental interactions 
(Cannon and Greenamyre, 2013),  endotoxin factors (Tufekci, et al., 2010), metals (such as 
iron) (Mark, et al., 2015)  as well as ageing (Subramanian, 2010) nitric oxide metabolism and 
mitochondria respiration dysregulation (Park, et al.,2018).  
 
It was noted that there is a low risk of developing PD among adults under 60 with no known 
genetic predisposition (mutations) and no history of prolonged exposures to environmental 
contaminants, such as heavy metals and pesticides (Abdullahi, et al., 2014). However, the risk 
of developing idiopathic PD radically increases after the age of 60. This age-related increase 
may be a result of some factors; the onslaught of endogenous and exogenous cellular insults 
on neurons over extended periods; accumulation of genetic mutations; a combination of both. 
Despite the premise that PD arises from polygenic inheritance and a possible consequence of 
gene-environmental interactions, over 90% of PD cases are sporadic, whilst approximately 5 -
10% are of familial origin, caused by gene mutations which results in the familial forms of the 
disease  (Bonilla-Ramirez, et al., 2013). Fig.1.2 shows how ageing affects the progression of 
PD.  
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Figure 1.1: A proposed model of Aging and progression of PD; from  Ageing, 
Neurodegeneration and Parkinson’s disease– Hindle J, 2010. 
(1)More rapid turnover of dopamine- more likelihood of dyskinesia (2) Reducing 
compensatory mechanisms (3) Increasing cellular dysfunction and accumulation of other 
pathologies (4) Aggregation of complications/more rapid progression.  
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Presently, no curative treatment is available for either the sporadic or genetic forms of 
Parkinsonism. Current treatment regimens are aimed at ameliorating the symptoms by 
replacing deficient dopamine – which improves motor activity. There is a great drive towards 
improving the quality of life of PD patients. As a result, translational clinicians/scientists are 
working hard to develop innovative treatment approaches for AR-JP patients based on our 
growing understanding of the genetics and related pathophysiology (Jankovic and Aguilar, 
2008). In the quest to elucidate the underlying cause of PD, protein misfolding has been 
unravelled in the pathogenesis of PD.  
 
In idiopathic PD, aggregation of heavily ubiquitinated WT (WT) α–synuclein is found in Lewy 
bodies within the dopaminergic neurons, axons, and synapses of the substantia nigra (Crichton, 
et al., 2006). The Synucleins are a family of small highly charged proteins, which are expressed 
in neural tissues (George, 2002). Two forms of these proteins, α-synuclein and β-synuclein are 
found in brain tissues, chiefly in the neocortex, hippocampus, striatum, thalamus and 
cerebellum; whilst the gamma-synuclein is found predominantly in the peripheral nervous 
system, that is, in motor neurons, sympathetic neurons and primary sensory neurons Perez, et 
al.,  (2004). 
 
 Alpha-synuclein plays a vital functional role in the modulation of dopamine release (as a 
regulatory protein) by binding to and inhibiting tyrosine hydrolase. This enzyme is crucial in 
the biosynthesis of dopamine- this enzyme is delineated as a rate-limiting enzyme. Eriksen, et 
al (2003) observed that the dopaminergic neurons are peculiarly and selectively vulnerable to 
the toxic effects of α-synuclein. Excessive production of WT α-synuclein exhibits a triplication 
of the α-synuclein gene, leading to an autosomal dominant PD (Singleton, et al., 2003). The 
presence of Lewy bodies in the affected regions of the brain indicates the misfolding of these 
proteins (α-synuclein).  
 
Dauer, et al (2002) highlighted the relevance of α-synuclein in the development of PD. They 
exemplified this in a knock-out and knock-in mice for the gene. They demonstrated in their 
studies that mice lacking this gene have decreased striatal dopamine function, a reduction in 
motor response to amphetamine and an increase in the release of dopamine following a paired-
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pulse stimulus. Increased levels of α-synuclein in transfected human culture foetal 
dopaminergic neurons lead to apoptotic cell death. It was observed that inhibition of dopamine 
synthesis (in these cells), prevented apoptosis. This may be due to a reaction between α-
synuclein and endogenous levels of dopamine in the generation of ROS (Dauer, et al., 2002).  
 
An association/link between α-synuclein and Fe was demonstrated in vitro. It was observed 
that Fe enhanced intracellular aggregation of α-synuclein (Ostrerova, et al., 1999; Golts, et 
al.,2002; Hasegawa, et al., 2016). In vitro studies lead to the formation of advanced glycation 
end products (Uversky, et al., 2001; Munch, et al., 2000) while α-synuclein liberated hydroxyl 
radicals when incubated with Fe2+ (Tabner, et al., 2001). 
 
Iron is a key driver in the oxidative process leading to the pathogenesis of PD. As an 
unavoidable consequence of ageing, there is an increase in the levels of brain Fe in certain 
regions of the brain such as in the putamen, prefrontal cortex, motor cortex, sensory cortex, 
and thalamus (Crichton, et al., 2006). It is localised within the H- and L-ferritin in the substantia 
nigra (Zecca, et al., 2001; 2004) and neuromelanin (Zecca, et al., 2004) with no apparent 
adverse effects. There is significant variation in the distribution and concentration of Fe in 
different brain regions.  
 
Areas associated with motor function tend to have more Fe than non-motor related regions. 
The main differences in the brains of PD patients and those of normal subjects are that there 
are clearly defined 2-fold elevation of Fe in the substantia nigra and the lateral Globus pallidus, 
in comparison with age-matched controls (Gotz, et al., 2004). Metal dyshomeostasis is strongly 
implicated in the pathogenesis of PD and it was one of the earliest forms of chronic 
neurodegenerative diseases associated with dysregulation of metal homeostasis.  
 
The earliest research on the possible effect of metal perturbation and PD dates to the works of 
Hallgren and Sourander 1958 (Editorial, Neurobiology of Disease, 2015), where they describe 
the increased levels of iron in the substantia nigra of PD patients. Later studies showed 
alternations in the levels of metals in the brain of PD patients, post-mortem compared to non-
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PD match controls of similar age (Wenstrup, et al., 1990). Kumudini and his colleagues (2014) 
demonstrated that elevated iron levels stimulated oxidative stress in PD and metal-induced 
oxidative stress is implicated in the pathogenesis of PD (Kumudini, et al., 2014). 
 
A further role of metals in the pathological process of the disease was elucidated based on 
observational studies which evaluated occupational and environmental exposures as well as 
levels of metals in biological fluids employing case-control study designs (Cicero, et al., 2017). 
Taba, et al (2002) observed that the prevalence rates of PD in Europe (using Estonia as a case 
study) are not significantly higher in urban areas than rural ones. In Africa, a case-control study 
on risk factors for PD in southwestern Nigeria found blacksmithing (OR 8.0 95% CI 1.3- 
50.7)[6] to be significantly associated with PD (Falope, et al., 1992; Akinyemi, 2012; 
Akinyemi and Okubadejo, 2010). 
 
Environmental link in the aetiology of PD was underscored by the landmark epidemiological 
study of about 20,000 pairs of twins. The findings in this study show no definite genetic cause 
was identified to explain the occurrence of PD. This finding made the researchers conclude 
that PD was an environmentally influenced disorder (Tanner, et al., 1999). 
 
Several environmental risk factors have been associated with PD. Lauretti, et al (2017) posited 
that circadian rhythm dysfunction is a risk factor for developing PD. Besides, a notable shift 
towards environmental risk factors was accentuated when illicit drug users inadvertently 
generated a product of narcotic synthesis, MPTP (1-methyl-4-phenyl-1, 2, 3, 6-
tetrahydropyridine). which was reported to have resulted in Parkinsonism, among users.  
 
Furthermore, exposures to different pesticides (such as rotenone, paraquat i.e. N, N’-dimethyl-
4, 4’—bipyridine dichloride), maneb, and manganese, ethylene-1, 2-bisdithiocarbamate, 
polymer among others have been associated with an increased risk of PD (Bjorklund, 1995; 
Bjorklund, 1997; Goldman, 2014; Bjorklund, 2018; Bjorklund, 2018). In addition to pesticides, 
some commonly encountered environmental toxicants have been implicated in PD for 
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examples of heavy metals, solvents, and several other pollutants (Bjorklund, 1997; Goldman, 
2014). 
 
Chronic environmental exposure to metals is another risk factor implicated in PD. Exposure to 
a low dose of certain metals, cumulatively, results in accumulation of these metals in the brain. 
For example, studies in a rat showed that there is an interaction between Mn and Fe from the 
plasma to the brain and other organs (Gorell, et al., 1999). Gorell and his colleagues (1999) 
demonstrated that these metal transfer across the blood-brain barrier (BBB) is synergistic rather 
than competitive. Thus, suggesting that excessive intake of Fe alongside Mn will accentuate 
the risk of tissue damage in the brain than by one metal alone. Chronic exposure of rats to Mn 
alters Fe homeostasis by causing a unidirectional influx of Fe from systemic circulation across 
the BBB (Zheng, et al., 1999).  
Earlier studies by Olanow, et al (1996) showed the deleterious effect of chronic exposure of 
metals. In their investigation, they observed L-DOPA resistance Parkinsonian syndrome in 
Rhesus monkeys exposed to Mn and a focal mineral deposit in the Globus pallidus and 
substantia nigra pars reticularis, consisting primarily, of iron and aluminium. Zn and Mn 
influence the neurotransmitter concentrations in the synaptic cleft by modulating 
neurotransmitter receptors and transporters as well as iron channels (Takeda, 2004). 
Specifically, Zn is seen to act as an inhibitory neuromodulator to glutamate release in the 
hippocampus while manganese induces both functional and toxic effects in the synapse 
(Takeda, 2004).  
 
In vitro Mn has been shown to induce cell death in dopaminergic cells such as SH-SY5Y and 
CATH.a cells, causing an increase in the endoplasmic reticulum (ER) stress-associated genes, 
inclusive of parkin (Higashi, et al., 2006). Concomitant exposure of these cell lines to Cu and 
Mn shows enhanced cytotoxicity and clastogenicity of levodopa and dopamine (Snyder and 
Friedman, 1998). 
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1.8 Mitochondrial dysfunction and PD 
Several lines of evidence strongly suggest mitochondrial dysfunction as a major causative 
factor in PD. There is ongoing intensive research to unravel the molecular mechanism. At the 
cellular level, mitochondria play a key role, both as regulators of ATP production via oxidative 
phosphorylation and as regulators of intracellular calcium homeostasis and production of 
reactive oxygen species (Crichton, 2006). Excitotoxicity is associated with the mitochondria. 
This is due to increased mitochondrial calcium overload which results in the generation of ROS 
leading to the release of pro-apoptotic mitochondrial proteins; culminating in the demise of the 
cell by either apoptosis and/or necrosis (Rego and Oliveira, 2003).  
 
Besides, mitochondria play a unique role in regulating the factors that either suppress or 
promote protein misfolding, such as molecular chaperones, the protein degradation system, and 
free radical production. Mitochondria defects can lead to the aggregation of α-synuclein. The 
translocation of the misfolded proteins to the mitochondria membrane plays an important role 
in activating or perpetuating neurodegeneration by causing changes in membrane permeability 
and the release of cytochrome c (Crichton, 2006). 
 
In the striatum of PD patients, there is a defect in mitochondria oxidative phosphorylation. This 
defect results in a reduction in the activity of NADH CoQ (known as complex 1). The reduced 
activity of complex 1 is specifically found in the SNpc, and not in other parts of the brain. Such 
specificity plays a significant role in the degeneration of nigrostriatal dopaminergic neurons 
(Ebadi, et al., 2001). Further investigations suggest that the inhibition of complex 1 may be the 
central cause of sporadic PD and iron accumulation in the mitochondria, both in vitro and in 
vivo, adversely alter complex 1 (Crichton, 2006). Besides, disorders in complex 1 cause 
aggregation of α-synuclein and this contributes to the demise of dopaminergic neurons.  
 
Other mitochondria complexes (II and IV) are also implicated. For example, the production of 
Nitric oxide (NO) - either from the mitochondria or inducible NOS within the cell cytosol 
inhibits components of the mitochondria respiratory chain, complexes I, II and IV (precisely in 
a reduced state of GSH). This cause a cellular energy-deficient state (Brown, 1999; Brown, 
2001; Brown and Borutaite, 2002; Brown and Borutaite, 2007). 
46 
 
 
Figure 1.2: Overview of the aetiology and pathogenesis of Parkinson’s disease- Hind J, 
(2010). 
 
The pathogenesis of PD is multifactorial, and this is orchestrated by a stream of events (see 
Fig. 1.4)  which ultimately leads to neuronal cell death. These include oxidative stress,  
impaired mitochondrial function, excitotoxicity via glutamate pathways, protein misfolding 
and aggregation due to ubiquitin proteasomal system dysfunction, impaired lysosome, and 
chaperone-mediated autophagy (Hindle, 2010). Associated with these is the development of 
cytoplasmic inclusion bodies called Lewy bodies that contain neurofilament proteins and 
ubiquitinated α-synuclein. Besides, inflammation and humoral immune reactions have been 
noted to contribute to the processes linked to cell death through apoptosis (McNaught, 2002). 
Most of these mechanisms align with the changes in ageing. Many environmental agents may 
be inhibitors of proteasomal function and, in rat models, proteasomal inhibition alone can 
reproduce the key features of PD. 
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1.9 Role of Dopamine in PD 
In the healthy state, dopamine is produced in the SN and transmitted to the putamen and caudate 
nucleus with a resultant inhibitory effect on movement. In contrast, acetylcholine, which is 
synthesised in the basal ganglia, has an excitatory effect on movement. A fine balance between 
these two systems (dopaminergic and cholinergic) must be maintained to ensure a fine gait and 
movement. The degeneration of dopaminergic neurons in the SNpc (as seen in PD) results in 
an imbalance between acetylcholine and dopamine - the shift of balance towards cholinergic 
activity produce the characteristic symptoms of rigidity, tremor, and bradykinesia.  
 
‘Oxidative stress hypothesis’ has been proposed to explain the role of oxidative stress vis-a-vis 
the degeneration of dopaminergic neurons (Kim, et al., 2002). During a normal life span (70-
80 years), there is about 3-5% decrease of dopaminergic neurons every decade. However, at 
the time of diagnosis of PD, there is a loss of about 60-80% of dopamine-containing neurons. 
This hypothesis insinuates the initiation of nigral dopaminergic neuron loss with the depletion 
of glutathione, implying PD may be a consequence of aberrant oxidation of dopamine.  
 
Cellular metabolism of dopamine generates H2O2 which is reduced to hydroxyl radicals in the 
presence of iron thereby propagating neuronal damage (Kim, et al., 2009). The antioxidant, 
glutathione (GSH) helps to maintain a healthy milieu in the SN neuronal cells against oxidative 
stress. A shift in the balance between form prooxidant to antioxidant result in the death of the 
nigral dopaminergic neuronal cells, by apoptosis (See Fig. 2). 
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Figure 1.3: The antioxidant properties of GSH as relevant to SN dopaminergic neuronal 
cells in PD – Crichton, et al., 2006. 
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Metal Dysregulation and PD 
Heavy metals play a critical role in many neurological diseases. Several epidemiological 
studies have shown an association between PD and exposure to metals, some of which include 
mercury, lead, manganese, Cu, iron, aluminium. Metal accumulation in the nervous system 
inevitably leads to a toxic environment, resulting in a predicted pattern often associated with 
metal toxicity; oxidative stress, mitochondria dysfunction and protein misfolding (6-13). A 
damaged neuron requires a greater amount of energy to synthesize neurotransmitters, as well 
as maintain homeostasis. The resulting burden combined with neurotoxicity may lead to 
neuronal death. Given that the nervous system regenerates poorly, the resultant impairment and 
the associated neurodegeneration become progressive with age, which is typical of PD. 
 
The contribution of metals in the aetiology of PD is very crucial;  attracting attention, great 
interest to both neurotoxicologist and medicinal chemist (Montgomery, 1995; Chin-Chan, et 
al., 2015; McAllum, et al.,  2016; Schuh, 2016; Lucchini, et al., 2017). As previously observed, 
PD falls within the group of disorders in which the pathogenesis may be due to the abnormal 
function of a normally present metal. The role of metals may either be as metallic toxicants or 
through depletion of metals that are essential for biological activities and maintenance of health 
(Bjorklund, et al., 2018).  
 
1.9.1 PD and Iron 
Iron is an essential element which is crucial for physiological processes in several organs, 
including the brain. Its role in the pathophysiology of PD has been extensively studied and its 
neurotoxic effect has been well reported (Obeso, et al.,2000; Double, et al., 2003; Castellanos 
et al., 2005; Moore, et al., 2005). Iron deficiency impairs health functions in both the central 
and peripheral nervous system and has been implicated in PD with restless leg syndrome 
because it results in depletion of brain dopamine and 5-HT levels (Piao, et al., 2017).  
 
Double, et al., (2003) demonstrated that microinjection of Fe in the SN has a neurotoxic effect 
on tyrosine hydroxylase immunopositive neurons. Accumulation of iron in deep grey matter 
nuclei in the basal ganglia and midbrain have been associated with PD pathology as well (Xuan, 
et al., 2016; Xuan, et al., 2017). Uneven distribution of Fe in the brain has been reported 
50 
 
(Dexter, et al., 1989; Riederer, et al., 1992; Behnke, et al., 2003; Oakley, et al., 2007). 
Examination of postmortem PD brains have shown increased levels of total Fe in the SNpc, 
caudate nucleus, putamen, or cerebral cortex, but not in the cerebellum, - an index to the fact 
that the underlying mechanisms for Fe accumulation may be specific for the SNpc (Behnke et 
al., 2003; Dexter, et al., 1989; Oakley, et al., 2007; Riederer, et al., 1989). In contrast, there is 
a reduced level of this metal in the Globus pallidus compared to control values (Dexter, et al., 
1989).  
There is ambiguity about the presence of increased Fe and the onset of neurodegeneration. 
Riederer, et al (1989) in their investigation, noted the insignificant difference in Fe content in 
brain tissues showing moderate neurodegeneration, implying that Fe accumulation in PD may 
be a possible consequence of underlying mechanisms of neuronal death or else its levels should 
be expected to increase in the early stages of the disorder. Some underlying mechanisms may 
initiate neuronal death at the early onset of the disorder leading to Fe accumulation which, in 
turn, may potentiate oxidative damage (See Fig. 1.3). 
 
Figure 1.4: Fe induces oxidative stress in PD, resulting in the death of the nigral 
dopaminergic neuronal cells by a process of Adapted apoptosis (Crichton, et al., 2006) 
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Behnke, et al (2003) in their studies found ferritin-reactive microglia around degenerating 
neurons. This is interesting, since ferritin is the main Fe-binding protein, and the result suggests 
that Fe accumulates within microglia cells. This has invariably thrown up some hypotheses. 
On one hand, is the speculation that microglia release Fe that could be toxic to the surrounding 
neurons. On the other hand, that Fe may accumulate in both neurons and microglia but due to 
the greater sensitivity of neurons to the toxic effect of this metal, which possibly explains why 
only, the surviving ferritin-positive microglia may be found in post-mortem brain tissues 
surrounding degenerating neurons (Rivera, et al., 2010). This, therefore, underpins the need for 
an investigation of the role of microglia in brain Fe accumulation. 
 
Advancements in neuroimaging techniques have made it possible to quantify and establish the 
distribution of metals in the brain. Through neuroimaging, the content of Fe is seen to increase 
in PD in the SNpc in living patients. For instance, several investigators have been able to 
establish, by transcranial sonography, that the SN in PD patients is associated with a high 
ultrasound echo (referred to as “hyperechogenic”). This reflects the deposition of metal in this 
region of the brain (Behnke, et al., 2003; Becker, et al., 2001; Rivera-Mancia, 2010; Martinez-
Hernandez, et al., 2011).  
 
In their investigation of vulnerability factors for PDs, Behnke, et al (2003) made the following 
observations: firstly, that hyperechogenicity may be present in up to 90% of PD patients and 
may also be found in healthy subjects, but in the latter, it is a reflection of nigrostriatal 
dysfunction, because of its association with decreased [18F] DOPA uptake (Berg, et al., 2002; 
Behnke, et al., 2003; Wegrzynowicz, 2018). Secondly, they also observed that 
hyperechogenicity in healthy elderly subjects was associated with motor alterations, such as 
hypokinesia (Behnke, et al., 2003). This increase response during ultrasound examination of 
the brain, they suggested may likely be due to Fe accumulation, since the echogenicity with 
post-mortem human brain tissue, correlates well with Fe content, but not so with Cu, 
magnesium, Zn or calcium (Behnke, et al., 2003; Berg, et al., 2002).  Other imaging findings 
by Vymazal, et al., (1999) and Brar, et al., (2009) further support Fe accumulation in SNpc in 
PD and its role in nigrostriatal dysfunction in this disorder. Taken together, all these findings 
strongly implicate Fe as a major player in the aetiology of PD. 
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It is very vital to note also that Fe content in the brain increase during normal ageing and it is 
often associated with a decrease in motor performance (Thomas, et al., 1993; Bartzokis, et al., 
1994; Bartzokis, et al., 2007). However, when compared with those of PD patients, it has been 
established that Fe levels are higher than expected compared to the normal ageing process 
(Focht, et al., 1997; Wayne, et al., 2004).  
 
Several investigators have made some attempts to elucidate the possible mechanism underlying 
the increase in brain Fe content in PD. One significant observation is based on the fact that 
excitotoxicity might be involved in PD, which invariably leads to Fe accumulation. Since Fe 
uptake is enhanced by N-Methyl-D-Aspartate (NMDA) receptor activation, via nitric oxide 
(NO) signalling (Munoz, et al., 2011). Glutamate and NO are involved in excitotoxic death 
(Chen, et al., 1995), which has been proposed to occur in PD (Wang and Qin, 2010; Dong, et 
al., 2009; Koutsillieri and Riederer, 2007). This may imply that Fe accumulation in PD may be 
associated with neuronal death through glutamate receptors (Dugan, et al., 1994; Jellinger, 
1999; Lau and Tymianski, 2010). Cheah et al., (2002) in their investigations supported this 
neurotoxic pathway, by establishing the fact that Fe chelation reduces NMDA-induced 
excitotoxicity.  
 
Further evidence implicating Fe in the possible aetiology of PD is the effect of the Cu protein, 
Ceruloplasmin (Cp) on the oxidation state of Fe. Cp and hephaestin oxidize Fe2+ to Fe3+ to 
facilitate iron removal (Loeffler, et al., 1996; Qian and Ke, 2001; Popescu and Nichol, 2011). 
Jiang, et al., (2015) demonstrated this in a double knockout mouse lacking both cap and 
hephaestin, by iron overload and neurodegeneration. Furthermore, Jiang, et al (2015) and 
Wang, et al (2015) have explored the role of these two proteins in PD. In their investigations, 
using a model of 6-hydroxydopamine (6-OHDA), they observed a decreased expression of 
hephaestin (Wang, et al., 2007); while Hochstrasser, et al (2004) found an association between 
mutations of Cp genes and PD. These suggest that iron overload may be in part a consequence 
of altered oxidation of Fe, preventing its extrusion from neurons.  
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Evidence implicating Fe involvement in the pathophysiology of PD was demonstrated by Hare, 
et al (2013). They found an upregulation of divalent metal transporter 1(DMT1) in the SNpc 
of PD patients as well as the SNpc of mice exposed to 1-methyl-4-phenyl-1, 2, 3, 6 
tetrahydropyridines (MPTP) - an established neurotoxin known to induce several features of 
PD.  Zhang, et al (2009) verified these findings when they treated dopaminergic cell lines 
(MES23.5) with an active metabolite of MPTP- 1-methyl-4-phenylpyridinium (MPP+). They 
observed an upregulation of DMT1 which was correlated with Fe accumulation. Besides, it 
was observed that rodents that carry a mutation that impairs DMT1 Fe transport were protected 
from injury caused by both MPTP and 6-OHDA. Fe as divalent metal, therefore, plays a critical 
role in the pathogenesis of PD. Once Fe accumulates in PD, it enhances neuronal death, through 
oxidative stress.  
Fe also induces lipid peroxidation (Muller, et al., 1985; Minotti and Aust, 1992; Oteiza, 1994) 
and increases ROS production by the autoxidation of 6-OHDA (Mendez-Alvarez, et al., 2001). 
Also, Fe stimulates the formation of intracellular aggregates of α-synuclein and favours 
oxidative damage. It has been established (Narhi, et al., 1999; Lee, et al., 2002; Li, et al., 2005) 
that familial PD is associated with mutations in α-synuclein which enhances the aggregation of 
the protein (Narhi, et al., 1999). This, therefore, implies persons with mutations in α-synuclein 
could be more susceptible to oxidative damage by Fe. The Fe-induced oxidative damage is 
mediated through the Fenton reaction, in which hydrogen peroxide (H2O2) (Meneghini, et al., 
1993). The source of the H2O2 in this reaction, among several sources, maybe from monoamine 
oxidase activity and from Fe-induced oxidation of dopamine (Campos, et al., 2015). This leads 
to the enhancement of this damaging mechanism. Aracena, et al (2006) reported an increase in 
glutathione biosynthesis in survival cells after Fe overload-implicating oxidative stress as a 
direct precursor Fe neurotoxicity. 
 
1.9.2 PD and Cu 
As an essential trace element, Cu acts as a co-factor of several enzymes, such as cytochrome c 
oxidase and SODs (Banci, 2013; Desai, et al., 2008), and plays a vital role in electron transport, 
oxygen transport, protein modification and neurotransmitter synthesis (Banci, 2013; Desai, et 
al., 2008). Various studies have shown that Cu may lead to both toxic and protective effects 
under certain experimental conditions. In peripheral tissue, Dexter, et al (1989) and Popescu, 
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et al (2009) reported incidence of toxicity with Cu and at the same time noted some protective 
effects in cases of Cu deficiency.  
 
According to Rivera-Mancia et al (2010), cases of toxicity arising from a high concentration 
of Cu were not directly associated with PD, whilst decreased levels of Cu has been reported in 
PD (Dexter, et al., 1989; Popescu, et al., 2009). The protective role of Cu becomes relevant in 
cases of Cu-deficiency in PD (Rivera-Mancia, et al., 2010). Excessive Cu has been associated 
with increased generation of ROS, DNA, and mitochondrial dysfunction. Cu has been shown 
to enhance the self-aggregation of the β-amyloid peptide (20), increased level of Cu in the 
Cytochrome. In patients with PD disorders, the concentration of Cu is altered in both the CSF 
and brain (56,117) and this has been implicated in the pathophysiology of this disorder. Free 
Cu has been implicated in oxidative stress mechanisms, alpha-synuclein oligomerization and 
Lewy body formation, as well as GABA-A and NMDA receptor neurotransmission 
modulation. Cu can influence iron content in the brain through ferroxidase ceruloplasmin 
activity (Montes, et al., 2014).  
 
1.9.3 PD and Manganese 
At higher concentrations, Manganese (Mn) has been shown to exert neurotoxic effects resulting 
in impairment of dopaminergic, glutamatergic, and GABAergic transmission, as well as 
mitochondrial dysfunction, oxidative stress and marked neuroinflammation (Cicero, et al., 
2017). The principal anatomic target of manganese neuronal accumulation is the Globus 
pallidus in the basal ganglia, leading to Parkinsonism (Tuschl, et al., 2013). A pathognomonic 
sign of such accumulation from Magnetic Resonance Imaging (MRI) is a T1-weighted image, 
showing an appearance of hyperintense basal ganglia (Tuschl, et al., 2013).  
 
Manganism may either be congenital or acquired. Quadri, et al (2012) reported an autosomal 
recessively inherited disordered of manganese metabolism which is caused by a mutation in 
the SLCC30A10 gene. Acquired causes of manganism maybe due to intravenous use of 
methcathinone, excessive nutritional intake, or impaired hepatic excretion of manganese, 
which may lead to hepatocerebral degeneration (Ferrara and Jankovic, 2009). 
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Several epidemiological studies have investigated the possible link between chronic 
manganese exposure as an environmental factor and PD. Results from such studies show that 
occupational exposure for a duration greater than 30 years (Lai, et al., 2002; Sayed, et al., 
1990), 20 years (Gorell, et al., 1997) and 10 years (Recite, et al., 2017) were consistent and 
showed that progression of Parkinsonism increased with cumulative manganese exposure. 
Persons with manganese-induced Parkinsonism have a clinical resemblance to idiopathic PD, 
though there is a preservation of dopamine synthesis in manganism (Tuschl, et al., 2013). In 
case-control studies that evaluated blood levels of manganese in PD subjects compared to 
controls, the outcomes reveal a positive association between high manganese levels and PD 
(Ahmed and Santosh, 2010; Hegde, et al., 2004; Kumudini, et al., 2014; Squitti, et al., 2007a). 
However, less consistent results were obtained from CSF analysis in which higher levels of 
manganese was reported in a study (Hozumi, et al.,2011). Six other investigators reported no 
substantial difference between PD subjects and match controls (Alimonti, et al., 2007; Bocca, 
et al., 2006; Forte, et al., 2004; Gazzanigga, et al., 1992; Jimenez, et al., 1998; Pall, et al., 1987). 
 
1.9.4 PD and Selenium 
Selenium (Se) is an essential trace element. It is specifically incorporated into selenoproteins, 
in the form of selenocysteine. The human selenoproteome consists of 25 proteins and it is 
classified into housekeeping and stress-related proteins. Se exerts a very vital antioxidant 
activity through its oxidoreductase functions, such as the glutathione peroxidase which protects 
against hydrogen peroxide and lipid peroxides, which are influenced by dietary selenium levels 
(Cicero, et al., 2017). Dysregulation of Se may result in an imbalance which may increase 
oxidative stress implicated in neurodegeneration (Ellwanger, et al., 2016).  
 
Data from case-control studies reported ambiguous results, while some studies suggested 
higher blood levels of Se in PD as compared to controls (Quareshi, et al., 2006; Zhao, et al., 
2013), others suggested lower levels (Ahmed and Santosh, 2010; Hegde, et al., 2004). A larger 
proportion of investigators on this subject reported no relevant difference between groups 
(Baillet, et al., 2010; Fukushima, et al., 2010; Gellein, et al., 2008; Takahashi, et al., 1994; 
Younes-Mhenni, et al., 2013). 
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1.9.5 PD and Zinc 
Zinc is essential for most physiological functions and its status in the human body is affected 
among others, by factors that affect homeostasis (Maret, 2013; Sandstead, 1991). Unlike other 
transition elements, Zn is redox neutral and readily binds to proteins with the appropriate amino 
acid motifs- and there are well over 3000 proteins known to have such signatures (Andreini, et 
al., 2006). This explains the ubiquity of zinc in several physiological functions, ranging from 
enzymes and transcription factors to signalling proteins (inclusive of storage proteins, proteins 
with structural metal sites, as well as those involved in DNA repair, replication, and 
translation). 
Zn plays a vital role in PD neurodegenerative process by impinging on lysosomal functions. A 
compromised autophagy-lysosomal pathway is increasingly implicated in the pathogenesis of 
neurodegenerative diseases, including PD (Cicero, et al.,2017). In an earlier study, Dehay, et 
al (2013) in their investigations, observed a link between PD and mutations in lysosomal-
related genes (such as glucocerebrosidase) and lysosomal type 5 ATPase. For example, 
mutations in PARK9 results in Kufor-Rakeb syndrome, which is characterised by juvenile-
onset Parkinsonism, pyramidal signs, and dementia (Cicero, et al., 2017).  
 
Tsunemi and Krainc (2014) reported that the loss of PARK9 results in the dyshomeostasis 
intracellular zinc levels, which contributes to lysosomal dysfunction and, subsequently, the 
accumulation of alpha-synuclein. Despite the plethora of laboratory investigations implicating 
Zn in the aetiology of the PD neurodegenerative process available case-control studies, 
evaluating environmental/occupational exposure to Zn have failed to demonstrate any 
significant association with PD (Gorell, et al., 1997; Lai, et al., 2002; Seidler, et al., 1996). 
However, results from studies on blood Zn levels in PD and matched controls support a 
possible inverse association (Ahmed and Santosh, 2010; Hegde, et al., 2004; Squitti, et al., 
2007a; Zhao, et al. ,2013). 
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1.9.6 PD and Mercury  
Elevated levels of mercury (Hg) has been linked with the incidence of PD (Ohlson, et al., 1981). 
Also, a parallel has been drawn between the effects of Hg exposure (or ingestion) and the 
associated effects of PD (Bjorklund, et al., 2018). It has been shown that exposure to Hg results 
in loss of dopamine receptors, tubulin degeneration, axon degeneration and glutathione 
depletion (Bjorklund, et al., 2018). Besides, an increase in glutamate level is seen in persons 
exposed to Hg over a long period as well as tau phosphorylation, mitochondria dysfunction and 
increase in amyloid-β level (which promotes α-synuclein aggregation) (Bjorklund, et al., 2018). 
All these observed effects of Hg exposure have corresponding similarities in symptoms of 
idiopathic cases of PD. 
 
Studies have shown that there is a six-fold frequency of detectable blood Hg levels in persons 
with PD compared with match controls (Dantzig, 2006). Exposure to Hg has a deleterious 
effect and it is implicated as a significant risk factor in the aetiology of PD. Ngim, et al (1989) 
in their epidemiological studies, where they examined the association between body burden 
and mercury level and idiopathic PD, observed an 8-fold increase in the risk of developing PD. 
Occupational exposure is a great source of Hg toxicity and in most industrialised countries, the 
use of dental amalgams has been directly linked with elevated mortality of PD (as well as 
dementia) has been well documented (Bjorklund, et al., 2018). 
 
1.9.7 PD and Other Metals  
Some other metals with neurotoxic effects have been associated with secondary Parkinsonism. 
Although data showing a possible association between PD and other metals are poorly 
represented in literature, some have shown a positive association, such as nickel (Ahmed and 
Santosh, 2010), cadmium (Chen, et al., 2016) and Lead (Chen, et al., 2016) and thallium 
(Galvan-Arzate, et al., 1998). Notable among these are cadmium and lead. Cadmium (Cd) is a 
transition heavy metal with no known biological activity and it is known to be carcinogenic 
(Bjorklund, et al., 2018). It can easily be absorbed through the nasal mucosa or the olfactory 
bulb, thereby, destroying the Blood-Brain Barrier (Wang, et al., 2013).  
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In vitro studies have revealed that Cd can induce oxidative stress, suppresses gene expression, 
and inhibits DNA damage repair and apoptosis. Wang, et al (2013) while investigating the 
neurotoxic effect of cadmium, observed that Cd may interfere with the normal functions of the 
nervous system and that infants and children were more susceptible than adults. Chronic 
exposure to Cd has been linked as a possible aetiological factor of neurodegenerative disease, 
including PD (Okuda, et al.,1997), presenting with symptoms such as headache, olfactory 
dysfunction, slowing of vasomotor functioning, decreased equilibrium and PD-like symptoms 
(Wang, et al.,  2013). 
 
Just like Cd, lead (Pb) is a non-essential heavy metal and a ubiquitously distributed pollutant 
in the ecosystem. The major route of entry into the body is by inhalation and oral ingestion 
(Chen, et al., 2016). Lead exposure has been shown to result in oxidative stress, mitochondria 
dysfunction, and disruption of Ca2+ homeostasis. The principal target of Pb-induced toxicity is 
the nervous system (Chen, et al., 2016). Another naturally occurring trace element that is 
extremely toxic is thallium (Cvjetko, et al., 2010). Exposure to thallium (Tl) interferes with 
several K+-dependent processes because of the similarities in size between K and Tl, as well as 
the univalent nature of both ions. One of the affected processes is the generation of ATP 
(Galvan-Arzate, et al., 1998; Ibrahim, et al., 2006; Eskandari, et al., 2010). At the cellular level, 
elevated levels of Tl have been shown to cause a decrease in ATP production, increase in ROS 
formation, glutathione oxidation and decrease in dopamine levels in the brain (Budtz-
Jorgensen, et al., 2007; Eskandari, et al., 2010). 
 
1.10 Synergistic Toxicity 
The toxicity of metals can be accentuated with combined exposure. Metal synergistic effects 
were seen between metals and PD with combined exposures of iron-Cu, lead-Cu and lead-iron 
when compared to the effects of single metals (Monte, et al., 2002; Bjorklund, et al., 2018; 
Bjorklund, et al., 2018). The synergistic effect of the metal combination is very pronounced 
with Hg. When combined with other metals such as aluminium, manganese, zinc, and 
cadmium. It significantly exacerbates Hg toxicity even at low non-toxic doses (Blanusa, et al., 
2005; Blaurock-Busch, et al., 2012). Similar synergistic effects are seen with metals 
combination with pesticides (Pape-Lindstrom and Lydy, 1997; Singh, et al., 2017; 
Uwizeyimana, et al., 2017).  
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In animal studies designed to investigate the acute effect of low levels of Pb, Hg and Mn 
individually and in combination on the central and peripheral nervous activities, Papp, et al 
(2006) observed a pronounced synergistic effect. Also, Haley (2005) demonstrated accentuated 
metal toxicity arising from its synergistic effect by combining Hg with safe levels of aluminium 
hydroxide or the antibiotic neomycin. This resulted in a significant increase in neuronal 
mortality. Similarly, Zn also exacerbated the toxicity of Hg, by increasing cytotoxicity and the 
inhibition of tubulin (Boyd, 2007; Zahir, et al., 2005). Interestingly, a PD-associated protein 
(DJ-1protein) with protective functions, can bind both Hg and Pb. The genetic variant of DJ-1 
protein does not exert any protective effect on Hg toxicity and therefore increases the risk for 
PD (Migliore and Coppede, 2009; Dias, et al., 2013). 
 
Some epidemiological studies have shown a strong association between pesticide exposure and 
PD (Parron, et al., 2011; Dick, 2006; Gorell, et al., 1998; Freire and Koifman, 2012). Whilst 
this may be true, pesticides and metals promote the aggregation of α-synuclein (a presynaptic 
protein) with neurodegenerative effects. Its aggregation is an important step in the aetiology of 
PD (Uversky, et al., 2001; Uversky, et al., 2002; Uversky, et al., 2010; Rokad, et al., 2017). 
For instance, ions of Cu (II) is efficient in the aggregation of α-synuclein and related 
physiological content without changing the resulting fibrillary construction (Uversky, et al., 
2010; Uversky, et al., 2007).  
 
Binofil, et al (2006), observed that some metals selectively bind to the N & C-terminal of α-
synuclein. For instance, some divalent metals such as Mn and Fe bind with C-terminus of α-
synuclein with low-affinity (non-specific binding interface) whereas Cu, on the other hand, 
interacts at the N-terminal region of α-synuclein at high affinity, being the most potent metal 
in the aggregation of α-synuclein filament assembly (Binofil, et al., 2012). Metals 
synergistically or in combination with other chemicals can have a deleterious effect on the 
physiological functions of the human body. Fe combines with the herbicide paraquat 
synergistically to accelerate the age-related loss of nigral dopaminergic neurons (Peng, et al., 
2007). 
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1.11 Effect of metal exposure on dopaminergic neurons 
The dopaminergic neurons in the substantia nigra have long axons that consist of tubulin 
molecules (Castel, et al., 1991; Lie, et al., 2002). Low doses of Hg inhibit the formation of 
tubulin; whilst other ATP- or GTP-binding proteins are not affected (Vogel, et al., 1985; Leong, 
et al., 2001). There are about 14 sulfhydryl groups (SH-) in tubulin, Hg binds to sulfhydryl 
with greater affinity. In contrast, other metals, such as aluminium, zinc, iron and lead are 
incapable of inhibiting the binding of tubulin to GTP (Pendergrass, et al., 1997; Mutter, et al., 
2004). 
 
Several investigators (Hirsch, et al., 1991; Mann, et al., 1994; He, et al., 1996; Berg, et al., 
1999) have demonstrated, from analysis of brain tissues from PD patients, that there are high 
levels of aluminium, iron, and zinc in the substantia nigra compared to those of match controls. 
Of significant interest is the fact that there is that the accumulation of iron in the substantia 
nigra is twice as much as those of matched controls (Dexter, et al., 1987; Dexter, et al., 1989; 
Youdim, et al., 1993; Sofic, et al., 1998). An elevated proportion of trivalent iron was found in 
Lewy bodies and dopaminergic neurons of the substantia nigra of PD patients.  
 
Unilateral injection of Fe(III) chloride into the substantia nigra, in adult rats, resulted in a 
selective decrease in striatal dopamine (about 95%) as well as impairment of dopamine-related 
behavioural responses, suggesting (that elevated) iron may be implicated in the initiation of the 
loss of dopaminergic neurons in PD (Bharath, et al., 2002; Kaur, et al., 2004; Drechsel and 
Patel, 2008; Tanaka, et al., 1991). Besides, Fe exposure to manganese oxide have been also 
associated with the loss of dopaminergic neurons. In their investigations, (Ulin, et al., 1989; 
Tedroff, et al., 1992; Racette, et al., 2012) reported a reduction of 11C-nomifensine (a potential 
ligand for the evaluation of monoamine re-uptake sites) at the presynaptic dopaminergic 
terminals, within the striatum following subcutaneous injections of manganese oxide. 
 
Exposure to metals with a high affinity for sulfhydryl groups such as Hg, Cd, Cu and Zn also 
leads to a reduction in D2 dopamine receptor sites. (Scheuhammer and Cherian, 1985). 
Scheuhammer and Cherian (1985) in their investigations of the effects of heavy metals cations, 
sulfhydryl reagents and other chemicals agents on striatal D2 dopamine receptors. They 
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demonstrated that low concentrations of Hg were capable of completely abolishing D2 
dopamine receptors; whilst the administration of 3mM of Cu or cadmium only resulted in a 40-
60% reduction in dopamine receptors. 
 
The lethality of Hg mercury is premised on the fact that Hg targets the areas of the brain in 
which its detoxification is impracticable (Rouleau, et al., 1999; Mieiro, et al., 2010; Mieiro, et 
al., 2011; Pereira, et al., 2014). Even at the lowest levels, inorganic mercury results in the 
destruction of intracellular microtubules and the degeneration of axons (Choi, et al., 2011). 
This interesting neurodegenerative cascade is unique to mercury and not reported in metals like 
cadmium, aluminium, lead, or manganese. Hg depletes glutathione (Richardson and Murphy, 
1975; Gstraunthaler, et al., 1983; Graff et al., 1999) and causes the impairment of mitochondrial 
functions (Southard and Nitisewojo, 1973; Lund, et al., 1991; Carocci, et al., 2014). 
 
1.12 Oxidative stress in PD 
In the pathogenesis of PD, a prime cause is an oxidative stress (Jenner, et al., 1992; Ebadi, et 
al., 1996; Zhang, et al., 2000; Jenner, et al., 2003; Hwang, 2013; Tsang, et al., 2009; Dias, et 
al., 2013; Blesa, et al., 2015). Oxidative stress opens a cascade of biochemical and metabolic 
events. It causes mitochondrial dysfunction (Lin and Beal, 2006). There is an upregulation of 
ROS production in PD patient, oxidative stress (Hartley, et al., 1993) and impairment of 
mitochondria functionality (Guo, et al., 2013). The increased level of oxidative stress in PD 
patients mirrors an elevated level of iron levels (Bharath, et al., 2002; Jenner, et al., 2003), 
nucleic acid oxidation (Kikuchi, et al., 2002; Zhang, et al.,1999), and elevated lipid 
peroxidation (Dexter, et al., 1989; Fahn, et al.,1992), as well as low contents of the antioxidant 
glutathione (GSH) in the dopaminergic regions of the brain (Perry, et al., 1982; Perry and 
Wong, 1986; Venkateshappa, et al., 2012).  
 
Elevated levels of nitrated and oxidized proteins are found within the substantia nigra of PD 
patients (Danielson and Andersen, 2008). In vivo studies as well as post-mortem studies reveals 
nigral cells degeneration because of oxidative stress (Hirsch, 1993; Foley and Riederer, 2000). 
Danielson et a (2008) demonstrated that oxidative stress has a significant impact on 
neurodegeneration in animal models of PD. Fe also induces oxidant and oxidative stress to the 
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dopaminergic nigrostriatal system, which underscores an important contribution to the 
pathogenesis of PD (Rauhala, et al., 1998; Lin, et al., 1999). The post-translation of α-synuclein 
and other neuronal proteins could be due to redox metal ions and oxidative stress (Norris, et 
al., 2003; Miotto, et al., 2014). 
 
1.13 Risk Factors  
It has been established that some metals with neurotoxic effects are potent risk factors in the 
aetiology of PD. Specifically, metals with neurotoxic effects have been associated with 
secondary Parkinsonism (Taba, et al., 2017). Heavy metals are significant environmental 
pollutants and their toxicity is of increasing significance for ecological, nutritional and 
environmental reasons (Jaishankar et al., 2014). The global atmospheric, soil and surface water 
concentration of metals have been on the rise (Hope, 1994; Fortoul, et al., 2002). There is an 
increase in metal accumulation in tissue samples (Fortoul, et al., 2002), plants (Jaishankar, et 
al., 2013) and marine life (Nagajyoti, et al., 2010) - at an alarming concern to public health 
practitioners and environmentalist.  
 
There has been great debate as to what constitutes a ‘heavy metal’ and which element should 
be classified as heavy metal (Adal, 2015). Some authors base their definition on atomic weight 
(Tchounwou, et al., 2012), delimiting heavy metal as a group of metals with a specific density 
greater than 4.0g/cm3 or greater than 5.0g/cm3 and which adversely affect the environment and 
living organism (Jarrup, 2003; Castro-Gonzalez, et al., 2008). Some of these metals are very 
useful in maintaining various biochemical and physiological functions in living organisms. 
Commonly found heavy metals in wastewater are arsenic, cadmium, chromium, Cu, lead, 
nickel and zinc- all of which cause great risk to human health and the environment (Lambert, 
et al., 2000) others include manganese, mercury and Vd. 
 
Some of these metals play a crucial biological function in both plants and animals, their unique 
chemical and oxidation-reduction properties confer on them additional benefits that help them 
to maintain homeostasis, transport, compartmentalization and binding to designated cell 
constituents (Jashangar, et al.,  2014). An issue of greater concern is the ability of these metals 
to bind with proteins sites which are not made for them, by displacing original metals from 
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their natural binding sites causing cellular dysfunction. This insidious capacity makes heavy 
metal poisoning of great interest to the toxicologist. Environmental exposure to heavy metal is 
a prime agent associated with cognitive and neurological deficits (Neal, et al., 2012). They play 
a significant role in neurodegeneration because these disorders incorporate different 
pathological conditions, that share similar critical metabolic processes, such as protein 
aggregation and oxidative stress - both of which are associated with the involvement of metal 
ions (Gaeta, et al., 2005).  
 
Gaeta, et al., (2005) identified two key components/ pathways that define the aetiology of 
neurodegeneration. They pointed out that these two key components – extrinsic and intrinsic 
components (among others) are linked to metal ions. They identified the extrinsic component 
which is environment-related as extrinsic neurotoxins. For example, metal and infective 
damage, and the excitotoxicity – which is related to intrinsic neurotoxins, such as metals and 
excitatory amino acids.  
 
The neuroscience community paid little attention to the neurometabolic of metals until about 
two decades ago (Zatta, et al., 2003). In the recent past, the neurobiology of heavy metals is 
now receiving growing interest and has been linked to major neurodegenerative diseases 
including ALS (Trojsi, et al., 2013); PD (Cotzias, et al., 1976, Taylor, et al., 2000) and AD 
(Uversky, et al., 2001; Mates, et al., 2010; Notarachille, et al., 2014). 
 
Vd is one heavy metal that may have laid below the radar of metal biologist, largely because it 
has no known biological function. However, Todorich, et al (2011) observed that Vd disrupts 
iron homeostasis in oligodendrocyte progenitors (OPCs). In their investigation, they posited 
that exposure of gestating rats (at 2nd post-natal week) to Vd produces hypo-myelination with 
a variety of related neurobehavioural phenotypes. The severity of some metal toxicity depends 
on the concentration and the duration of exposure.  
 
Adal (2015) reported a link between chronic exposure to metal dust and pneumoconiosis, 
neuropathies, hepatorenal degeneration and a certain variety of cancers. Whilst the duration of 
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exposure and the concentration of redox-active metal exacerbate the toxicity associated with 
heavy metals, the irreversible nature of some of these metals in biological systems and their 
non-biodegradability make them important environmental hazards. This is largely due to the 
fact that the elimination of metals from the environment is difficult, if not impossible because 
they cannot be decomposed (Jamal, et al., 2013); this makes research into the health 
implications of this heavy metal globally imperative. Trojsi et al (2013) identified 
cyanobacteria, heavy metals and pesticides as potential risk factors associated with the 
aetiologies of ALS. Several scholars have highlighted some notable health impact of some 
heavy metal at the cellular and functional levels, elucidating their physiological and 
biochemical pathways. 
 
1.14 Pathophysiology of Metal Toxicity 
There are several investigators from existing literature that have explored the role of redox-
active metals in cellular dysfunction and homeostatic imbalance. Smith, et al (1994) and Sayre, 
et al (2002) implicated aluminium, lead, mercury, zinc, Cu, and iron in AD pathogenesis. They 
further argued that disruption in the homeostasis of Cu and iron is particularly significant when 
considered against the backdrop of oxidative stress parameters, such as lipid peroxidation and 
the oxidative damage to neurofibrillary tangles (NFT), senile plaques and nucleic acid 
(Nunomora, et al., 1999). Heavy metals bind to oxygen, nitrogen and sulfhydryl groups in 
proteins resulting in the alteration of enzymatic activity. The affinity of metal ions for the 
sulfhydryl group serves as a protective role in heavy metal homeostasis as well. 
 
Marcus, et al (1998), Nunomura, et al (1999), Sayre, et al  (1994), Smith, et al  (1994, 1996, 
and 1997) all emphasised the role of oxidative stress in the aetiology of idiopathic AD. 
However, there is a degree of uncertainty whether the presence of the enhanced oxidative event 
is the cause or the result of the diseases. Busciglio, et al (1995), Nunomura (1999) and Odetti, 
et al (1998) observed that in AD, oxidative stress is a pre-existing condition that subsequently 
leads to neuronal changes associated with the disease process. However, in Down’s syndrome, 
evidence of oxidative stress is found long before neuropathological changes, even in the foetal 
stage. Lovell, et al (1998) found out that multivalent transition metals such as Cu and 
manganese are essential in most biological reactions such as the synthesis of DNA and proteins. 
They also observed that the levels of Cu and iron are increased in senile plaques (SP) and their 
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presence in SP and neurofibrillary tangles induces hydrogen peroxide dependent oxidation. 
This indicates that Cu plays a role in modulating oxidative events, which results in 
neurodegeneration. Some metals, like lead, cadmium and Vd, however, have no known 
biological activity. 
 
Other metals have been implicated in oxidative stress and neurodegeneration. Iron implicated 
in redox transitions consequently generates oxygen free radicals. The cellular damage is 
mitigated by the production of lactoferrin, which protects against severe inflammation. 
Lactoferrin level is increased in patients with neurodegenerative disease (Fillebeen, et al., 
1999). Brown, et al., (1998, 2004) reported that a transmembrane glycoprotein (Prion protein) 
incorporates Cu and has SOD. They suggested that PrP may play a role in protecting cells from 
oxidative damage. The misfolding of this protein is responsible for spongiform 
encephalopathies (Prion disease).  
 
Vd has been shown to cause a sustained decrease in blood glucose levels in insulin-deficient 
rats (Shecter, 1990; Brichard, et al., 1991; Shecter, et al., 1993 and Fantus, et al., 1991). It was 
reported by Zaporowska and Wasilewski (1992) that Vd reduces the deformation of erythrocyte 
and produces peroxidative changes in erythrocytes membrane, leading to haemolyses. Vd has 
also been associated with hepatotoxicity (Youves, et al., 1991a and 1991b), reproductive and 
developmental toxicity (Liobet, et al., 1986) and demyelination (Mustapha, et al., 2014). 
 
1.15 Metalloproteins and functional relevance 
Proteins contain metal-binding sites. These metal-binding sites are responsible for catalyzing 
important biological processes such as photosynthesis, respiration, water oxidation, molecular 
oxygen reduction and nitrogen fixation (Lu, et al.,2009). Most biologically active metals 
possess characteristics that are linked to their chemical properties (Wright, et al., 2007). The 
neurotoxic actions of aluminium, zinc and lead are associated with the induction of oxidative 
stress through their capacity to interact with reactive oxygen species (thus, increasing their 
oxidant activity (Oteiza, et al., 2004). Half of the metals must associate with an enzyme to 
function (Waldron, et al., 2009). These metalloproteins are rich in thiol ligand which allows 
66 
 
high-affinity binding with some heavy metals such as cadmium, Cu, silver, and zinc among 
others (Adal, 2015).  
 
Other proteins involved in both heavy metal transport and excretion through the formation of 
protein-ligand complexes are ferritin, transferrin, albumin, and haemoglobin. Schwarz, et al., 
(2009) in their review highlighted the importance of trace element molybdenum (Mb) as an 
important co-factor in wide varieties of enzymes. They pointed out that Mb is essential in most 
organisms and forms the centre of a large valence of an enzyme, such as nitrogenase, nitrate 
reductase, sulphite oxidase and xanthine oxidoreductase; two scaffolds hold Mb in situ- the Fe-
Mb co-factor and protein-based co-factor. 
 
1.16 Experimental Models of PD 
There are several animal PD models used in research, however, the most popular are the 
pharmacological and the genetic models. The pharmacological animal models include the           
6-hydroxydopamine (6-OHDA), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP), 
rotenone, and paraquat. The genetic models include those with mutations in the α–synuclein, 
PINK1 (based on loss of function), Parkin, or LRRK2 genes (Smith, et al., 2005; Nuytemans, 
et al., 2010). The 6-OHDA animal model was the first model of PD to be associated with 
dopaminergic neuronal death within the SNpc. This model is generated by injecting the toxin 
directly into the SNpc, medial forebrain bundle or striatum (Blandini, et al., 2008; Ren, et al., 
2013). The MPTP animal model uses MPTP, which is a highly lipophilic molecule that 
readily crosses the blood-brain barrier, this leads to a selective and irreversible loss of 
dopaminergic neurons in the SN in both non-human primates (Schober, 2004; Meredith and 
Rademacher, 2011) and rodents (Betarbet, et al., 2002; Blesa, et al., 2012).  
 
Despite the popularity of these models, the fruit fly (Drosophila melanogaster), remains one of 
the most used model organisms for biomedical research for several reasons. The low cost, rapid 
generation time, and excellent genetic tools have made the Drosophila melanogaster (DM) an 
indispensable model for basic research. The fly genome has been completely sequenced and 
annotated, encoding about 14,000 genes on four chromosomes, making it an attractive research 
model (Pandey and Nichols, 2011). Besides, 75% of disease-related genes in humans have 
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functional orthologs in the fly (Reiter, et al., 2001; Lloyd and Taylor, 2010). D. melanogaster 
has many fundamental cellular processes, genes and signalling pathways in common with 
humans, and most genes linked to familial PD have at least one fly homolog (Muñez-Soriano, 
2011). Furthermore, fruit flies can perform complex motor behaviours, such as walking and 
climbing (Muñez-Soriano, 2011). 
1.17 The Life Cycle of Drosophila melanogaster  
 
 
Figure 1.5: Drosophila melanogaster reproductive life cycle 
 
D. melanogaster has a reproductive life cycle of 10 to 12 days at 25°C. Newly laid eggs hatch 
into a larva after 1 day. The larva stage lasts about 4 days and in the last 2 days of this stage, 
it crawls out of the food substrate and develops into a pupa. After 5 to 7 days of pupation, the 
adult fly emerges from its pupal case (eclosion) (Nichols, 2006). The average lifespan of 
wild-type (WT) D. melanogaster ranges from about 39 to 86 days, depending amongst other 
68 
 
factors on strain and gender (Sanz, 2010). For the males from the strain used in this study as 
WT, Dahomey, the average lifespan was reported to be 39 days (Sanz, 2010).  
 
In the Drosophila melanogaster, the PINK1 gene is located on the X chromosome, which 
means that all males are hemizygous, whereas females could theoretically be heterozygous or 
homozygous. However, the w+ flies carried a balancer gene: FM7.GFP. This gene functions 
as a marker, as a suppressor of genetic cross-over and carries a recessive female sterile 
mutation (Greenspan, 2004). Thus, females homozygous for the balancer gene are not fertile. 
This trait is introduced to make sure that the w- PINK1 gene remains expressed in future 
generations and is not taken over by the balancer gene. The marker makes it possible to 
identify flies carrying the balancer gene, as it results in a bar phenotype in males and females 
(Greenspan, 2004). Male flies carrying the PINK1 gene have a lack of eye colour, resulting in 
white eyes. These males are sterile and only produce progeny to a limited extent. 
 
1.18 Why Drosophila Fly model 
A compelling interest in DM as a research model may be attributed to the very rapid life cycle. 
A single mating pair can produce hundreds of genetically identical offspring within 10 to 12 
days at 25oC, in contrast to the rodent models which produce a handful offspring every 3 to 4 
months (Pandey and Nichols, 2011). The fruit fly is a model organism, defined by four 
developmental stages (the egg, the larva, the pupa, and the adult stages) that are unique with 
specific advantages (Pandey and Nichols, 2011). The embryo, for instance, finds novel use in 
fundamental developmental studies that examine pattern formation, cell fate determination, 
organogenesis and neuronal development, and axon pathfinder.  
 
The larva, especially the third instar larva, is commonly used to study developmental and 
physiological processes, as well as simple behaviour (e.g. foraging). At the larva stage, the 
future adult is fully represented as the imaginal disc (made up of undifferentiated epithelium). 
It undergoes extensive morphological changes from the late third instar (larva) stage through 
the pupal phase to the final adult structure (Pandey and Nichols, 2011). Thus, the pupa stage 
provides a good model to investigate certain developmental processes. In its complexity, DM 
has mirror structures that perform the equivalent functions of the mammalian heart, lung, 
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kidney, gut, and reproductive tract. Take the brain of the adult DM, for instance, over 100,000 
neurons form discrete circuits and neuropil that mediate complex behaviours (such as circadian 
rhythms, sleep, learning and memory, courtship, feeding and aggression, grooming and flight 
navigation).  
Interestingly, the observed response of flies to CNS acting drugs is akin to that observed in 
mammalian systems (McClung and Hirsh, 1998; Moore, et al., 1998; Bainton, et al., 2000; 
Nichols, et al., 2002; Rothenfluh and Heberlein, 2002; Satta, et al., 2003; Wolf and Heberlein, 
2003; Andretic, et al. ,2008). Although there are some differences between flies and humans, 
the extent of conserved biology and physiology positions DM as an invaluable tool in the drug 
discovery process.  
 
Genetic PD models have been established in D. melanogaster based on mutations found in α-
synuclein, Parkin, PINK1, DJ-1 and LRRK2 genes (Muñez-Soriano, 2011). In our current 
investigation, a D. melanogaster model based on mutations in PINK1 is used. The D. 
melanogaster PINK1 gene encodes a protein containing the same domains as its human 
equivalent. D. melanogaster PINK1 models have been generated by transposon-mediated 
mutagenesis and RNAi. PINK1 mutants show male sterility, muscle degeneration, 
hypersensitivity to oxidative stress, mitochondrial defects, reduced lifespan, and dopamine 
neuronal degeneration accompanied by locomotor defects (Muñez-Soriano, 2011). 
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1.19  The genes associated with PD and the approximate frequencies 
 
Monogenic mutation in specific genes can cause either autosomal recessive juvenile 
Parkinsonism (AR-JP) or autosomal dominant Parkinsonism (Nuytemans, et al., 2010). 
Mutations in six genes have been linked to either of these types of Parkinsonism. Four 
mutations for the AR-JP; PARKIN, DJ-1, phosphatase, and Tensin homolog (PTEN)-induced 
kinase 1 (PINK1) and P-type ATPase (ATP13A2) have been delineated. For the autosomal 
dominant Parkinsonism, two mutations have been identified, i.e. α-SYNUCLEIN -a non-A4 
component of amyloid precursor (SNAC) and leucine repeat-rich kinase 2 (LRRK2) 
(Nuytemans, et al., 2010). It is interesting to note that PARKIN accounts for well over 50% 
of patients with AR-JP and some of these reported pathogenic mutations include missense 
and nonsense mutations, deletions, rearrangements, and duplications (Bonilla-Ramirez, et al., 
2013). Bonilla-Ramirez, et al (2013) reported that the PARKIN gene which is located on 
chromosomes 6 (6q25.2-q27), contains 12 exons and encodes a 465 amino acid protein 
known as Parkin. Parkin is affiliated with the E3 ubiquitin ligase subset of the RBR protein 
family involved in protease degradation (Rankin, et al., 2011).  
In the past two decades, concerted efforts have been made to unravel the genes associated 
with PD (Hatano et al., 2009). About 80% of cases of PD are sporadic or idiopathic type. 
Studies has unveiled the loci of genes responsible in patients with familial PD. Several PARK 
genes have been directly attributed to familial PD or as risk actors. Table 1.6 provides an 
overview of the genes/genetic factors as well as the chromosomal locations of the affected 
genes.  
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Table 1.6: The genes and genetic factors associated with PD and the approximate 
frequencies 
Symbols/ 
Inheritance 
Gene Locus Frequen
cies 
/onset  
Functions  References 
*PARK1/ 
PARK4 
Dominant  
α-
Synuclei
n 
(SNCA).  
4q21.3-
q22 
Around 
40 
Membrane 
trafficking 
Romo-Gutierrez et al., (2015). 
Singleton et al., (2003) 
*PARK2 
 
Recessive 
Parkin 6q25.2-
6q27 
<40 UPS, E3-ligase Lucking et al., (2000) 
Poole et al., (2008) 
Romo- 
Gutierrez et al., (2015) 
PARK3 
Dominant  
Unknown 2p13 35-89   Hatano et al., 2009 
PARK5 UCHL1 4p13 ~50 UPS, 
Ubiquitin, 
Hydrolase 
Hatano et al., 2009 
*PARK6 PINK1  1p36.12 1-8%  
/32 ±7 
Mitochondria, 
kinase 
Kompoliti & Verhagen, 2010 
*PARK7 
Recessive  
DJ-1 
 
1p36 In 1-2%/ 
27-40 
Oxidative 
stress  
Romo-Gutierrez et al., (2015). 
Hatano et al., 2009 
*PARK8 
Dominant  
LRRK-2 12q12 ~65 Membrane 
trafficking, 
kinase 
Yescas et al., (2010) 
Thaler et al., (2012) 
Romo-Gutierrez et al., (2015) 
*PARK9 
Recessive  
ATP13A
2 
1p36 11-16 Lysosome? 
Autophagy? 
Hatano et al., 2009 
Park et al., (2011) 
PARK10 
Dominant  
Unknown 1p32 65.8  Hatano et al., 2009 
Grünewald 
et al., (2012) 
PARK11 
Dominant  
GIGYF2 2q36-27 Late IGF-1 signaling Ramirez et al., (2006) 
Hatano et al., 2009 
PARK12 
X-linked 
Unknown Xq21–
q25 
Late  Hatano et al., 2009 
 
PARK13 
Dominant  
HTRA2/ 
OMI 
2p13.1 Late  Mitochondria, 
Protease 
Hampshire et al., (2001).  
 
*PARK14 
Recessive  
PLA2G6  22q13.1 >1% / 
20-25 
Phospholipase 
enzyme  
Paisan-Ruiz et al., (2009). 
Sina et al., (2009).  
Lu et al., (2012).  
Tomiyama et al., 2011. 
Gui, et al.,(2012) 
PARK15 
Recessive  
FBXO7 22q11.2
-qter 
10-19 UPS, E3-ligase Hatano et al., 2009 
PARK16 
Risk factor 
Unknown  1q32 - - Klein and Westenberger (2012) 
PARK17 
Dominant 
VPS35 16q11.2 - - Klein and Westenberger (2012) 
PARK18 EIF4G1 3q27.1   Klein and Westenberger (2012) 
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Dominant 
*APOE4 
Risk  
ε2 and 4  19q13.2 11.2 % of 
APOE ε2 
carriers  
- Pankratz et al., 2006.  
Huan et al., (2004); Federoff et 
al., (2012) 
*GBA 
Dominant 
/risk 
GBA 
gene 
1q22  Storage of 
lysosomal 
glycolipid 
Klein and Westenberger (2012) 
COMT Catechol-
O-
methyltra
nsferase  
- - Monoamine 
degradation 
enzyme 
Klein and Westenberger (2012) 
*MAPT 
Risk  
Tau 17q21.1 - - Lill et al (2012) 
*Genetic factors associated with dementia in PD 
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1.20 Research Focus and Experimental Model 
The effects of pharmacological doses of heavy metals on neuronal cells have barely been 
studied. All organ systems are affected by heavy metal exposure. The most affected include 
the CNS, PNS, GI, renal, haematopoietic, and cardiovascular organ systems (Adal, 2015). The 
organ system affected, and the severity of the toxicity varies with the heavy metal involved, 
chronicity, and extent of exposure, as well as the age of the individual. 
 
For this research, I will be considering three redox-active heavy metals: iron, Cu and Vd. 
Although the toxicological effects of these heavy metals have been well described in some 
detail, possible sub-toxic pharmacological, cell biological or neuroprotective effects following 
preconditioning, have not been investigated.  
 
The PD pathology is characterised by distinct types of cellular defects: abnormal protein 
aggregation, oxidative damage that relates to mitochondrial dysfunction and a selective loss of 
dopaminergic neurons in the substantia nigra pars compacta (SNpc). This research was 
designed to specifically investigate the possible effects of these heavy metals on these cellular 
defects. For in vitro studies, CAD (Cath.-a-differentiated) cell lines will be used. The CAD 
cells are variant of a CNS catecholaminergic cell line. It exhibits biochemical and 
morphological characteristics of primary monoamine neurons and provides a useful tool for 
studying PD. Importantly, it is a good model to study undifferentiated (immature) and 
undifferentiated (mature) neuronal neurons.  
 
Additionally, CAD cells express enzymatically active tyrosine hydroxylase and accumulate L-
DOPA, a precursor of dopamine. Ultra-structurally, processes from differentiated CAD cells 
have abundant parallel microtubules and intermediate filaments, and bear varicosities that 
contain both large dense-core vesicles/granules (120–160 nm) and smaller clear vesicles (60–
80 nm). Thus, makes it suitable to use differentiation and the effects of environmental heavy 
metals on the different stages of development, in terms of oxidative and ER stress, and 
functional properties, pertinent to PD pathology. We further explored the interplay between Vd 
and iron in an in vivo model (WT and PINK1 mutant Drosophila melanogaster).  
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This model is universally used for relevant scientific investigations. Its low cost has a rapid 
generation time and is a powerful genetic tool for research work into ageing-related diseases. 
The mutant, PINK1 is based on loss of function of PINK 1 gene. This mutant is related to early-
onset familial PD; it was reported that this gene is involved in mitochondrial fusion or fission 
dynamics, electron transport chain function and quality control, although the exact mechanism 
and interconnection between them are not fully understood (Pickrell and Youle, 2015). 
Dopamine degeneration seen in this PINK-1 model is accompanied with locomotive deficits 
(Park, et al.,2006) and the drosophila PINK1 is predicted to have over 60% similarity with 
human PINK1 and shares 43% amino acid identity with human (Muñoz Soriano and Paricio, 
2011). In the brains of PD patients, the SNpc has also been found to have higher levels of iron 
than age-matched controls and elevated iron has been associated with mitochondrial 
dysfunction. Iron elevation in the SNpc might contribute to the oxidative and ER-induced 
damage observed in PD brains. We explored the relationship/interplay between Cu, iron and 
Vd toxicity to elucidate the links between environmental heavy metal stressors and PD disease. 
 
1.21  Outline and Aims of the thesis 
Heavy metals can be divided into two classes: first, those required by living organisms as 
essential micronutrients, such as calcium, manganese, molybdenum, zinc, Cu, and iron.  The 
second, those devoid of any clear biological function, thus, potentially toxic even at a very low 
concentration. These include cadmium, chromium, mercury, lead and Vd (Marchetti, et al., 
2005). Most of these latter heavy metals are released into the environment as a consequence of 
historical handcraft and industrial processes, and specialised cells, such as neurons, lack the 
intrinsic ability to distinguish between physiological and toxicological elements. Whilst Cu 
and iron can be placed in the first of these categories, as essential trace metal, Vd, on the other 
hand, falls into the class of metals with no known physiological function in humans. Clarkson 
(1993), in his review of molecular and ionic reviews of toxic metals, reported that these toxic 
elements can interact with specific sites on membrane transport protein and enzymes; he called 
this mechanism “ionic mimicry”. However, some micronutrient heavy metals ions that are 
involved in key steps of neurotransmission, can interfere in brain function, and cause different 
neurological and neurodegenerative disease.  
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1.22 Central Hypothesis 
Sub - toxic doses of heavy metals differentially modulate downstream signalling, 
cytoarchitecture, and neuroplastic events, through mitochondrial oxidative stress pathways in 
healthy and PD neurons. 
 
1.23 Aims 
The overall aims of this thesis were to establish the effects of selected endogenous 
micronutrients (Cu, iron) and exogenous environmental (Vd) heavy metals on viability, 
neuronal oxidative status, function, development/cell architecture, in an in vitro and in vivo 
model of PD. Furthermore, we will explore the mechanism by which these pharmacological 
(sub-toxic) and cellular defects are accomplished, and finally how iron manipulation can 
protect against these deleterious effects. 
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Chapter 2:  General Methods and Materials 
 
2.1.1 Methods 
 
2.1.2 CAD cell 
For the cell culture experiments, Cath. A-differentiated (CAD) cells were used. CAD cell is a 
variant of a central nervous system (CNS) catecholaminergic cell line. Originally, this was 
derived from a brain tumour in a transgenic mouse carrying the wild-type SV40T antigen under 
transcriptional control of rat tyrosine hydroxylase promoter (Qi et al.,  1997). 
CAD cells do not have the immortalising oncogene but express neurone specific proteins as 
well as synaptic vesicles proteins. They are good models to investigate the effects of heavy 
metals on neuronal cell architecture for several reasons. First, they exhibit biochemical and 
morphological characteristics of primary neurons. They express enzymatically active tyrosine 
hydroxylase and accumulate DOPA- a precursor of dopamine, and, reversible morphological 
differentiation can be initiated.  Neuronal cell differentiation can be initiated by the removal of 
serum from the media (DMEM). In serum-free media, cell proliferation ceases and cell 
differentiation commences which becomes very visible from Day 3 and extended long 
processes become established by Day 6.  
 
2.1.3 CAD cell culture 
Cath.-a-differentiated (CAD) cultures and experiments were performed in CL1 facilities under 
sterile conditions. CAD cells were grown at 37°C and in 5% CO2 on 75 cm2 tissue culture 
flasks (Sarstedt, Newton, NC) in Dulbecco's modified Eagles' medium DMEM⁄F-12 Media - 
GlutaMAX™-I (GIBCO, Grand Island, NY), supplemented with 10% foetal bovine serum. 
(FBS; Sigma, St. Louis, MO) Cells were passaged every 3-4 days at a 1:4 dilution.  
 
2.1.4 CAD cell line passaging  
Original media from the T75 flask were decanted, then  10 ml complete media were then added 
to the flasks to dislodge the cells. These were then transferred into a sterile a 15ml sterile falcon 
tube and centrifuged at 1000 rpm for 5 mins. The supernatant was then decanted and 5 ml 
complete medium added to resuspend the pellet. The cells were divided 1:3-4 into 75 cm2 
flasks, with 20 ml total medium in each flask. 
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2.2 Cryopreservation and Storage of CAD cell lines 
Sub-confluent cultures (70-80%) were dislodged by gentle pipetting, and then transferred to a 
15 ml falcon tube and centrifuged at 200xg for 5 mins. at 4 ºC. The pellet was re-suspended in 
DMEM⁄F-12 Media - GlutaMAX™-I supplemented with 10% FBS and 10% DMSO. The cell 
suspension was immediately divided into aliquots of 2ml in cryogenic vials which were stored 
at –80 ºC for 24 hours and then transferred to liquid nitrogen the next day for storage. 
 
2.2.1.1 Resuscitation of Frozen CAD cell lines 
A cryogenic vial of cells from liquid nitrogen storage is collected wearing appropriate personal 
protective equipment. The vial was left to stand for about one minute (at room temperature) for 
it to warm up and then quickly transferred to a 37°C water bath, making sure the vial is not 
completely submerged. It was ensured that the water level did not exceed the thread and lid of 
the vial to prevent contamination. The cryovial was gently swirled in the water bath to enhance 
homogenous thawing of the frozen cell culture. With the content of the cryovial nearly 
completely thawed, the cryovial was sterilised with 70% (v/v) EtOH.  
 
The ampoule was then wiped with a tissue soaked in 70% alcohol before opening. The whole 
content of the ampoule is then pipetted into a 15 ml sterile falcon tube. The pre-warmed 
medium was added to attain a total volume of 10 ml and the tube then centrifuged at 1000 rpm 
for 5 min. The supernatant was removed, and the pellet was re-suspended in DMEM⁄F-12 
media - GlutaMAX™-I supplemented with 10% FBS. Using a 2 ml serological pipette, in the 
tissue culture flow hood, the content of the cryovial was pipetted into the pre-warmed 75 cm2 
culture flask. The flask was placed in the 37°C CO2 incubator. 
 
 
2.2.2 MTT cell proliferation assay 
50 µL Phosphate Buffered Saline (PBS) (136.9 mM 2.68 mM KCl, 4.3 mM Na2HP04, 1.4 mM 
KH2P04, pH 7.4) containing 5 mg/ ml MTT was added to the cultures and incubated at 37°C 
and in 5% CO2 for  2.5 hours. Then the MTT- containing medium was removed, the surface 
of the wells was rinsed with 300 µl PBS before the application of 250 µL isopropanol. After 
the purple crystals had dissolved, the optical density of 100 µL sample was 
spectrophotometrically read at 595 nm. (Thermo Lab systems Multiskan Ascent, V1.3). 
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2.2.3 Lactic dehydrogenase (LDH) release assay 
 
2.2.3.1 CytoTox 96 non-radioactive assay (Promega, UK) 
CytoTox 96 is a non-radioactive colourimetric cytotoxicity assay. It is used to quantify lactate 
dehydrogenase (LDH); which is a stable cytosolic enzyme that is released during cell lysis 
(necrosis). The supernatant, which contained the LDH was retained and used for LDH assays.  
Before the assay, the samples were diluted with PBS (1:5). 50uL of each sample were 
transferred into each well of the assay plate (in triplicates) and 50uL of substrate mix was added 
to each sample and incubated for 30mins on the bench at room temperature- and protected from 
light. After 30 mins., 30uL of Stop Solution was added to each well and the absorbance was 
measured at 490nm on a Multiscan Ascent Plate Reader, Version 2.6. 
  
2.2.4 Calcium imaging 
Calcium ions play an integral role in neuronal function. They are intracellular signals that can 
elicit such responses as altered gene expression and neurotransmitter release from synaptic 
vesicles. Within the cell, calcium concentration is highly dynamic due to the presence of 
pumps that selectively transport these ions in response to a variety of signals. Calcium 
imaging takes advantage of intracellular calcium flux to directly visualize calcium signalling 
in living neurons.  
 
In this investigation, cultured CAD cells were probed with the molecular dye; Calcium-
Green-1 AM (Invitrogen) as specified in the manufacturer manual (ref). Calcium Green is 
used to investigate how intracellular calcium fluctuates in relation to neuronal activity. A 
2mM stock of the Calcium-Green probe was prepared in DMSO D-8779 500Ml, lot 
100K3729 by Sigma). This was stored at -20ºC. On the day of the imaging experiments, the 
probe stock was brought to room temperature and then diluted in HEPES physiological buffer 
(150mM NaCl, 1mM MgCl2, 10mM HEPES, 2mM CaCl2, 5mM KCl) to a 1μM solution.  
 
The cells were plated in flat bottom µ-dishes, (brand: 60 µ-Dish, 35mm, high glass flat 
bottom-81158 Ibidi GmbH). The cells were washed with (once) 1mL of physiological buffer 
and incubated for 40 mins. in 1mL of the probe solution. After the incubation period, the cells 
were washed again with the HEPES physiological buffer and left in the buffer until the start 
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of the imaging experiments. All the drugs applied to the clonal cells during the experiments 
were dissolved in the HEPES physiological buffer as stock solutions 10 times more 
concentrated than the final desired concentration for the experiments.  
 
To evaluate the effects of Cu (at a final concentration of 40μM) on cellular calcium fluxes, 
baselines were taken for around 5 seconds and then Cu was injected into the dish. Careful 
pipetting was ensured by injecting against the dish wall to avoid causing fluid turbulence, 
thereby compromising the images. The cells were imaged in the presence of Cu (10 & 40µM) 
and potassium chloride (KCl). The incubation period for each treatment was for the periods of 
250 cycles (0.63s each) before the application of the same volume of the depolarising buffer 
(500mM of KCl in HEPES physiological buffer, giving a final concentration of 49.6mM) and 
then imaged for another period of 250 cycles. KCl, which caused depolarization of the neurons 
due to a rise in the intracellular calcium concentration, serve as good positive control. All the 
solutions were stored at 37ºC to avoid any stress on the cells during the sample preparation and 
the imaging experiment. 
 
For the imaging, the Zeiss LSM 850 with Airyscan microscope was used. The laser used for 
imaging was set at 514nM:1.1% (Ch2GaAsp:524-620). The spectrum window was set between 
24620 and a pinhole of 49um was used. A size 63 oil lens with an LA (lens aperture) of 1.4 
was used to capture each image and the time between each frame (time series) was set at zero. 
The duration for one frame was 633.02ms. To extract the figures and fluorescence intensities, 
the Zeiss software was used. Cells bodies were isolated by the selection of their corresponding 
areas and graphs of fluorescence intensity divided by the corresponding area versus time (in 
imaging cycles) were plotted in the software. The reported figures correspond to isolated cells 
with the strongest basal signals, gathered from replicates. 
 
2.2.5 Cell differentiation  
To differentiate CAD cells, the growth media (with 10% FBS) in which the cells had been 
plated was removed and replaced with serum-free DMEM Nutrient Mixture F-12. After 
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replacement by serum-free media, the cells were returned to the incubator and left for six days 
to differentiate.  
   
2.2.6 Cell Lysate Preparation  
For different experiments, protein lysates were required. To prepare the lysates, cells were 
plated on plates or flasks. Before detaching the cells, they were rinsed with cold phosphate-
buffered saline (PBS) -to get rid of the media. The flask, with new fresh PBS, was placed on 
an iced bucket for some mins. Afterwards, the cells were detached from the plate or the flask 
and transferred into a 15ml falcon tube which was centrifuged for 5 mins. at 1000 rpm at RT. 
After centrifuging, the supernatant was discarded, and the cell pellet was resuspended in cold 
PBS, transferred to Eppendorf tubes, and immediately stored on ice. In the next step, samples 
(in Eppendorf) were centrifuged for 5 mins. at 1000 rpm and 4°C and the supernatant was 
discarded afterwards. Cell pellets were transferred into a tissue grinder and grounded with 1ml 
of PBS. Subsequently, the samples were transferred into an Eppendorf tube and stored at -
20°C. 
 
2.2.7 Western Blot 
 
2.2.8 Gel Casting  
To cast the gels for a sodium-dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE), the Hoefer® Dual Gel Caster (see Table X) was used. This consists of a glass plate, 
ceramic tile, spacers, and caster. The glass plate was placed on a ceramic tile with the T-shaped 
spacers placed between the glass and the tile on each side to ensure a gap of 1 mm between the 
glass and ceramic tile. Glass and tile were fixed unto the Hoefer® Dual Gel Caster and checked 
for leakages by filling the gap with deionized water (dH2O). When no dH2O exited the system, 
the dH2O was discarded and replaced by the prepared running gel (Table 2). The percentage of 
acrylamide used was responsible for the pore size of the gel and determined the time proteins 
take to run through the gel.  
 
For all the experiments, a 10% SDS gels were made. The gap between the glass and the ceramic 
tile was filled up to approximately ¾ with running gel. 1 – 2 ml saturated butanol to enhance 
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an even gel surface and to dispose of possible air bubbles. After 20 – 30 mins. the gel was 
polymerised, and the stacking gel was prepared. The stacking gel contains a smaller percentage 
of acrylamide. This part of the gel was not used to separate the proteins but to ensure that all 
proteins loaded enter the running gel at the same time.  
 
Before the stacking gel could be placed on top of the running gel, the butyric acid was 
discarded. Once the stacking gel was poured on top of the running gel, the T-shaped comb was 
positioned in the stacking gel creating 10 wells for the sample loading carried out later. The 
stacking gel polymerised within 20 mins. Prepared gels may be used afterwards or stored o/n 
in TBS soaked paper towels- this enhances polymerisation. Gels that were stored at +4°C o/n 
were unwrapped and placed in the Hoefer® Mini Vertical Protein Electrophoresis Unit and 
loaded with the samples. 
 
2.2.9 Sample Preparation  
To investigate specific protein abundance, cell samples generated as described (in 2.2.9) were 
thawed and 10 µl of each sample were transferred to a new sample tube. 10 µl sample was 
mixed 1:1 with Laemmle sample buffer Samples were prepared either in reducing (R) or non-
reducing (NR) conditions. As for reducing agent 0.1 M DTT (dithiothreitol, Table 1) was 
diluted 1:5 in the sample. Samples were then mixed and heated in a 95°C hot water bath for 5 
mins. before being spun down on a table-top centrifuge. 
  
2.2.9.1 SDS-PAGE  
The SDS-PAGE was used to separate proteins by their molecular mass. Therefore, a total 
volume of 10 µl of each sample prepared as described (in 2.210.2) was loaded into one well in 
the stacking gel (see table 2.2). Due to the Laemmle sample buffer,  all proteins are negatively 
charged and run from the cathode to the anode through the gel when connected to power. The 
running gel containing 10 % acrylamide (See Table 2.2)  forms a grid forming pores that small 
proteins can easily pass through but make it difficult for bigger proteins to run through. The 
gel was run at 10mA for 15 mins. to help the samples to settle in the stacking gel before the 
current was increased to 15mA (but the double current for 2 gels) and the gel was run for 
another 1-1.5 hours until the sample buffer (See Table2.2) got to the bottom end of the gel. As 
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a scale for protein size, a standardised marker (HyperPAGE,) was run on every gel next to the 
samples. 
  
2.2.9.2 Blotting 
After the SDS-PAGE, proteins were blotted on a nitrocellulose membrane using electric 
current. For the protein transport from the gel unto the membrane, the membrane was pre-
incubated in transfer buffer. Transfers were done on a lockable cassette. The cages were filled 
in the following order: sponge, two filter papers, nitrocellulose membrane, gel, two filter 
papers, and sponge. All materials used were soaked in transfer buffer (See Table 2.2) for at 
least 30 mins. before transfer - to ensure that neither the gel nor the membrane was running 
dry. After the cages were locked, they were placed in a Hoefer® Mighty Small Transfer Tank 
filled with transfer buffer with the cathode facing the side of the gel and the anode facing the 
nitrocellulose membrane. The transfer was performed at 50 V and >300 mA enabling the 
negatively charged proteins to travel towards the anode and therefore entering the membrane 
when exiting the gel. Two cooling units were placed on the sides of the tank to prevent 
temperature increases due to the electricity. The transfer was due 2.5 hours later. 
 
2.2.10 Analysis of metal content in CAD cells 
CAD cells were passaged and seeded as previously described (Sections 2.1.3 and 2.1.4) into 
two 75cm3 flasks. After 24 hours the process of differentiation was initiated as previously 
described (See Section  2.2.5) and the undifferentiated cells were left to proliferate. After 100% 
confluency was attained, the undifferentiated cells were rinsed with cold PBS and detached. 
After detaching, the falcon tubes were centrifuged for 5 mins. (at 1500 rpm) and transferred 
into  1.5ml Eppendorf tubes, centrifuged again and stored at -20oC for ICP-MS analysis for 
metal contents. Similarly, the differentiated (6 days DIV) cells were detached and stored at -
20oC for ICP-MS. 
 
2.2.10.1 Sample Preparation 
1.5ml of Nitric acid (65% HNO3) was added to each thawed cell pellets and vortexed. The 
cells were left for 24 hours to be digested in the fume hood, and vortexed again.  1.2ml of the 
digested sample was removed and dispensed into fresh Eppendorf tubes and centrifuged (5’, 
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@14,000rpm). 500uL of the digest was then diluted with 4.5ml 2.5% HNO3. 1ml of the 
clarified sample was decanted into a 15ml falcon tube. The clarified sample was diluted 1/10 
(2% nitric acid). The analysis was carried out with Ag as an internal standard (Ag 100 ppb) 
which was added to the samples and standard curve. ICP-MS analysis was done in duplicates. 
  
Standard solutions of known metal concentration were analysed before and after the samples 
(“front standard curve” and “back standard curve”) and these were used to define limits for 
quantitation. The final working range was noted and used to quantify the metal content. 
  
2.2.11 Immunofluorescence  
Immunofluorescence (IF) assay was performed to establish the effect of Vd on ER stress, PDI 
expression and neuronal differentiation. CAD cells were plated on coverslips (18mm), which 
were placed in 6-well plates. 2ml of CAD cells suspended in FBS-supplemented in DMEM/F-
12 media was added to a 6cm cell culture dish (TPP© Tissue Culture Dishes, Sigma, Z707678), 
with additional 2ml of fresh media; to give a 1:1 dilution of cells. These were left for 24 hours 
to attach to the coverslips and differentiated as described in 2.2.5. For chronic studies, cells 
were spiked with Vd (10µM or 100µM), one-hour post differentiation and left on SFM for 6 
days.  
 
For acute studies, cells could differentiate (6 days DIV) and spike with Vd (10µM or 100µM) 
and left for 24 hours. The media was removed in preparation for antibody application and the 
cells were washed twice in cold PBS supplemented with 1mM calcium and 0.5mM magnesium 
(PBS++). Each wash was left for 5 mins. After washing, the cells were fixed with 4% 
paraformaldehyde (PFA) to preserve the cell’s structure and to preserve cell structure and to 
prevent decay- this is made possible by PFA enhancing the formation of covalent bonds 
between proteins. The cells were incubated in PFA for 1mins. at RT. Subsequently, the PFA 
was removed and the cells were washed as previously described.  
 
To eliminate unspecific antibody binding to free aldehyde groups in the samples- “quenching” 
was necessary. Cells were incubated in 50mM ammonium chloride (NH4Cl) in PBS
++ for 15 
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mins. at RT. NH4Cl quenches free aldehyde groups and allowing a better signal contrast. 
Following this, NH4Cl was discarded and the cells were washed again in PBS
++ three times for 
5 mins. in cold PBS++. 0.2% Bovine serum (BSA) in PBS++ was used to block unspecific 
binding sites. Cells were incubated in BSA two times for 5 mins. at RT. The coverslip was 
taken out of the blocking solution and placed face-down on the drop of antibody solution. 
Coverslips with control cells were placed on one drop of 0.2% BSA in PBS++. Cells were 
incubated in antibody solution for 2 hours (for MAP2) and 1 hour (for PDI) at RT and then 
washed trice in cold PBS ++ for 5 mins. between each wash. Secondary antibodies (See Table 
2.5) were applied in the same way as described for the primary antibodies and incubated for 25 
mins.  
 
Due to the light-sensitive nature of the secondary antibody, Samples were covered with foil to 
prevent fluorophore-exhaustion. Excessive antibodies were washed off with cold PBS two 
times for 5 minutes. For nucleus-localisation, DNA was stained with DAPI diluted 1:1000 in 
PBS ++ and applied as previously described for antibodies. DAPI intercalates into the DNA and 
emits fluorescent light when excited with light in the ultraviolet range. After 5 minutes. of 
incubation at RT, coverslips were mounted on microscopy slides using mounting medium by 
Vectashield® (See Table 2.2) as mounting medium; the cell-coated side of the coverslip was 
placed face down. The edges of the coverslips were sealed with nail polish.  
 
Immunofluorescent pictures were taken by the confocal ZEISS ApoTome Microscope. The 
secondary antibodies tagged with Alexa-fluorophore-594 gave a signal with a wavelength of 
594 nm when excited with a wavelength of approximately 570 nm. Immunofluorescent images 
of DAPI and Alexafluorophore-594 were taken separately and merged using the ZEISS 
ApoTome software 
 
2.2.12 Drosophila melanogaster stocks and culture conditions. 
Drosophila melanogaster PINK1 (w- PINK1B9/FM7.GFPw+) mutant and WT (WT) were used 
for this experiment. Flies were kept in an incubator with a 12-hour day-night cycle at 25oC. 
Fly food was prepared by mixing 15.025g of instant medium (Applied Scientific Jazz-Mix 
Drosophila Food) with 46ml of deionized water (formula with this food: water ratio was 
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found to have the best consistency) per bottle; 250mL. Following this, each bottle was 
slightly shaken to ensure even distribution of water. Each bottle was plugged with a foam 
plug and left to set for at least an hour at room temperature before transferring the flies 
(progenies) into them. Fresh food was prepared every two weeks and flies were flipped into 
new bottles.  
 
2.2.13 Dosage and treatment 
A low dose (oxidative stress dose) of Vd (1µM) was used. This concentration of Vd was 
calculated using the equation by Hong, et al  (2011) to convert dosages used in human studies 
to effective and non-toxic doses that could be used in the Drosophila melanogaster 
experiments. To investigate the effect of chronic exposure of Vd on motor activities, lifespan, 
iron chelation and oxidative stress markers, 3 or 4 groups (depending on the experimental 
design) were used. These consisted of: a control group (with no treatment), positive control 
(treated with L-dopa; 1.6mg) a treatment group (Vd-1µM). Each group comprised of five 
replicates and each bottle had 10 flies.  
 
To prevent oxidation of L-Dopa, 20.8mg of ascorbic acid was added to each bottle containing 
L-Dopa (like the amount used in a study by Pendleton et al.,  2002). At the start of each 
experiment, flies were allowed to lay eggs on food once the larvae appeared, the adult flies 
were released from the bottles, after 6 days the progenies were transferred to fresh food and 
redistributed onto treatments the next day (which is counted as day zero). To establish the 
effect of synthetic iron chelation on motor activity and lifespan, a dose-dependent effect of 
DFO (0 µM, 5 µM, 10 µM, and 20 µM) was tested –in both WT and mutant flies. From the 
result of this experiment, established optimal concentration of synthetic iron chelator 
Deferoxamine (DFO) Mesylate salt were used added in the subsequent experiment-: 5 µM; 
WT and 20 µM; PINK1. 
 
2.2.14 Climbing assay and life span 
The motor functions were tested against different treatment regimen for the symptoms in 
PINK1 mutant vs WT flies. This was measured by testing their climbing ability. Fourteen 
days after the flies were originally placed on food with treatment, their progeny was tested 
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using a climbing test adapted from Pendleton, et al., 2002; Nichols, et al., 2012 and Cha, et 
al., 2005 - conducted with moderate modifications. All groups were tested at random, groups 
of 10-15 flies (depending on the experiments) were transferred into empty 100-ml Pyrex 
graduated cylinder with a foam plug, and a height of 8 cm horizontal line above the bottom of 
the cylinder was drawn in a paper as a criterion. The flies were allowed 10 mins. to 
acclimatise. The flies were then gently tapped down and allowed to climb up past the 8 cm 
mark (in 8 seconds) on the chart, and afterwards tapped down again.  
 
A digital camera was placed in front of the cylinders at 30 cm from the paper, and a timer 
was used to record the time. The total number of flies that crossed the 8 cm mark was 
recorded (as the “Escaped flies”- in this escaped ability test). This was repeated two more 
times. The climbing assay was performed at 10 am and at the same time every two to three 
days. An average of the total number of flies that escaped was noted and the percentages of 
flies that escaped were then calculated; against the total number of flies that survived at each 
time-point- this was defined as climbing scores. Each treatment group contain five replicates. 
The mean of each group was calculated using the data of the three replicates tests. Adjusted 
two-way analysis of variance (ANOVA) with post-test Bonferroni correction was performed 
using GraphPad Prism, version 7 (GraphPad Software, San Diego California USA). 
 
2.2.15 Sample preparation for biochemical assays 
At the end of exposure (14 days), the flies from each group of control and treated (Vd only; 
Vd + DFO) groups were anaesthetized in ice. The flies were then snapped frozen in liquid 
nitrogen and vortexed at high speed to separate the fly head from the body (since we are only 
interested in measuring the RONS in the head). The detached fly heads were transferred into 
pre-weighed Eppendorf tubes and weighed. It was then homogenised in 0.1M phosphate 
buffer, pH 7.0 (1 mg: 10µL), centrifuged for 10 min at 4000g (temperature, 4oC). The 
supernatants obtained were stored at -20o C and used to determine the RON’s level, protein, 
and total thiol content. The assays were performed in duplicates for each of the three 
replicates of the treatment groups (Vd only; Vd + DFO) treatment groups.  
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2.2.16 Measurement of DCFH oxidation for RONS – Kinetic assay  
To determine the RONS level following chronic exposure to Vd and influence of Fe 
chelation, 2’, and 7’-Dichlorofluorescein (DCFH) oxidation was measured as an index of 
oxidative stress according to the method of Perez-Severiano, et al  (2004). From the frozen 
supernatant, five microliters (5µL, 1:10 dilution) of each supernatant from Vd only- and Vd + 
DFO- treated and control flies (for both WT and mutant) were transferred into a 96-well 
plate. Subsequently, 5µL of 200 µM DCFH-DA (final concentration of 5 µM) was added to 
the samples and the fluorescence product of DFH oxidation (i.e. DCF), was measured for 10 
mins. (at 30-sec intervals), using Synergy H4 hybrid multi-mode microplate reader (See 
Table 4.1) with excitation 488 and 525 nm emission. All the experiments were conducted in 
duplicates for each of the three replicates of Vd ±DFO – treated and control flies (for both 
WT and mutant). The rate of DCF formation was expressed in percentage of the control 
group. 
 
2.2.17 Total Thiol (T-SH) assay – WT & Mutant. 
The total thiol content for both WT and mutant flies was determined using the method of 
Ellman (1959). The reacting mixture contained 170 µL of 0.1 M potassium phosphate buffer 
(pH 7.4), 20 µL of the sample as well as 10 µL of 10 mM DTNB. It was incubated for 30 
mins. at room temperature, the absorbance was measured at 412 nm and used to calculate the 
sample total thiol levels (in µmol/mg protein) using GSH as standard. 
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2.3 Materials  
2.3.1 List of Materials for Western Blot 
 
Table 2.1: Materials and suppliers 
Product Manufacturer  
Acrylamide (30%) Bio-Rad 
Anti-rabbit IgG, HRP-linked  Cell Signaling Technologies  
Bromophenol  Sigma Aldrich 
Butanol  Sigma Aldrich 
Chemiluminescence  film GE Healthcare DAPI 
DTT  Sigma Life Science 
Foetal bovine serum  Sigma Life Science 
Fura-2 Calcium Dye  Thermo Fisher Scientific 
Gibco™ DMEM/F12 Thermo Fisher Scientific 
Gibco™ PBS Thermo Fisher Scientific  
Goat-anti-rabbit IgG HRP-linked  Cell Signaling Technologies  
Hoefer® Dual Gel Caster   Hoefer Inc., USA  
Hoefer® Mini Vertical Protein Electrophoresis Hoefer Inc., USA  
HyperPAGE  Bioline 
Mighty Small Transfer Tank  Hoefer Inc., USA 
MTT Invitrogen 
Nitrocellulose membrane  GE Healthcare 
Parafilm®   Pechinery Plastic Packaging 
Rabbit-anti-GAPDH Proteintech 
Rabbit-α-PDI polyclonal Benham Group, Durham University, UK 
SDS  Sigma Aldrich 
TEMED Sigma Aldrich 
Tween 20 Thermo Fisher Scientific 
Xograph Imaging System  Xograph Healthcare 
ZEISS LSM 880 with Airyscan Carl Zeiss AG 
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2.3.2 List of Materials 
Table 2.2: Materials for Western blot, Calcium Imaging and corresponding suppliers 
Product Manufacturer 
Acrylamide (30%) Bio-Rad 
Ammonium Chloride  Sigma Life Science 
Ammonium persulfide Sigma Life Science 
Anti-rabbit IgG, HRP-linked Cell Signaling Technologies 
Bromophenol  Sigma Aldrich 
BSA Sigma Scientific  
Butanol Sigma Aldrich 
Calcium Chloride Sigma Aldrich 
Chemiluminescence film  GE Healthcare 
DAPI  Thermo Fisher Scientific 
DMSO  Sigma Aldrich 
DTT  Sigma Life Science 
Foetal bovine serum  Sigma Life Science 
Fura-2 Calcium Dye  Thermo Fisher Scientific 
Gibco™ DMEM/F12  Thermo Fisher Scientific 
Gibco™ PBS  Thermo Fisher Scientific 
Glycine  Acros Organics 
Goat-anti-rabbit IgG HRP-linked  Cell Signaling Technologies 
Hoefer® Dual Gel Caster Hoefer Inc., USA  
Hoefer® Mini Vertical Protein Electrophoresis 
unit 
Hoefer Inc., USA 
HyperPAGE Bioline Bioline 
Magnesium Chloride Sigma Aldrich  
Methanol  Fisher Scientific 
Mighty Small Transfer Tank  Hoefer Inc., USA 
MTT Invitrogen  
NaCl Sigma Aldrich 
Nitrocellulose membrane GE Healthcare  
Parafilm® Pechinery Plastic Packaging 
PFA Fisher Scientific  
Rabbit-anti-GAPDH Proteintech  
Rabbit-a-PDI polyclonal Benham Group, Biosciences, Durham 
University, UK 
SDS Sigma Aldrich  
ß-mercaptoethanol Sigma Life Science 
TEMED Sigma Aldrich 
Triton X-100 Merck 
Trizma® Base Sigma Life Science 
Tween 20 Thermo Fisher Scientific 
Vectashield mounting media VECTASHIELD® 
Xograph Imaging System Xograph Healthcare 
ZEISS ApoTome  Carl Zeiss AG 
ZEISS LSM 880 with Airyscan Carl Zeiss AG  
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2.3.3 List of Materials & Chemicals 
 
Table 2.3: Materials for in vivo experiments and corresponding suppliers 
Product  Supplier 
WT (WT) flies 
- Dahomey; Drosophila melanogaster 
Dr Ed Okello’s lab- Institute of Cellular 
Medicine, Medical School, Newcastle 
University 
PINK1  mutant flies – 
(w- PINK1 B9/FM7. GFP w+ )  
-Drosophila melanogaster PINK1 
Dr Ed Okello’s lab- Institute of Cellular 
Medicine, Medical School, Newcastle 
University 
250ml flies’ bottles Scientific Laboratory Supplies 
Applied Scientific Jazz-Mix Drosophila  Food Fisher Scientific ( Loughborough, UK) 
Carbon dioxide Sigma Aldrich (Dorset, UK) 
Fly pad Blades Biological (Kent, UK) 
Controlled room (12 hourly day-night cycle 
@25oC) 
Lab 
Brush Blades Biological (Kent, UK) 
Filter using Whatman #1 paper Fisher Scientific ( Loughborough, UK) 
Microplate reader - Thermo scientific 
multiskan FC. 
Thermo Fisher Scientific Oy 
 P.O Box 100, FI-01621 Vantaa, Finland 
 
Refrigerated centrifuge (4oC)-  
Eppendorf Centrifuge 5415R.  
Spec:CF3CH2F. 
Eppendorf AG 22331 Hamburg, Germany 
Liquid nitrogen Biosciences Nitrogen Tank 
Synergy H4 hybrid multi-mode microplate 
reader 
 BioTek Instruments, Inc., P.O. Box 998, 
Highland Park, Winooski, Vermont 05404-
0998 USA. 
Vortex (machine) Genie-2; Model:G-560E Scientific Industries Inc. Bohemia, NY, 
11716, USA 
Plugs  Blades Biological (Kent, UK) 
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2.3.4 List of Reagents and Buffer Composition for Western blot 
 
Table 2.4: Composition of Buffers used 
  Buffer  Composition 
Blocking buffer, western blot  5 % SMP in PBS 
Electrode buffer  190 mM glycine 
25 mM Tris-Cl 
0.1 % SDS 
pH 8.6 
HEPES physiological buffer  
Calcium imaging 
150 mM NaCl 
5 mM KCl 
2 mM CaCl2 
1 mM MgCl2 
10 mM HEPES 
pH 7.4 
Laemmli sample buffer  60 mM Tris-Cl 
10 % glycine 
5 % ß-mercaptoethanol 
2 % SDS 
0.01 % bromphenol blue 
pH 6.8 
Running gel 0.375 M Tris Base 
10 % acrylamide 
0.1 % SDS 
0.1 % APS 
0.04 % TEMED 
pH 8.8 
Stacking gel 0.125 M Tris Base 
5 % acrylamide 
0.075 % APS 
0.075 % TEMED 
pH 6.8 
Transfer buffer 190 mM glycine 
25 mM Tris Base 
20 % methanol 
In dH2O 
Washing buffer, western blot 2.5 % SMP in PBS 
0.02 % Tween 20 
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2.3.5 List of Antibodies for Western blot 
 
Table 2.5: List of primary and secondary antibodies used 
Primary AB Dilution  Application 
Rabbit-α-PDI polyclonal 1:3000 Western blot Rabbit 
Rabbit-α-PDI polyclonal  1:2000 Immunofluorescence 
Rabbit-α-PDI polyclonal 1:2000 Western blot 
Rabbit- α-GAPDH 1:2000 Western blot 
MAP2  Western blot 
 
Secondary AB Dilution Application 
Goat-α-Rabbit-HRP 1:2000 Western blot 
α-Rabbit 
AlexaFluorophore594 
1:500 Immunofluorescence 
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2.3.6 List of Antibodies for immunofluorescence and Biochemical assays 
 
Table 2.6: List of primary and secondary antibodies used immunofluorescence 
Primary AB Dilution  Application 
Rabbit-α-PDI polyclonal 1:3000 Western blot Rabbit 
Rabbit-α-PDI polyclonal  1:200 Immunofluorescence 
Rabbit-α-PDI polyclonal 1:2000 Western Blot 
Rabbit- α-GAPDH 1:2000 Western Blot 
MAP2 1:1000 Western Blot 
MAP2 1:50 Immunofluorescence 
 
Secondary AB Dilution Application  
Goat-α-Rabbit-HRP 1:2000 Western Blot 
α-Rabbit  1:500 Immunofluorescence 
Alexa Fluorophore 596 1:500 Immunofluorescence 
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Table 2.7: Chemicals for biochemical assays and corresponding suppliers 
Product Supplier 
Absolute Ethanol Fisher Scientific, UK 
Ascorbic acid (vitamin C powder) Sigma Aldrich (Dorset, UK) 
Bovine Serum Albumin (BSA) Sigma Aldrich (Dorset, UK) 
Bradford Reagent Sigma Aldrich (Dorset, UK) 
Coomassie Brilliant Blue G-250  Sigma Aldrich (Dorset, UK) 
DCFH-DA  (2,7-Dichloroflouresceine 
diacetate) 
Sigma Aldrich (Dorset, UK) 
Deferoxamine (DFO) Mesylate salt  Sigma Aldrich (Dorset, UK) 
Dibasic Phosphate buffer (K2HPO4) Sigma Aldrich (Dorset, UK 
DTNB (Ellman's Reagent) (5,5-dithiol-bis-
(2-nitrobenzoic acid) 
Thermofischer Scientific   
Ethanol Sigma Aldrich (Dorset, UK) 
L-DOPA (3,4-Dihydroxy-L-phenylalanine) Sigma Aldrich (Dorset, UK) 
Methanol  Fisher Scientific, UK 
Methanol Fisher Scientific, UK 
Monobasic Phosphate buffer (KH2PO4) Sigma Aldrich (Dorset, UK) 
Phosphoric acid (H3PO4) Sigma Aldrich (Dorset, UK) 
Potassium Phosphate Buffer Fisher Scientific, UK 
Reduced Glutathione- GSH Abcam 
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Chapter 3:  In-vitro effect of subtoxic concentration of Cu 
relevance to PD 
 
3.1  Introduction  
This chapter is devoted to elucidating the effects of Cu, an endogenous heavy metal, on 
neuronal metabolic function, cytotoxicity, functional responses, and neuronal maturation, with 
possible implications on synaptic plasticity and neurodegeneration. The increased 
concentrations of Cu in the cerebrospinal fluid of patients with PD, its cellular toxicity in 
dopaminergic neurons, as well as the formation of reactive oxygen species (ROS) informed the 
need to explore the potential effect(s) of low and sub-toxic concentrations of Cu as a possible 
contributor to the aetiology of PD. However, whilst most studies have focused on mechanisms 
underlying Cu-induced neurotoxicity, the sub-toxic pharmacological effects of such heavy 
metals have been somewhat undervalued. We seek, in this study, to explore this important 
issue.  
Some micronutrient heavy metal ions that are involved in key steps of neurotransmission, can 
interfere with brain function and have been implicated in different neurodegenerative diseases. 
This chapter is aimed at elucidating the effect of sub-toxic pharmacological effects of Cu on 
the cellular functionality of neuronal cells at different stages of development; undifferentiated, 
differentiating, and differentiated Cath. A-differentiated (CAD)  cells.  
 
3.1.1 Copper: an essential element 
Cu is an essential trace element involved in many important physiological processes in 
biological systems. It represents the prosthetic group of enzymes that takes part in the transfer 
of electrons in several key reactions in metabolism (Luza and Speisky, 1996; Chen, et al., 
2009). In the brain, Cu-dependent enzymes, such as dopamine β hydroxylase, Cu-monoamine 
oxidase, and peptidyl glycine α-amidating monooxygenase, catalyses the formation and the 
metabolism of neuronally active substances. Due to the high Cu level in the brain, the role of 
this metal in CNS functions is invaluable. Unbound Cu is deleterious and potentially 
carcinogenic; under this condition, its redox activity may lead to cellular damage, due to release 
of reactive oxygen species (ROS) (Arciello, et al., 2006); through modification of proteins, 
lipids and nucleic acids, with clear structural and functional implications. 
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ROS (superoxide anion, hydrogen peroxide and hydroxyl radical) are physiological by-
products of oxidative metabolism of cells, the electron transport chain of mitochondria –being 
also a major source of ROS and a target of this action (Halliwell, et al., 1990). In the biological 
system Cu, as well as Iron, can promote ROS formation, bind directly to free thiols of cysteines, 
leading to oxidation and cross-links between proteins, This inevitably leads to enzyme 
inactivation and the impairment of structural proteins (Cecconi, et al. ,2002). 
 
3.1.2 Cu and Oxidative Stress 
Cu plays a critical role in cellular functions. It is central in neural cells where it is utilised for 
neurochemical activities as well as general metabolism. Its capacity to cycle between the two 
oxidation states (Cu+ and Cu2+ respectively) is employed by various enzymes involved in 
various biochemical reactions essential for brain development and function (Hatori, et al., 
2016). Two vital Cu-dependent enzymes include cytochrome c oxidase (involved in electron 
transfer and ATP production in the mitochondria) and superoxide dismutase (SOD1 and 
SOD3). These are responsible for detoxification of reactive oxygen species (ROS) in the 
cytosol and cell surface. These two subserve the housekeeping functions in cells. The other 
group contributes to the functional identity of specific neurons including dopamine-β-
hydroxylase (central in the biosynthesis of norepinephrine), and peptidyl-glycine-a-
monooxygenase (PAM) – involved in the production of all amidated neuropeptides (Hasan 
and Lutsenko, 2012). 
 
3.1.3 Cu homeostasis and PD  
Due to the compartmentalisation of proteins requiring Cu, there is the need for timely 
delivery of Cu to these compartments for functional maturation of the resident enzymes 
(Hatori, et al., 2016). It is noted that Cu delivery from the cytosol to its target protein is 
facilitated by chaperones (Field, et al., 2002). The chaperone for SOD is CCS (Cu Chaperone 
for SOD) which delivers Cu to SOD1 (Williams, et al.,2016). A plethora of chaperones 
mediate the delivery of Cu transfer into mitochondria and subsequent incorporation of Cu 
into cytochrome c oxidase. These are Cox11, Cox17, SCO1 and SCO2. 
 
In the cytosol, Atox1 (a cytosolic chaperone) shuttles Cu to the Cu transporters ATP7A and 
ATP7B. These are both located in the secretory pathway (Field, et al., 2002; Lutsenko, et al., 
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2012). These transporters (ATP7A and ATP7B) transports cytosolic Cu into the lumen of the 
trans-Golgi network (TGN) and various vesicles; energy from this process is derived from the 
hydrolysis of ATP. This subsequently activates PAM, DBH, SOD and other Cu-dependent 
enzymes (Hatori, et al., 2016). Identities of metallochaperones have been well defined.  
However, the mechanism underpinning the regulation of Cu flow to the different cellular 
compartment is yet to be elucidated. It has been suggested that the distribution of Cu between 
proteins is driven/mediated by the relative abundance of Cu-binding molecules and the 
differences in their affinity for Cu (Banaci, et al., 2010).  
 
This principle is true for the cytosolic distribution of Cu in steady-state. Prompt regulation of 
intracellular Cu fluxes is critical for the development of distinctive neurochemical 
characteristics of neurons. During the transition from the proliferative phase to a 
differentiated state, neuronal cells undergo remarkable metabolic restructuring which is 
defined by changes in the metabolome (Lutsenko, et al., 2008)  and the protein expression 
profiles (Banci et al., 2010). There is an active synthesis of neurotransmitters and 
neuropeptides in differentiated neurons within the secretory pathway. These processes require 
Cu (Bousquet-Moore, et al., 2010). 
 
The role of Cu as a neurotransmitter, its location in the secretory pathway and its 
neurochemical activities makes the dysregulation of this metal pivotal in the pathogenesis of 
numerous neurological diseases such as Parkinson Disease,  Alzheimer Disease, 
Amyotrophic Lateral Sclerosis and Huntington Disease (Desai and Kaler, 2008).  
 
Dysregulation of  Cu homeostasis may result in the serious disorders such as hepatocerebral 
dystrophy (Wilson's Disease),  renal tubular dysfunction, liver cirrhosis, the emergence of 
Kayser-Fleischer rings and damage of different brain structures, in particular the thalamus, 
subthalamic nuclei, brainstem, and frontal cortex (Das and Ray, 2006; Manto, 2014). Besides, 
this disorder may manifest as Parkinsonism and/or cognitive impairment (Lorincz, 2010). 
This cascade of events is a consequence of oxidative stress induced by free Cu2+ (Ranjan, et 
al., 2015). 
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Furthermore, impairment of Cu may cause a decrease in neuronal cell viability or induce 
synaptic alterations (Sadiq, et al., 2012; Marchetti, et al., 2014), upsets neural synaptic 
activity in vivo and in vitro. It is interesting to note that major sources of Cu toxicity are 
associated with exposures to environmental contamination and occupational hazards among 
others (Gaetke, et al., 2014).  
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3.2 Methods   
3.2.1 MTT cell proliferation assay 
 
50 µL Phosphate Buffered Saline (PBS) (136.9 mM 2.68 mM KCl, 4.3 mM Na2HP04, 1.4 mM 
KH2P04, pH 7.4) containing 5 mg/ ml MTT was added to the cultures and incubated at 37°C 
and in 5% CO2 for 2.5 hours. Then the MTT- containing medium was removed, the surface of 
the wells was rinsed with 300 µl PBS before the application of 250 µL isopropanol. After the 
purple crystals had dissolved, the optical density of 100 µL sample was spectrophotometrically 
read at 595 nm  (Thermo Lab systems Multiskan Ascent, V1.3). 
 
3.2.2 Lactic dehydrogenase (LDH) release assay 
3.2.2.1 CytoTox 96 non-radioactive assay (Promega, UK) 
 
CytoTox 96 is a non-radioactive colourimetric cytotoxicity assay. This was used to quantify 
lactate dehydrogenase (LDH). This is a stable cytosolic enzyme that is released during cell 
lysis (necrosis). The supernatant, which contained the LDH was retained and used for LDH 
assays.  Before the assay, the samples were diluted with PBS (1:5). 50uL of each sample were 
transferred into each well of the assay plate (in triplicates) and 50uL of substrate mix was added 
to each sample and incubated for 30 mins. on the bench at room temperature and protected 
from light. After 30 mins., 30uL of Stop Solution was added to each well and the absorbance 
was measured at 490nm on a Multiscan Ascent Plate Reader, Version 2.6. 
  
3.2.3 Calcium imaging 
In this investigation, cultured CAD cells were probed with the molecular dye; Calcium-
Green-1 AM (Invitrogen) as specified in the manufacturer manual (ref). Calcium Green is 
used to investigate how intracellular calcium fluctuates with neuronal activity. A 2mM stock 
of the Calcium-Green probe was prepared in DMSO D-8779 500Ml, lot 100K3729 by 
Sigma). This was stored at -20ºC. On the day of the imaging experiments, the probe stock 
was brought to room temperature and then diluted in HEPES physiological buffer (150mM 
NaCl, 1mM MgCl2, 10mM HEPES, 2mM CaCl2, 5mM KCl) to a 1μM solution.  
The cells were plated in flat bottom µ-dishes (brand: 60 µ-Dish, 35mm, high glass flat 
bottom-81158 Ibidi GmbH). The cells were washed with (once) 1mL of physiological buffer 
and incubated for 40 mins. in 1mL of the probe solution and once more after incubation 
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period- with the HEPES physiological buffer and left in the buffer till the start of the imaging 
experiments- ready for imaging. To evaluate the effects of Cu (at a final concentration of 
40μM) on cellular calcium fluxes, baselines were taken for around 5 seconds and then Cu 
was injected into the dish. Careful pipetting was ensured by injecting against the dish wall to 
avoid causing fluid turbulence, thereby compromising the images.  
 
The cells were imaged in the presence of Cu (10 & 40µM) and potassium chloride (KCl). The 
incubation period for each treatment was for the periods of 250 cycles (0.63s each) before 
and after the application of the same volume of the depolarising buffer (500mM of KCl in 
HEPES physiological buffer, giving a final concentration of 49.6mM). 
 
3.2.4 Western Blot  
3.2.4.1 SDS-PAGE  
The SDS-PAGE was used to separate proteins by their molecular mass. Therefore, a total 
volume of 10 µl of each sample prepared as described (in Section 2.2.9.1) was loaded into one 
well in the stacking gel (See Table 2.4). Due to the Laemmle sample buffer, all proteins are 
negatively charged and run from the cathode to the anode through the gel when connected to 
power. The running gel containing 10 % acrylamide (See Table 2.1) forms a grid forming pores 
that small proteins can easily pass through but make it difficult for bigger proteins to run 
through.  
 
The gel was run at 10mA for 15 mins. to help the samples to settle in the stacking gel before 
the current was increased to 15mA (but the double current for 2 gels) and the gel was run for 
another 1-1.5 hours until the sample buffer (See Table 2.4) got to the bottom end of the gel. As 
a scale for protein size, a standardised marker (HyperPAGE,) was run on every gel next to the 
samples.  
 
3.2.4.2 Blotting 
After the SDS-PAGE, proteins were blotted on a nitrocellulose membrane using electric 
current. For the protein transport from the gel unto the membrane, the membrane was pre-
incubated in transfer buffer. Transfers were done on a lockable cassette. The cages were filled 
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in the following order: sponge, two filter papers, nitrocellulose membrane, gel, two filter 
papers, and sponge. All materials used were soaked in transfer buffer (See Table 2.4) for at 
least 30 minutes. before transfer to ensure that neither the gel nor the membrane was running 
dry.  
 
After the cages were locked, they were placed in a Hoefer® Mighty Small Transfer Tank filled 
with transfer buffer with the cathode facing the side of the gel and the anode facing the 
nitrocellulose membrane. The transfer was performed at 50 V and >300 mA enabling the 
negatively charged proteins to travel towards the anode and therefore entering the membrane 
when exiting the gel. Two cooling units were placed on the sides of the tank to prevent 
temperature increases due to the electricity. The transfer was due 2.5 hours later. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
102 
 
3.3 Results  
3.3.1 Dose-dependent effect of Cu on undifferentiated, differentiating, and 
differentiated CAD cells 
 
As a first step, a dose-response effect of Cu on the viability of undifferentiated, differentiating, 
and differentiated CAD cells was investigated. This was aimed at determining the subtoxic 
concentration of Cu for further experiments to help choose a suitable range of doses as a 
subtoxic dose to use for the series of experiments planned. Dose-response effect of Cu at 
different stages of development (undifferentiated, differentiating and differentiated) of CAD 
cells- MTT 
Concerning metabolic function, Cu did not affect mitochondrial functionality at lower doses 
for both acute and chronic exposures- at different stages of maturation. However, it reduced 
mitochondrial viability for chronic differentiating and acutely treated cells- at higher 
concentrations. 
 
Results of dose-response treatment of CAD cells at different stages of development. Acute 
(24hours) treatment of undifferentiated cells (Panel A), chronic (6 days) treatment of 
differentiating cells (Panel B) and acute treatment of differentiated cells (Panel C). The mean 
IC50 values were determined using GraphPad Prism© 7.05 fitting the data to a sigmoidal fit of 
a variable slope. The mean IC50 values for undifferentiated CAD cells = 8 x 10
-5 M; 
differentiating cells = 12 x 10-5 M; and differentiated cells = 14 x 10-5 M were similar. All 
values are means ± SD, from at least 6 separate experiments and n=4 for each experiment. ** 
p < 0.01; *** p < 0.001. 
 
 
 
 
A B C 
Figure 3.1: : Dose-response effect of Cu at Different level of development of CAD cells. 
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3.3.2 Effect of Cu exposure on undifferentiated, differentiating, and differentiated CAD 
– MTT 
The subtoxic concentration of Cu (10μM) did not affect mitochondrial viability in both acute 
and chronic exposed CAD cells. 40μM reduced mitochondrial viability for chronic 
differentiating and acutely treated cells- but with no effect on undifferentiated cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Exposure of CAD cells to sub-toxic (10 µM) and low-dose Cu (40 µM)- MTT 
An MTT assay was carried out to confirm the effect of Cu (24 hours) exposure on 
undifferentiated (A, B) and differentiated cells (E and F) and chronic (6 days) exposure on 
differentiating CAD cells (C and D). Cu concentrations tested were 10 µM and 40 µM. Values 
are mean for n= 4 samples. (* p<0.05; **P<0.01; *** p<0.001). ns = non-significant. Overall, 
Cu (10 µM) did not affect MTT values (mitochondrial viability) (Fig. 2.2A, C and E) for both 
acute and chronic exposures. In contrast, Cu (40 µM) had no significant effect upon 
 
 
 
 
  
 
A B 
C D 
E F 
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undifferentiated cells, but reduced MTT values for chronic differentiating and acutely treated 
differentiated cells (Fig. 2.2B, D and F). 
3.3.3 Lactate dehydrogenase assay 
Since an MTT assay is not a clear indicator of cytotoxicity, and LDH assay was used to find 
out whether the culture conditions and treatments elicited a cytotoxic effect on neurons. LDH 
assays are another type of colourimetric assay used to quantify the levels of LDH released into 
the cell culture medium due to cell lysis. The resulting red colour from the enzymatic reaction 
can be measured spectrophotometrically (absorbance), and a stronger colour indicates a higher 
degree of cell lysis. An increase in the amount of LDH release is indicative of toxicity. 
 
3.3.4 Effect of 10 µM and 40 µM Cu exposure on undifferentiated, differentiating, and 
differentiated CAD - lactate dehydrogenase (LDH) 
Subtoxic dose (10 µM) treatment of CAD cells at different stages of development showed a 
decreased released of LDH in undifferentiated, differentiating and differentiated cells. Also, 
treatment with 40 µM showed a decrease in LDH release in both differentiating and 
differentiated CAD cells, with reference to the control. However, treatment with 40 µM in 
undifferentiated showed an increase (non-significant) in LDH release. 
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Figure 3.3: Exposure of CAD cells to sub-toxic (10 µM) and low-dose Cu (40 µM)- LDH 
An LDH assay was carried out to probe the effect of Cu (24 hours) exposure on undifferentiated 
(A, B) and differentiating cells (E and F) and chronic (6 days) exposure on differentiating CAD 
cells (C and D). Cu concentrations tested were 10 µM and 40 µM. Values are mean for n= 4 
samples. (* p<0.05; **P<0.01; *** p<0.001). ns = non-significant. Acute and chronic exposure 
with 10 µM  Cu is not cytotoxic there is a suggestion of modest but significant neuroprotection 
in culture. Acute exposure of differentiated cells and chronic exposure of differentiating cells 
to 10 µM and 40 µM  Cu again shows lack of toxicity at these concentrations, again with a 
suggestion of neuroprotection, with lower LDH release in the presence of Cu.  
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3.3.5 Deferoxamine (DFO)-mediated iron-chelation on undifferentiated, differentiating, 
and differentiated CAD cells. 
The influence of iron chelation on cell viability (MTT) in acute exposure of differentiated and 
undifferentiated CAD cells to Cu was explored. There is an accumulation of iron in PD patient, 
which may potentiate oxidative stress, which is implicated as an underlying cause of neuronal 
cell death. The next set of experiments were designed to investigate the effect of Fe chelation 
on acute and chronic exposure of Cu at different concentrations of Cu. This was performed to 
elucidate the potential effect of iron chelation on cell viability, hence, ameliorate possible 
mitochondria stress response due to Cu insult. 
 
  
 
CAD cell stage & treatment 
regime 
Control 
 
+ 25 µM DFO 
 
+ 50 µM DFO 
Acute undifferentiated 8 x 10-5 M ≥10 x X10-5 M 
                          
2 x X10-5 M *           
Chronic differentiating 12 x 10-5 M 14 x 10-5 M 
                          
13 x X10-5 M 
 
Acute differentiated  14 x 10-5 M n.d. 
                    
 
3 x X10-5 M* 
                 
    
    
nd= not determined. 
Table 3.1: Effects of Iron chelation upon Cu-induced toxicity (Acute and chronic 
treatments) in CAD cells 
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3.3.6 Effect of Deferoxamine (DFO)-mediated iron-chelation on undifferentiated, 
differentiating, and differentiated CAD cells. 
MTT assay on mitochondrial functionality showed that acute exposure CAD cells (at different 
stages of maturation) to 50µM DFO increase the sensitivity of undifferentiated and 
differentiated cells to Cu (approximately 4-fold) with reference to controls. For the chronically 
treated differentiating CAD cells, there was no apparent difference in Cu IC50 in the presence 
of DFO (Table 3.1). 
 
 
 
 
 
 
 
  
 
Figure 3.4: Fe chelation in undifferentiated, differentiating and differentiated CAD 
Cells.  
Effects of iron chelation (DFO) upon Cu-induced cell toxicity following acute 24h for 
undifferentiated and differentiated and chronic 6-day exposure for differentiating CAD cells. 
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Values are mean for n= 4 samples. (* p<0.05; **P<0.01; *** p<0.001; ****p<0.0001) ns = 
non-significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
109 
 
3.3.6.1 Effect of Cu upon functional CAD monoaminergic Neurons – calcium imaging 
Following identification of two subtoxic Cu concentrations (10 µM and 40 µM), the latter 
displaying mitochondrial oxidative stress effects, the effects of Cu on functional responses 
were explored using a calcium imaging approach in undifferentiated and differentiated CAD 
cells. Baseline control recording was measured initially in undifferentiated CAD cells (Fig. 
2.5). 
3.3.6.1.1 Control calcium signal 
Basal reading was obtained before investigating the functional response of cells to Cu. KCl, 
used as a positive control, showed a surge in calcium flux in the cell body of CAD cells with 
reference to the same cell before injection of KCl.  
 
     Cell body- before depolarisation               Cell body after depolarisation 
        
 
C 
A B 
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Figure 3.5: Basal reading showing the functional response of undifferentiated CAD cells 
upon KCl induced depolarisation. 
Panel A/B and the adjunct Fig. (C ) shows representative baseline recordings of calcium signal 
in CAD neuronal cell body. Panel B shows the effect of depolarisation induced calcium 
signalling following injection of KCl (50 mM). A surge in calcium signal is seen which is 
represented by a spike and an extended signal (approx. 50 secs). 
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3.3.6.1.2 Effect of Cu upon calcium imaging in undifferentiated CAD cells 
Cu (10 µM) elicited no detectable effect on calcium signalling (Fig. 3.6A) but completely 
suppress the depolarisation response in the cell bodies of undifferentiated cells (Fig. 2.6B) 
compared to control (Fig. 2C). 
 
 
Figure 3.6: Calcium modulation in undifferentiated CAD cells in the presence of [10 
µM] Cu. 
Spiking with Cu (10 µM) did not elicit any calcium signal (A). In the presence of Cu, KCl-
induced-depolarisation was very modest (B) compared to the control response. Representative 
images and data for n=6 separate experiments with at least 10 individual cells per experiment 
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3.3.6.1.3 Effect of Cu upon Calcium Imaging in differentiated CAD Cells  
The next sets of experiments were designed to elucidate the effect subtoxic and low doses of 
Cu (10 µM and 40 µM) on both the cell body and neuronal process of differentiated CAD cells.  
There was no marked difference in the effect of  Cu on both the cell body and process - with 
subtoxic dose (10 µM ) as against treatment with low dose (40 µM), where a prominent surge 
in Ca influx was noted in the cell body and a concurrent inhibition in the processes, following 
KCl-induced mobilisation. 
 
 
 
 
Figure 3.7: Effect of Cu (10µM) on differentiated CAD cells. 
Sub-toxic dose Cu (10 µM) caused an increase in signal intensity in the cell soma and process- 
with a slightly higher increase in signal strength in the processes. There was a delay in signal 
intensity following KCl-induced depolarisation. Selective suppression of depolarisation (KCl-
induced) calcium intensity is apparent in the processes (with normalised intensity/area <400) 
but this was absent in the cell body (normalised intensity/area >600) of differentiated neurons. 
The signal intensity of the cell body was returned to baseline (post depolarisation) but that of 
the processes failed to return to baseline. 
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3.3.6.1.4 Effect of Cu (40µM) upon Calcium Imaging in differentiated CAD Cells  
Low dose (40µM) treatment of differentiated CAD cells indicated an opposite effect on both 
the cell body and the processes. There was a surge in Ca signal following KCl-induced 
depolarisation, in the cell body. In contrast, there was an inhibition of Ca signal in the process. 
 
 
Figure 3.8: Effect of Cu (40µM) on differentiated CAD cells. 
Low-dose Cu (40µM) bi-directionally modulates calcium levels in the neuronal processes 
(inhibits-blue) and cell body (elevates-red) of DIV 6 differentiated CAD neurons in cultures. 
Low-dose Cu (40µM) selectively suppresses depolarisation-induced calcium in the processes, 
but not the cell body of differentiated neurons in cultures (Fig. 2.9), which has implications for 
neurotoxicity and synaptic plasticity. Representative images and data for n=6 separate 
experiments with at least 10 individual cells per experiment. 
 
 
 
 
 
 
 
 
 
 
 
  
0 1 0 0 2 0 0 3 0 0 4 0 0 5 0 0
0
2 0 0
4 0 0
6 0 0
T im e ( S e c )
N
o
r
m
a
li
s
e
d
 I
n
te
n
s
it
y
/A
r
e
a
C e l l  B o d y
P r o c e s s
+ C u D e p o la r i s a t io n
0 1 0 0 2 0 0 3 0 0 4 0 0 5 0 0
0
2 0 0
4 0 0
6 0 0
T im e ( S e c )
C
e
ll
 B
o
d
y
+ C u
+ K C l
0
2 0 0
4 0 0
6 0 0
P
r
o
c
e
s
s
s
 
114 
 
3.3.6.1.5 Bidirectional modulation of calcium homeostasis +/- Cu (40µM) in differentiated 
neuronal CAD cells 
The inhibitory effect of Ca (40µM) on the process of differentiated CAD cells was noted in the 
process (indicative a blockage of neurotransmitter release) as against the cell body where an 
increase in Ca signal was observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Effect of Cu (40µM) on Calcium-induced depolarisation in differentiated 
CAD cells 
Calcium modulation in neuronal cells. Live cell imaging with CAD cells with low dose Cu 
(40µM) bi-directionally modulates calcium levels-inhibiting calcium signal in the process (blue 
line) and concurrently elevates the calcium level in the cell body (red line). Representative 
images and data for n=6 separate experiments with at least 10 individual cells per experiment. 
 
 
-Cu +Cu 
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3.3.7 Effect of Cu (24 hours) on differentiated CAD cells 
 
Microtubule-associated protein 2 (MAP-2) is a structural protein, necessary along with other 
cytoskeletal proteins, to maintain neuroarchitecture. It is sensitive to many physiological 
inputs, and plays a vital role in the growth, differentiation, and plasticity of neurons, responding 
to growth factors, neurotransmitters, synaptic activity, and neurotoxins. Modification and 
rearrangement of MAP-2 is an early obligatory step in many processes which affects neuronal 
function. The brain microtubule-associated protein MAP-2 family is composed of high-
molecular-weight (MAP2a and MAP2b) and low-molecular-weight (MAP2c and MAP2d) 
isoforms. This investigation was designed to elucidate the possible effect of Cu (sub-toxic 
doses) on differentiation using MAP-2 as a marker. 
 
Figure 3.10: MAP-2 Isoforms: Multiple isoforms are expressed in neurons: MAP2A- 
280kDa, MAP2B - 270kDa, MAP2C, MAP2D - 70 & 75kDa - (Sanchez, et al., 2000); 
G.W. Huntley, 1998). 
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3.3.7.1 Effect of Cu (10µM) on differentiated CAD cells - 24 hours 
The selective effects of Cu upon cell bodies and processes reported in the previous section were 
explored further by investigating the effects of Cu (10µM and 40µM) on MAP-2 expression in 
differentiated CAD cells. Sub-toxic Cu negatively modulated differentiation by selectively 
reducing MAP-2a isoform, with no significant effect upon MAP-2b isoform, for both 10 and 
40 µM concentrations of Cu (Figures 3.11 and 3.12). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11:  Quantitative analysis of immunoblot data on MAP-2 expression following 
acute exposure (24 hours) of Cu (10µM) compared to control on differentiated CAD 
cells.  
Results show there was a significant reduction in the expression of MAP-2A (Panel A, 
p<0.05) in comparison to untreated control. There was a moderate increase in MAP 2B in 
comparison to control, but not statistically significant (Panel B, p>0.05). Panel C shows a 
comparison of MAP2A vs MAP2B. Figures are mean values ±SD, n =6 
 
 
 
 
 
 
 
 
A B 
C 
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3.3.7.2 Effect of Cu (40µM) on differentiated CAD cells - 24 hours 
Acute exposure (24 hours) of differentiated CAD cells to low dose Cu (40µM) resulted in a 
reduction in expression of MAP 2a and MAP 2b isoforms.  
 
 
 
 
 
 
 
Figure 3.12:  Quantitative analysis of immunoblot data on MAP-2 expression following 
acute exposure (24 hours) of Cu (40µM) compared to control on differentiated CAD 
cells. A significant reduction in the expression of MAP-2A (Panel A, p<0.05) in 
comparison to control, but not statistically significant ((Panel B, p>0.05). Panel C shows 
a comparison of MAP-2A vs MAP-2B. Figures are mean values ±SD, n=6. 
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3.4 Discussion 
Cu homeostasis is tightly regulated by the activity of Cu pumps at the cellular levels. Failure 
of these pump leads to the accumulation of Cu and cell toxicity. Impaired functions of mutated 
Cu-ATPase (ATP7B), which exports Cu through the trans-Golgi network causes Wilsons’ 
Disease (an autosomal recessive disorders)  which is associated with Cu overload and resultant 
cell degeneration (Brewer, 200; Brewer, 2009). Sokol, et al (1994) and GU, et al (2000) 
investigated the mechanisms underlying liver Cu toxicity in Wilson’s Disease. In their findings, 
they suggested that the mitochondrion is the prime target.  
 
Arciello, et al (2004) in their investigation of Cu-dependent toxicity, using SH-SY5Y 
neuroblastoma cells noted that Cu (in complete medium for 24 hours) had a toxic effect which 
they adduced to the impairment of the capability of the mitochondria dehydrogenase to reduce 
tetrazolium salt, and to a lesser extent the loss of the integrity of the plasma membrane. They 
concluded that the mitochondria are an early and susceptible target of Cu-mediated oxidative 
stress in neuronal cells and posited that mitochondrial damage triggers the neurodegenerative 
processes associated with Cu overload in Wilson’s Disease.  
 
This chapter is devoted to elucidating the effect of sub-toxic concentrations of the endogenous 
heavy metal Cu on the cell biology and functionality of monoamine neuronal cells at different 
stages of maturation. As a first step, the dose-response effect of Cu was performed using acute 
(24 hours) and chronic (6 days) exposure times on metabolic activity (MTT) and cytotoxicity 
(LDH). This was to determine suitable concentrations for subsequent experiments on neuronal 
functionality and differentiation. Neuron metabolic rates were relatively resistant to applied Cu 
with similar IC50 values (approx. 10mM) (Fig. 2.1).  
 
Based on the results, 10µM Cu was shown to have no significant effect upon metabolic rate or 
cytotoxicity, while 40µM of Cu reduces metabolic rate for differentiating (6 days exposure) 
and differentiated (24 hours exposure) cells but remained non-cytotoxic for all conditions. This 
will probably reflect the increased excitability of differentiated cells. Cu is critical in neuronal 
transmission (Zischka and Einer, 2018), memory and learning (Kapkaeva, et al., 2017). A 
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disturbance to Cu homeostasis could be a consequence of either genetic or environmental 
factors or a combination of both factors (Gaetke, et al., 2014).  
 
Accumulation of Cu in specific brain regions such as the thalamus, subthalamic nuclei, 
brainstem, and cortex has resulted in Cu-induced neuronal cell loss; as seen in Wilson’s Disease 
(Kapkaeva, et al., 2017). Accumulated Cu level in this disease pathology has been noted to be 
in the range of 128-,000μg/g dt. (Faa, et al.,1995). Significant neurological disorder such as 
tremor, ataxia, bradykinesia, rigidity, chorea, and dystonia (Cordato, et al., 2004) and 
biochemical interruptions (disturbance in glucose consumptions) have been associated with 
Wilson’s Disease (Cordato, et al., 2004). Increased Cu-induced oxidative stress has been noted 
in these changes (Ranjan, et al., 2015). Functional brain concentration of Cu2+ is about 100 µM 
depending on certain conditions and specific sites (Kapkaeva, et al., 2017). Shao (2013) and 
his colleagues estimated the basal level of Cu (in the brain dialysate) to be 1.7µM but noted 
that this value increased to 10µM following global cerebral ischaemia. However, Kapkaeva, et 
al (2017) in their investigations proposed an oxidative mechanism of Cu2+ toxicity, when they 
observed that a 50µM of Cu2+ in culture,  induced a strong dose-dependent death of neuronal 
hippocampal cells. They also observed a further reduction in cell viability of cultured 
hippocampal neurons on the application of 200µM of CuCl2 (24 hours exposure).  
 
In contrast, 10µM CuCl2 did not have any significant influence on cell viability. Previous 
studies show that application of 10µM of Cu2+ is not cytotoxic for cultured neurons 
(Stelmashook, et al., 2016; Stelmashook, et al., 2019). This is in concert with our findings 
where we demonstrated that 10µM of Cu had no effect on mitochondrial viability for both acute 
and chronic exposures (with LDH assay confirming its non-toxicity on both cells 
undifferentiated and differentiated cells). 
 
The perturbation of Cu2+ homeostasis not only results in neuronal cell death but also causes 
synaptic alterations (Sadiq, et al., 2013; Opazo, et al., 2014). Results of calcium modulation 
were ambivalent; 40µM Cu bi-directionally modulates calcium levels in the neuronal processes 
and cell body. Whilst an inhibitory effect occurred in the processes, there was an elevation of 
calcium signal in the cell of (DIV 6) differentiated CAD neurons in cultures (Fig. 2.8). It also 
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selectively suppresses depolarisation-induced calcium in the processes (Fig 2.9), but not the 
cell body of differentiated neurons in cultures. This has implications for neurotoxicity and 
synaptic plasticity.  These findings are in concert with the findings of Colvin, et al (2015) 
where they noted that Cu levels are distributed diffusely in neurons, but higher in the processes 
relative to other metal ions, such as zinc.   
 
Kapkaeva, et al (2017) noted that treatment of cultured hippocampal neurons with 10µM Cu2+ 
significantly reduced the spike activity of cultured neuronal network (which was attenuated by 
the antioxidant - Trolox). Besides, they posited that when neurons were exposed/treated with 
sub-toxic Cu2+ it interrupts synaptic function and breaks the distribution of the signal in the 
neuronal network. This probably explains the selective suppression of KCl-induced 
depolarisation when differentiated CAD cells were spiked with 10µM Cu. The decrease in 
calcium intensity was apparent in the processes with normalised intensity <400 normalised 
intensity/area but absent in the cell body (normalised intensity >600 normalised intensity/area). 
Whilst the signal intensity of the cell body was returned to baseline (post-depolarisation) the 
signal intensity in the processes failed to return to baseline). Kapkaeva, et al (2017) further 
asserts that bioelectric activity of neurons is a probable key target of Cu-induced neurotoxicity 
in which free radicals can be involved.  
 
In terms of sensitivity of differentiated cells to Cu, Ogra and his colleagues (2016) suggested 
that the intracellular Cu concentration is increased by differentiation. In their research, they 
demonstrated that the process of differentiation induces Cu accumulation in PC12. This was 
followed by a concomitant increase in Cu transporter 1 (Ctr1) as a compensatory mechanism 
to ameliorate Cu accumulation. The increased Cu in differentiated cells are bound to MT-3 that 
they suggested as the possible factors underpinning the progression of the pathological changes 
observed in the nerve cells.  
 
Similarly, Hatori, et al (2016) observed an increase in cellular demand for Cu upon neuronal 
differentiation, notably in the secretory pathway. The flow of Cu to this compartment is 
facilitated through transcriptional and metabolic regulation (Hatori, et al., 2016). During 
neuronal differentiation, there is a change in the oxidation state of glutathione in the cytosol 
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and the redox state in the cytosol facilitates the reduction of the Cu chaperone – Atox1. The 
reduction of this chaperone results in the liberation of metal from its binding sites. Related to 
this (the expression of Atox1) is the upregulation the Cu transporter, ATP7A.  
 
These events result in a higher flux of Cu across the secretory pathway, thereby, increasing the 
supply of the co-factor to Cu-dependent enzymes which are elevated in differentiated neurons 
(Hatori, et al., 2016). This probably explains why differentiating and differentiated cells were 
more sensitive to Cu toxicity in both chronic and acute exposure. As previously reported (Fig. 
2.2 B, D and F) 40µM of Cu had no significant effect upon undifferentiated cells, but reduced 
MTT values for chronic differentiating and acutely treated differentiated cells- implying a 
reduced metabolic rate in both differentiating and differentiated cells. 
 
Altered metal homeostasis has been reported in PD (Rubio-Osornio, et al., 2013; Montes, et 
al., 2014). For example, augmentation of Fe and a decrease in Cu levels in the substantial nigra 
was reported (Kozlowski, et al., 2012). This elevated (and unbound) iron may contribute to 
increased oxidative stress, alpha-synuclein oligomerization, and Lewy body formation 
(Montes, et al., 2013). Besides, decreased Cu along with increased iron has been found in the 
caudate nucleus of PD patients (Montes, et al., 2013). Cu influences iron content in the brain 
through ferroxidase ceruloplasmin activity. Therefore, decreased protein-bound Cu in the brain 
may enhance the iron accumulation and the associated oxidative stress. Herein, we explored 
the interaction between iron and Cu-mediated metabolic rate reduction.  
 
Acute exposure of 50µM of DFO (a synthetic chelator) increased the sensitivity of 
undifferentiated and differentiated cells to Cu, by approximately four-fold compared to the 
control. This was not apparent in chronically treated differentiating cells. An adaptive response 
may probably explain the lack of sensitivity to Cu in chronically treated cells. The increase in 
sensitivity of undifferentiated and differentiated cells following iron chelation (with DFO) 
(acute) may not necessarily be related to the chelation of iron within the cells.  
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Gangania, et al (2017) in their investigation while elucidating the role of iron and Cu in the 
pathogenesis of PD, noted that serum Cu and Fe levels were significantly decreased in PD 
patients compared to the controls, but ceruloplasmin levels were slightly raised. Using the 
Spearman’s Correlation Coefficient to investigate the correlation, between iron-Cu, Cu-
ceruloplasmin, iron-ceruloplasmin in PD patients and controls, they reported no obvious 
correlation among parametric pairs- implying that the concentrations of Fe, Cu and 
ceruloplasmin may be relatively independent of each other (Gangania, et al., 2017). It is unclear 
if Cu modulates Fe flux or Fe modulates Cu flux. However, it is established that tight regulation 
of both Cu and Fe transport is critical to avoid neurological perturbation associated with metal 
imbalance (in cases such as PD and AD) and disease specifically associated with Cu (Menkes 
and Wilson’s Diseases) or iron (Friedreich’s Ataxia and ceruloplasminemia).  
 
Cu deficiency has been noted to result in elevated iron levels in the liver, which is partly due 
to decreased levels of ceruloplasmin activity. In contrast, Prohaska and Gybina (2005) 
observed that iron concentration is decreased following dietary Cu deficiency in rat brains. This 
may be associated with lower serum Fe because the injection of Cu-deficient rats with Fe 
reversed the serum and brain iron deficit (Prohaska and Gybina, 2005; Pyatskowit and 
Prohaska, 2008). 
 
As a redox-active metal, iron (Fe) is essential for cell respiration and metabolism. Pourcelot, 
et al (2015) demonstrated that cells deprived of Fe (by the addition of a chelating agent) resulted 
in growth arrest. However, this was reversed after replacing the media with an iron source 
(after 24 hours). Brain regions responsible for motor functions have been shown to have more 
Fe than non-motor related regions. Hence movement disorders are often associated with Fe 
loading (Myhre, et al., 2013; Ashraf, et al., 2018). While metal chelation may be beneficial, 
the ubiquity of their action in the body and their non-selectivity calls for care and caution in 
the application.  
  
Cytoskeletal homeostasis is very vital for the growth, survival, and maintenance of a functional 
nervous system (Ramocki and Zoghbi, 2008; Wilson and Gonzalez-Billault, 2015). 
Microtubules are important for neuronal growth, morphology, migration, and polarity. In this 
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study, we investigated MAP-2 - a differentiation marker to investigate the effects of subtoxic 
and metabolic stress concentrations of Cu upon neuronal maturation. Three isoforms of MAP-
2 have been delineated; high molecular weight MAP2a and MAP2b and the low molecular 
weight MAP2c have been identified in the neurons (Dehmelt, et al., 2005).  
 
In this present study, MAP2a and MAP2b were the focus, as the only two detected. Following 
acute exposure (24 h) of differentiated CAD cells (peak differentiation - 6 days in culture) to a 
sub-toxic dose of Cu [10µM], expression of MAP2a, but not MAP2b, was significantly 
reduced. This finding agrees with extant literature which suggests that MAP2c is expressed in 
the developing brain and it is down-regulated during brain maturation, whereas the high 
molecular weight MAP2b is expressed in both developing and adult brain.  
It has also been established that MAP2a appears only after brain maturation (Dehmelt, et al., 
2005). Since MAP-2 is associated with microtubule assembly, cargo trafficking and plays a 
vital role in determining as well as stabilising the shapes of dendrites during neuronal 
development. The observed differential decreased expression of MAP2a in differentiated cells 
in response to Cu (40 µM) may relate to the observed differential modulation of overall 
metabolic activity and calcium signalling in the neuronal processes (Fig. 2.9), as well as the 
apparent suppression of depolarisation-induced calcium in the processes (but not in the cell 
body). This may have implications for synaptic plasticity and neurotoxicity. Recent evidence 
suggests that PD pathogenesis might be underscored by early cytoskeleton dysfunction 
(Brunden, et al., 2017; Pellegrini, et al., 2017).  
 
Overall, sub-toxic Cu (endogenous heavy metal) has a range of pharmacological effects upon 
monoaminergic neurons concerning metabolic function, signalling and maturation, with 
evidence for deleterious pharmacological effects exacerbated by reduced iron content. The next 
chapter will compare these finding to an exogenous environmental heavy metal, which has 
been proposed as a potential candidate for causing PD, namely Vd. 
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Chapter 4:  In-vitro effect of low and oxidative stress doses of 
vanadium and the influence of iron with relevance to PD 
 
4.1 Introduction 
Age is a major risk factor in the development of PD, With the global demographic shift to an 
ageing population, the prevalence of PD and its socio-economic impact is estimated to 
increase significantly by the year 2050. Environmental exposure to heavy metals is another 
putative risk factor in the development of PD. One of such metals is Vd - a contaminant in 
fossil fuels.  
 
Environmental pollution from oil spills and gas flaring as seen in the Nigerian Niger Delta is 
a source of Vd exposure to humans (Fatola, et al., 2019; Oghenetega, et al., 2019). Despite 
our current understanding of the mechanistic basis of the relationship between Vd toxicity 
and PD (oxidative stress, inflammation, ER stress, autophagy, to mention but a few), the 
search for effective therapies is still on.  
 
Vd, a heavy metal, is found in many carbon-containing deposits such as crude oil, coal, oil 
shale and tar. It is found mostly in the soil as vanadate which is generally very soluble and 
taken up by plants at levels reflecting its availability. As a heavy metal nutraceutical, Vd has 
been used at low doses in different health supplement formulations as antidiabetic (Domingo 
and Gomez, 2016), anticancer (Ray, et al., 2006; Chakraborty, et al., 2007; Korbecki, et al., 
20120 and many more Fatola, et al., 2019).  
 
Elementary Vd (V) is a soft, corrosion-resistant, steel grey solid in group Vb of the periodic 
table and belongs to the first transition series. Vd occurs in two isotopic forms: 50V and 51V- 
the most abundant being 51V (99.75% natural abundance) with atomic number 23 and atomic 
weight of 50.94. Some physicochemical properties are presented in Table 4.1.  It forms 
compounds, mainly, in three oxidation states: +3, +4 or +5. The most stable of these 
oxidation states is +4, in which Vd forms the oxoVd (+4) ion (vanadyl; VO2+) (Crans, et al., 
2004). Free elemental Vd is rare in nature, but it can be found in about 65 different minerals, 
including magnetite, carnotite and patronite. It can be found in phosphate rock and crude oils. 
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Its presence in crude oil means it constitutes an environmental pollutant as a bi-product of 
combustion as fumes in car exhaust and industrial effluents. Exposure to this metal, therefore, 
constitutes a health risk to humans and animals (Shrivasta, et al., 2007; 2011). 
 
Vd is valuable in the manufacturing industry and has gained ubiquitous relevance in welding 
and construction industries (Wenning and Kirsch, 1988). It is used as alloys to strengthen 
steels, jet engines (Plunkett, 1987; Olopade and Connor, 2011; Fatola, et al., 2019). The main 
route of entry into humans is via the nasal mucosa (Olopade and Connor, 2011). Vd has no 
known biological activity. It can be found in trace amounts certain types of food (such as 
mushrooms, parsley, dill weed, black pepper, shellfish, and some grains).  
A balanced diet provides about 0.01mg/day of Vd. In high doses, Vd is toxic, however, in 
minute doses it has increasingly been employed as a useful health supplement. Thus, 
presenting a “pharmacological paradox”. As a heavy metal nutraceutical, Vd has been used in 
different health supplement formulations and employed in treating health conditions, such as 
anaemia, diabetes, heart, disease, high blood pressure, high cholesterol, obesity. Inhaling 
large amounts of Vd can result in lung problems, such as bronchitis or pneumonia. It has been 
shown that workers exposed to Vd peroxide are more susceptible to eye, nose, and throat 
irritation (Hall, et al., 1997; Cooper, 2007; Gorguner and Akgun, 2010). 
  
As a heavy metal nutraceutical, Vd has been used at low doses in different health supplement 
formulations,  as antidiabetic (Domingo and Gomez, 2016), anticancer (Ray, et al., 2006; 
Chakraborty, et al., 2007; Korbecki, et al., 20120 and many more Fatola, et al.,2019). 
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4.1.1 Properties of Vanadium  
 
Table 4.1: Physical and Chemical Properties of Vanadium 
Properties Description  Source  
Physical 
description 
Sodium vanadate appears as colourless to yellow 
crystal or cream coloured solid 
Barceloux and 
Barceloux (1999) 
Molecular 
weight 
121.929 g/mol Barceloux and  
Barceloux (1999) 
Atomic weight  50.94u Assem, et al 
(2015) 
Atomic 
number 
23 Assem, et al 
(2015) 
Density  6.11g/cm3 Assem, et al 
(2015) 
Melting point 1910 ±10oC Assem, et al 
(2015) 
Boiling point 3420oC Assem, et al 
(2015) 
Halides Pentafluoride, tetrachloride, oxovanadium chloride, 
dichloride and trichloride 
Crans, et al (2004) 
Oxidation 
states 
−3, −1, +1, +2, +3, +4, +5 (an amphoteric oxide) 
 
Crans, et al (2004) 
Solubility: < 1mg/ml @ 22.22 OC Barceloux and 
Barceloux (1999) 
Acid  Dissolves in acid giving dioxovanadium (+5) ion 
(VO2
+) –which is chemically and structurally 
similar to phosphate (PO4
3-) 
Crans, et al (2004) 
Base Dissolves to form vanadate (VO4
3-) 
Compound  Sodium metavanadate (NaVO3)  Assem, et al 
(2015) 
Oxides  Vanadium (+3) dissolves in acid giving a hexaaqua 
ion 
Vanadium (+3) salts are strongly reducing  
Crans, et al (2004) 
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This chapter is aimed at investigating the effects of Vd, an exogenous heavy metal, on 
neuronal metabolic function, signalling responses, oxidative and ER stress, and neuronal 
maturation, all with possible implications for synaptic plasticity and neurodegeneration. 
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4.2 METHOD  
4.3 MTT ASSAY   
Cell viability assay – was carried out as previously described in Section 2.2.6. 
 
4.3.1 Analysis of metal content in CAD cells 
CAD cells were passaged and seeded as previously described (Section 2.2.2 and 2.2.3) into two 
75cm3 flasks. After 24 hours the process of differentiation was initiated as previously described 
(See 2.2.9) and the undifferentiated cells were left to proliferate. After 100% confluency was 
attained, the undifferentiated cells were rinsed with cold PBS and detached. After detaching, 
the falcon tubes were centrifuged for 5 minutes (at 1500 rpm) and transferred into 1.5ml 
Eppendorf tubes, centrifuged again and stored at -20oC for ICP-MS analysis for metal contents. 
Similarly, the differentiated (6 days DIV) cells were detached and stored at -20oC for ICP-MS. 
 
4.3.1.1 Sample Preparation 
1.5ml of Nitric acid (65% HNO3) was added to each thawed cell pellets and vortexed. The cells 
were left for 24 hours to be digested in the fume hood, and vortexed again. 1.2ml of the digested 
sample was removed and dispensed into fresh Eppendorf tubes and centrifuged (5’, 
@14,000rpm). 500uL of the digest was then diluted with 4.5ml 2.5% HNO3. 1ml of the 
clarified sample was decanted into a 15ml falcon tube. The clarified sample was diluted 1/10 
(2% nitric acid). The analysis was carried out with Ag as an internal standard (Ag 100 ppb) 
which was added to the samples and standard curve. ICP-MS analysis was done in duplicates. 
Standard solutions of known metal concentration were analysed before and after the samples 
(“front standard curve” and “back standard curve”). These were used to define limits for 
quantitation. The final working range was noted and used to quantify the metal content. 
 
4.3.2  LDH release assay  
 Lactic acid dehydrogenase (LDH) release assay- was done as previously described in Section 
2.2.3 
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4.3.3 Live Single-Cell Calcium Imaging 
 
Calcium mobilisation in undifferentiated and differentiated CAD cells was investigated by live 
single-cell calcium (Ca2+) imaging as described in Section 2.2.4 
 
4.3.4 Western blot  
 
Blotting by the SDS-PAGE was done as previously described in Sections 2.2.7 and 2.2.9.1 
 
4.3.5 Immunofluorescence  
Immunofluorescence (IF) assay was performed to establish the effect of Vd on ER stress, PDI 
expression and neuronal differentiation. CAD cells were plated on coverslips (18mm), which 
were placed in 6-well plates. 2ml of CAD cells suspended in FBS-supplemented in DMEM/F-
12 media was added to a 6cm cell culture dish (TPP© Tissue Culture Dishes, Sigma, Z707678), 
with additional 2ml of fresh media; to give a 1:1 dilution of cells. These were left for 24 hours 
to attach to the coverslips and differentiated as described in Section 2.2.5.  
 
For chronic studies, cells were spiked with Vd (10µM or 100µM), one-hour post-differentiation 
and left on SFM for 6 days. For acute studies, cells were allowed to differentiate (6 days DIV) 
and spike with Vd (10µM or 100µM) and left for 24 hours. The media was removed in 
preparation for antibody application and the cells were washed twice in cold PBS supplemented 
with 1mM calcium and 0.5mM magnesium (PBS++). Each wash was left for 5 minutes. After 
washing, the cells were fixed with 4% paraformaldehyde (PFA) to preserve the cell’s structure 
and to preserve cell structure and to prevent decay. This is made possible by PFA enhancing 
the formation of covalent bonds between proteins. The cells were incubated in PFA for 1min. 
at RT. Subsequently, the PFA was removed and the cells were washed as previously described.  
 
To eliminate unspecific antibody binding to free aldehyde groups in the samples - “quenching” 
was necessary. Cells were incubated in 50mM ammonium chloride (NH4Cl) in PBS
++ for 15 
minutes at RT. NH4Cl quenches free aldehyde groups and allowing a better signal contrast. 
Following this, NH4Cl was discarded and the cells were washed again in PBS
++ three times for 
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5 minutes in cold PBS++. 0.2% Bovine serum (BSA) in PBS++ was used to block unspecific 
binding sites. Cells were incubated in BSA two times for 5 minutes at RT. The coverslip was 
taken out of the blocking solution and placed face-down on the drop of antibody solution. 
Coverslips with control cells were placed on one drop of 0.2% BSA in PBS++.  
 
Cells were incubated in antibody solution for 2 hours (for MAP2) and 1 hour (for PDI) at RT 
and then washed thrice in cold PBS ++ for 5 minutes between each wash. Secondary antibodies 
(See Table 2.5) were applied in the same way as described for the primary antibodies and 
incubated for 25 minutes. Due to the light-sensitive nature of the secondary antibody, samples 
were covered with foil to prevent fluorophore-exhaustion. Excessive antibodies were washed 
off with cold PBS two times for 5 minutes.  
 
For nucleus-localisation, DNA was stained with DAPI diluted 1:1000 in PBS ++ and applied as 
previously described for antibodies. DAPI intercalates into the DNA and emits fluorescent light 
when excited with light in the ultraviolet range. After 5 mins. of incubation at RT, coverslips 
were mounted on microscopy slides using mounting medium by Vectashield® (See Table 2.2) 
as mounting medium; the cell-coated side of the coverslip was placed face down. The edges of 
the coverslips were sealed with nail polish. Immunofluorescent pictures were taken by the 
confocal ZEISS ApoTome Microscope. The secondary antibodies tagged with Alexa-
fluorophore-594 gave a signal with a wavelength of 594 nm when excited with a wavelength 
of approximately 570 nm. Immunofluorescent images of DAPI and Alexafluorophore -594 
were taken separately and merged using the ZEISS ApoTome software. 
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4.4 List of Materials   
 
Table 4.2: Materials and corresponding suppliers 
Product Manufacturer 
Acrylamide (30%) Bio-Rad 
Ammonium Chloride  Sigma Life Science 
Ammonium persulfide Sigma Life Science 
Anti-rabbit IgG, HRP-linked Cell Signaling Technologies 
Bromophenol  Sigma Aldrich 
BSA Sigma Scientific  
Butanol Sigma Aldrich 
Calcium Chloride Sigma Aldrich 
Chemiluminescence film  GE Healthcare 
DAPI  Thermo Fisher Scientific 
DMSO  Sigma Aldrich 
DTT  Sigma Life Science 
Foetal bovine serum  Sigma Life Science 
Fura-2 Calcium Dye  Thermo Fisher Scientific 
Gibco™ DMEM/F12  Thermo Fisher Scientific 
Gibco™ PBS  Thermo Fisher Scientific 
Glycine  Acros Organics 
Goat-anti-rabbit IgG HRP-linked  Cell Signaling Technologies 
Hoefer® Dual Gel Caster Hoefer Inc., USA  
Hoefer® Mini Vertical Protein 
Electrophoresis unit 
Hoefer Inc., USA 
HyperPAGE Bioline Bioline 
Magnesium Chloride Sigma Aldrich  
Methanol  Fisher Scientific 
Mighty Small Transfer Tank  Hoefer Inc., USA 
MTT Invitrogen  
NaCl Sigma Aldrich 
Nitrocellulose membrane GE Healthcare  
Parafilm® Pechinery Plastic Packaging 
PFA Fisher Scientific  
Rabbit-anti-GAPDH Proteintech  
Rabbit-a-PDI polyclonal Benham Group, Biosciences, Durham 
University, UK 
SDS Sigma Aldrich  
ß-mercaptoethanol Sigma Life Science 
TEMED Sigma Aldrich 
Triton X-100 Merck 
Trizma® Base Sigma Life Science 
Tween 20 Thermo Fisher Scientific 
Vectashield mounting media VECTASHIELD® 
Xograph Imaging System Xograph Healthcare 
ZEISS ApoTome  Carl Zeiss AG 
ZEISS LSM 880 with Airyscan Carl Zeiss AG  
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4.4.1 List of Antibodies    
 
Table 4.3: List of primary and secondary antibodies used 
Primary AB Dilution  Application 
Rabbit-α-PDI polyclonal 1:3000 Western blot Rabbit 
Rabbit-α-PDI polyclonal  1:200 Immunofluorescence 
Rabbit-α-PDI polyclonal 1:2000 Western Blot 
Rabbit- α-GAPDH 1:2000 Western Blot 
MAP2 1: Western Blot 
MAP2 1:50 Immunofluorescence 
Secondary AB Dilution Application  
Goat-α-Rabbit-HRP 1:2000 Western Blot 
α-Rabbit  1:500 Immunofluorescence 
Alexa Fluorophore 596 1:500 Immunofluorescence 
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4.5 Results 
4.5.1 Dose-dependent effect of vanadium on undifferentiated, differentiating, and 
differentiated CAD monoamine neuronal cells.  
 
The first set of experiments were designed to explore the dose-dependent effects of Vd on a 
range of immature, maturing, and matured monoamine neurons in culture. Immature CAD 
cells (undifferentiated) were exposed to Vd for 24 hours, whilst maturing cells 
(differentiating) were exposed for 6 days- spanning the period it takes for the process of 
differentiation to be complete (chronic exposure); after which (at the end of 6 days) 
mitochondrial viability assay was done. However, the matured (differentiated) cells, they 
were exposed to Vd by day 6 and left for 24 hours (acute exposure). 
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Figure 4.1: Dose-dependent effect of vanadium on undifferentiated, differentiating, and 
differentiated CAD cells 
 
Acute (24 hours) treatment with (sodium vanadate (vanadium) was performed for 
undifferentiated cells (Panel A), chronic (6 days) treatment for differentiating cells (Panel B) 
and acute treatment for differentiated cells (Panel C). Both differentiating and differentiated 
cells were insensitive to Vd up to 1000µM. In contrast, undifferentiated cells were sensitive 
to Vd, above 100 µM. Approx. 50% of the cells were insensitive to 1000µM. All values are 
means ± SD, from at least 6 separate experiments and n=4 for each experiment. ns p>0.05; 
*p<0.05; **p<0.01; ***p<0.001 versus zero Vd control. 
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4.5.2 The Temporal effects of vanadium on different stages of CAD cell development in 
culture - undifferentiated, differentiating and differentiated  
Dose-dependent effect of Vd on CAD cells. This was aimed at investigating the effect of 
chronic long-term Vd exposure on mitochondrial functionality (MTT assay) at different 
stages of development. Undifferentiated cells were spiked with Vd 24 hours after plating and 
exposed for 9 days; differentiating cells for 9 days while differentiated cells were exposed for 
5 days (after 6 days post-differentiation). 
 
Figure 4.2: A time-course chronic exposure of vanadium (0 – 1000µM) to CAD neurons 
at different stages of maturating cells. 
An MTT assay was carried out to investigate the effect of chronic exposure of Vd (0-1000 µM) 
on undifferentiated (A), differentiating (B) and differentiated (C). Vd concentrations tested 
were 10, 20, 50, 100, 200,500 and 1000µM. The mean IC50 values (See Table 3.1) were 
estimated using GraphPad Prism© 7.05 fitting the data to a sigmoidal fit of the variable slope 
when possible. These data indicated that undifferentiated cells were more sensitive to Vd 
exposure compared to differentiating and differentiated cells; a decline in the viability of 
viability with an increasing number of days indicative of an ageing-associated decline in cell 
viability. All values are means ± SD, from at least 3 separate experiments and n=4 for each 
experiment.   
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4.5.3 Dose-dependent effect of vanadium on undifferentiated and differentiated CAD 
monoamine neuronal cells, evaluation of their iron content - for days 1 & 5 
 
The levels of metals in undifferentiated and differentiated cells were then determined with a 
view to establishing if Fe levels at different stages of development may account for the 
variations in sensitivity of CAD cells to Vd exposure. We thus, established that the increased 
sensitivity of the undifferentiated cells was associated with significantly higher (p<0.005) 
levels of intracellular iron (about 3-fold increase) in undifferentiated versus differentiated CAD 
cells (Fig.4.4). 
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Figure 4.3: Dose-response to vanadium on oxidative stress (mitochondrial viability) in 
undifferentiated and differentiated CAD cells- for days 1 & 5. 
Results from mitochondrial viability investigation showed that undifferentiated neuronal cells 
are more sensitive (ca. 10-fold) to Vd than differentiated cells (panel B). This correlates with 
the significantly higher (p<0.005) levels of intracellular iron in undifferentiated versus 
differentiated CAD cells (See Fig.4.4). Values are mean ± SD for n = 4 replicates for 
mitochondrial viability assay. 
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4.5.4 IC50 cell viability values for CAD cell sensitivity to vanadium  
Values showing temporal sensitivity to Vd following chronic exposures of CAD neurons to 
Vd in undifferentiated, differentiating, and differentiated cells. 
  
Table 4.4: Estimated IC50 (µM) cell viability values for CAD cell sensitivity to 
vanadium 
Day post-
treatment Vd 
Undifferentiated cells 
approx. IC50 (µM) 
Differentiating cells 
approx. IC50 (µM) 
Differentiated cells 
approx. IC50 (µM) 
1    >1000             >1000 >1000 
2 300 >1000 >1000 
3 30 >1000 500 
4 30 150 750 
5 8 150 200 
6 30 150 * 
7 15 100 * 
8 15 50 * 
9 15 50 * 
*.= not determined  
 
 
 
 
 
138 
 
4.5.5 Metal content- in Undifferentiated and Differentiated CAD cells  
An inevitable consequence of ageing is an elevation of brain iron (Fe) levels in specific brain 
regions. There is significant variation in the concentration of Fe between different brain 
regions. It has been observed that the differential distribution of iron in the brain has a 
functional association. For example, regions associated with motor functions tend to have 
more Fe than non-motor related regions (Crichton, et.al, 2006). It has also been reported that 
Vd toxicity is exacerbated in the presence of Fe (Todorich, et al., 2011). This experiment was 
aimed at elucidating the levels of metals in undifferentiated and differentiated cells to 
establish if Fe levels at different stages of development may account for the differences in 
sensitivity/response of CAD cells to Vd exposure. 
 
4.5.6 Metal concentration in undifferentiated and differentiated cells Showing the 
values in parts per billion (ppb) of some metals analysed by ICP-MS.  
Values for Mg, Ca, Mn, and Fe as determined by ICP-MS (A, B & C). Other metals: Co, Ni, 
Cu, and Zn were analysed as well, but the concentrations of these metals were below the 
confidence limits (CL) and detection limit of the assay. Values for Mg, Ca, Mn, and Fe are 
within upper and lower confidence limits and that can be considered quantitative were noted. 
Values for Co, Ni, Cu, and Zn were outside the confidence limits and were not considered, 
therefore, not used quantitatively to determine their levels in the cells. 
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4.5.7 Metal concentrations in CAD cells  
The concentrations of selected analysed metals in part per billion (ppb) were recorded in 
Tables 4.5. The concentration of these metals in ppb/mg/ of protein content: Table 4.6.  
 
 
Table 4.5: Metal content in CAD cells in part per billion (ppb) 
CAD cells Mg Ca Mn Fe 
Undifferentiated  226.85 20.27 1.11 14.79 
Differentiated  63.31 70.82 0.49 4.8 
 
Table 4.6: Metal content in CAD cells in part per billion (ppb) in mg/of protein content 
CAD cells Mg Ca Mn Fe 
Undifferentiated  400.15 35.76 1.95 26.08 
Differentiated  230.02 257.29 1.77 17.51 
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4.5.8 Metal concentration in undifferentiated and differentiated CAD cells; values in 
parts per billion (ppb)/mg/protein and Atoms of Fe.  
Comparing the metal content in undifferentiated and differentiated  CAD cells. Results 
obtained shows that there is significantly higher (p<0.005) levels of intracellular iron in 
undifferentiated cells compared to differentiated CAD cells. 
 
Figure 4.4: Metal content in undifferentiated and differentiated CAD cells. 
Shows concentrations of a selection of analysed metals in part per billion/mg/of protein 
(ppb/mg/protein) (upper panel). There is a notable difference in metal levels in both the 
immature and maturation stages (lower panel ). The levels of Mg and Fe is higher in 
undifferentiated cells compared to differentiated cells. In contrast, Ca levels are higher in 
differentiated cells compared to undifferentiated cells.  All values are means ± SD, from 2 
separate experiments and n=4 for each experiment. Student t-test - **p<0.005. 
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4.5.9 Effect of synthetic iron chelation upon CAD monoaminergic cells - dose-dependent 
effects; undifferentiated and differentiated cells 
This experiment was designed to establish the effect of a synthetic chelator-Deferoxamine 
(DFO) Mesylate salt on CAD cells and to select a range of doses that are non-toxic for the 
subsequent series of experiments planned.  
 
 
Figure 4.5: MTT assay; a dose-dependent effect of synthetic iron chelator DFO on the 
viability of CAD cells 
No significant effects are seen on both undifferentiated and differentiated cells with DFO up 
to 250µM. A trend is evident for modestly higher sensitivity in differentiated cells Vs 
undifferentiated although this did not attain statistical significance (p > 0.05). 
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4.6 Vanadium and Fe chelation 
Iron is an essential transition metal which is critical for many physiological functions in the 
cell. It is tightly regulated. As an enzyme co-factor, it protects the cell from oxidative 
damage. However, in the aberrant state, it is toxic and implicated in iron-mediated oxidative 
and carbonyl stress resulting in the alteration of internal homeostasis milieu. In the 
mitochondria, an iron-containing protein, cytochromes, are involved in the sequential transfer 
of electrons along the respiratory chain - which entails oxidation and reduction cycling of 
iron. Vd toxicity is exacerbated in the presence of Fe in oligodendrocytes progenitor cells.  
 
This study was designed to investigate the possible benefits or otherwise of Fe chelation on 
cell viability.  The synthetic Fe chelator (DFO) was compared with a natural product (Aloysia 
citrodora Palau) which has been identified by our group as an efficient Fe chelator 
(Abuhamdah, et al., 2015). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
143 
 
4.6.1 Effect of iron chelation on cell viability: In the presence of vanadium  
 
The effect of both synthetic (DFO) and natural Fe chelators (A. citrodora essential oil) upon 
Vd (200μM)-induced oxidative stress (mitochondrial viability), following chronic (6 days) 
exposure in differentiating CAD cells was investigated. Both DFO and Aloysia oil, 
significantly reversed vanadium-induced toxicity, as compared with Vd-only treated cells. 
 
Figure 4.6: Effect of synthetic and natural Fe chelator on chronic exposure to vanadium 
of differentiating cells. 
The effect of the synthetic (DFO) and natural Fe chelator (Aloysia citrodora Palau L. 
essential oil) upon Vd (200μM)-induced oxidative stress (mitochondrial viability), following 
chronic (6 days) exposure for differentiating CAD cells. Both synthetic and natural chelators, 
significantly reversed Vd-induced toxicity, as compared with Vd only treated cells. The 
concentration of DFO used was 10µM and Aloysia citrodora Palau was 0.01mg/ml. Values 
are mean ± SD for n= 4 samples. ****p<0.0001. A repeated measure one-way ANOVA (with 
Tukey’s Multiple Comparisons Test) was performed. 
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4.7 Cytotoxicity of vanadium assay: The effect of 100µM vanadium exposure on 
differentiated CAD cells - LDH release 
 
An LDH assay was used to establish if the culture conditions and treatments elicited a cytotoxic 
effect on neurons. LDH assays are a colourimetric assay used to quantify the levels of LDH 
released into the cell culture medium due to cell lysis. The resulting red colour from the 
enzymatic reaction can be measured spectrophotometrically, and a stronger colour indicates a 
higher number of lysed cells. 
 
Figure 4.7: Exposure of differentiated CAD cells to oxidative stress dose (100µM) of 
vanadium cytotoxicity assay (LDH release). 
Acute exposure of differentiated CAD cells to oxidative stress dose (100µM) of Vd for 24 
hours showed no significant difference between the control group and the Vd treated group  
(p > 0.05). 
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4.8 Calcium and neuronal transmission   
In the neurons, calcium plays a two-fold role. First, as a charge carrier and secondly, as an 
intracellular messenger - which is involved in neuronal migration, growth-cone dynamics, 
dendritic development, and synaptogenesis. Calcium ions generate multi-faceted signals that 
control crucial functions in all types of neurons (Berridge, et al., 2000). In neuronal cells, 
calcium signals deploy their highly specific functions in well-defined cellular compartments. 
There functions range from vital cell functions, complete cell cycle to cell proliferation and 
ultimately cell death (Neher and Sakaba, 2008).  
 
In the nervous system, the functional role of calcium ion can be delineated across the entire 
neuronal cell circuitry (pre-synaptic, post-synaptic and the soma - specifically the nucleus - as 
well as the cytosol among others). For example, Ca2+ influx in the pre-synaptic neuron 
triggers exocytosis of neurotransmitters (within the storage vesicles). Postsynaptically, a brief 
rise in the calcium level in dendritic spines is crucial for the induction of synaptic plasticity 
(Zucker, 1999). In the nucleus, another cellular sub-compartment, calcium signal regulates 
gene transcription (Lyons and West, 2011).  
 
Eminently, intracellular calcium signals regulate a wide range of processes over a range of 
time, from the microseconds scale (neurotransmitter release) to the minutes and hours range 
as seen in gene transcription (Berridge, et al., 2003). Therefore, the time-course, the 
amplitude and importantly the auction site in the specific sub-compartment, are key 
determinants of the function of intracellular calcium signals. Therefore, visualization and 
quantitative investigation of neuronal calcium functions are essential to understanding the 
role of xenobiotics in the pathogenesis of neurodegenerative diseases/PD. 
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4.9 Effect of vanadium on calcium mobilisation in undifferentiated CAD 
cells  
Effect of sub-toxic and oxidative stress doses of Vd on cell signalling was elucidated. In these 
investigations Live imaging of undifferentiated cells (cell bodies) (Figs.4.9.1 and 4.9.2) and 
differentiated cells (cell bodies and processes) (Fig. 4.9.3 and 4.9.4) were exposed to Vd 
(10µM and 100µM). 
4.9.1  Effect of vanadium (10µM) on calcium mobilisation in undifferentiated CAD cells 
Sub-toxic dose (10μM) had no clear effect on the intracellular calcium levels in cell bodies.  
 
Figure 4.8: Effect of Vanadium (10 µM) on undifferentiated CAD cells. 
Results show Baseline levels (A); Control depolarisation (B); and effect if Vd upon cell body 
before and upon depolarisation (panel C) (Fig.3.7). A sub-toxic dose (10µM) of Vd did not 
affect the calcium modulation and did not modify depolarization-induced calcium elevation.  
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Representative images and data for n=6 separate experiments with at least 10 individual cells 
per experiment. 
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4.9.2 Effect of vanadium (100µM) on undifferentiated CAD cells 
Oxidative stress dose of Vd (100µM) had a short inhibitory effect and showed reduced/delay 
KCl-induced depolarisation.  
 
Figure 4.9: Effect of vanadium (100 µM) on undifferentiated CAD cells. 
Results show Baseline levels (A); Control depolarisation (B); and effect of Vd upon cell body 
prior to and upon depolarisation (panel C). A dual effect can be observed in live-cell imaging 
with undifferentiated CAD cells with sub-toxic, oxidative stress dose of Vd (100µM). It 
shows rapid transient inhibitory spike followed by protracted inhibition and a delayed 
depolarisation effect. Representative images and data for n=6 separate experiments with at 
least 10 individual cells per experiment. 
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4.9.3 Effect of vanadium (10µM) upon differentiated CAD cells 
A biphasic effect was seen following the spiking of differentiated cells with a subtoxic dose 
of Vd. Whilst there was a slight dip (inhibitory) in calcium signalling in the cell body, there 
was a slight increase in the processes - which had a modulatory effect on KCl-induced 
depolarization. 
 
 
Figure 4.10: Effect of vanadium (10 µM) on differentiated CAD cells. 
Live cell Ca2+ imaging of differentiated CAD cells. Panel A & B show control basal reading in 
cell body and processes. A modest double spike is evident; in the presence of Vd (Cell body 
(panel B) and cell processes (panel C). The effect of Vd (10µM, non-toxic/mild stress dose) 
upon cell body before and upon depolarisation (panel B). In the presence of Vd, the KCl-
induced depolarisation was very pronounced compared to the control response; in contrast, a 
modest single spike in the processes can be observed. Representative images and data for n=6 
separate experiments with at least 10 individual cells per experiment. 
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4.9.4  Effect of vanadium (100µM) upon calcium imaging in differentiated CAD cells 
Oxidative stress dose of Vd (100µM) did not affect the cell body but suppressed Ca 
signalling in the processes. KCl-induced depolarisation was delayed in the cell body but was 
completely inhibited in the processes.  
 
Figure 4.11: Effect of vanadium (100µM) differentiated CAD cells 
Result of baseline imaging in the presence of physiological vehicle (HEPES) + Control 
Depolarisation in the cell body (panel A) and processes (panel B). KCl induced 
depolarisation in cell body and processes (panel C). Live imaging cell body +/- Van/KCl 
(panel D); cell body only (panel E); and process only (panel E). Low dose Vd (100µM) had 
no apparent effect on the cell body (panel E); in contrast, it inhibits calcium mobilisation in 
the processes (panel F) as compared to the control (panel B). interestingly, it selectively 
suppressed the depolarisation-induced calcium in the process but caused a delayed increase in 
cell body compared to the control. Representative images and data for n=6 separate 
experiments with at least 10 individual cells per experiment. 
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4.10 Western blot: Effect of vanadium on cell differentiation 
As previously stated (See section 2.2.7), MAP-2 is sensitive to many physiological inputs and 
plays a vital role in the growth, differentiation, and plasticity of neurons, responding to growth 
factors, neurotransmitters, synaptic activity, and neurotoxins (Johnson and Jope, 1992; Gu, 
1995; Niang, et al., 1998). The focus of this study was to investigate the possible effect of acute 
exposure to Vd (10µM and 100µM) of CAD cells on differentiation using MAP-2 as a marker. 
4.10.1 Quantitative analysis of immunoblot data on MAP2 expression following acute 
exposure (24 hours) of vanadium (10µM) on differentiated CAD cells. 
Low dose Vd (10µM) increase (slightly) the expression of MAP 2C & 2D proteins. 
 
 
Figure 4.12: Protein abundance, by Western blot, of MAP2 in differentiated CAD cells 
treated with vanadium (10 µM)..4.13. 
Two isoforms of MAP2 can be seen from the blot inserts (panel D). An upper band MAP2C 
and a lower band MAP2D (panel A). Results show a slight increase in the expression of both 
isoforms following treatment- 2C (panel B) and 2D (panel D). Student t-test of control/GAPDH 
and Vd/GAPDH of both isoforms shows no significant difference (p>0.05) following treatment 
with 10 µM Vd. Blots were quantified with image J. Inserts show representative of western 
blots for 10 µM (panel D). All values are means ± SD, from at least 5 separate experiments and 
n=3 for each experiment. ns = not significant (p>0.05). 
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4.10.2 Quantitative analysis of immunoblot data on MAP-2 expression following acute 
exposure (24 hours) of vanadium (100µM) to differentiated CAD cells. 
Oxidative stress dose (100µM) of Vd significantly reduced the expression of MAP2C seen in 
treatment with 10µM. A clear absence of MAPs 2A, B, D is apparent. 
 
 
 
Figure 4.13: Protein abundance, by Western blot, of MAP2C in differentiated CAD cells 
treated with vanadium (100µM). 
The result shows a significant decrease in the expression of MAP2C isoforms following 
treatment. Student t-test of control/GAPDH and Vd/GAPDH shows a significant difference 
(p<0.001) following treatment with 100µM Vd. Blots (insert) were quantified by image J. All 
values are means ± SD, from at least 5 separate experiments and n=3 for each experiment and 
unpaired T-test with Welch’s correction was performed. ***= p<0.001. 
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4.11 Effect of vanadium upon ER Stress (PDI)  
Protein disulphide isomerase (PDIs) are molecular chaperones that belong to the family of 
foldases which are located primarily in the endoplasmic reticulum and catalyse the formation 
and isomerization of disulphide bonds. It aids in protein folding as well as perform key 
physiological functions in protein quality control, cell death, and cell signalling. Protein 
misfolding is implicated in most neurodegenerative disease (such as PD, Alzheimer, and 
amyotrophic lateral sclerosis, among others). Altered expression of PDIs is a prominent and 
key feature of these neurodegenerative conditions. These series of experiments were designed 
to investigate the effects of acute and chronic exposures of sub-toxic (low stress) and sub-
toxic high-stress dose Vd on differentiating and differentiated CAD cells. 
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4.11.1 PDI (Reducing condition): Quantitative analysis of immunoblot data on PDI 
following chronic exposure (6 days) to differentiating CAD cells; +/- vanadium (10µM; 
100µM)  
Under reducing conditions, chronic treatment with low dose Vd (10µM) resulted in two 
prominent bands of PDI which is indicative of post-translational modification. Low dose 
treatment caused a moderate decrease in PDI expression while oxidative stress dose (100µM) 
caused an up-regulation. 
 
Figure 4.14: Quantitative immunoblotting of PDI expression following chronic exposure 
(6 days) of vanadium (10µM & 100µM) in differentiating CAD cells. 
The PDI Mr 50,000 protein species is more prominently expressed than Mr 100,000 species 
(p < 0.001). There was no significant difference in PDI expression (lower band, Mr 50,000) 
following exposure to non-toxic (10µM) concentration of Vd (Panel A). In contrast, results 
indicated a significant increase in the expression of PDI (lower band, Mr 50,000), but the 
lower expression in the Mr 100,000 species, following exposure to 100µM  Vd. Student 
unpaired T-test with Welch’s correction was performed for control/GAPDH and Vd/GAPDH 
displayed a significant difference (p< 0.0001) in the of Mr 50,000 species (a 3.5- fold 
increase) compared to the control. Blots were quantified with image J. Inserts show 
representatives of western blots for 10µM  &100µM (panel C & D). All values are means ± 
SD, from at least 5 separate experiments and n=3 for each experiment. ****p<0.0001; ns= 
not significant. 
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4.11.2 PDI (Reducing condition): Quantitative analysis of immunoblot data on PDI 
following acute exposure (24 hours) to differentiated CAD cells; +/- vanadium (10µM; 
100µM) 
Under reducing conditions, acute treatment with oxidative stress dose of vanadium (100µM) 
also resulted in two prominent bands of PDI: indicative of post-translational modification. 
There was no significant change in PDI expression in relation to the control group. 
 
Figure 4.15: Quantitative analysis of immunoblot data on PDI expression following 
acute exposure (24 hours) of vanadium (10µM & 100µM) compared to control on 
differentiated CAD cells. 
The PDI Mr 50,000 protein species is 13-fold more prominent than 100,000 species (p < 
0.001). Results show a modest non-significant reduction in PDI expression following acute 
exposure to Vd mild stress concentration (10µM); p>0.05. Similarly, an oxidative stress 
concentration (100µM) shows no significant change in PDI expression for both species of 
PDI (Panels B and D). Student and unpaired T-test with Welch’s correction was performed of 
control/GAPDH and Vd/GAPDH of both concentrations (10µM & 100µM) were not 
significant (p>0.05). Blots were quantified by image J. Inserts show representative of western 
blots for 10µM & 100µM (panel C & D) respectively. All values are means ± SD, from at 
least 5 separate experiments and n=3 for each experiment. ***p<0.001; ns= not significant. 
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4.12 Analysis of PDI under non-reducing conditions  
The expression of PDI was probed by gel electrophoresis, under non-reducing conditions, 
following chronic and acute exposure of maturing and matured CAD cells to Vd.  
4.12.1 PDI: (non-reducing condition): Quantitative analysis of immunoblot data on PDI 
following chronic exposure (6 days) to differentiating CAD cells; +/- vanadium (10µM; 
100µM) 
Under non-reducing conditions, chronic treatment with low dose Vd (10µM) resulted in a 
significant decrease in PDI expression but caused a slight increase in PDI expression with 
oxidative stress dose (100µM). 
  
Figure 4.16: Results of quantitative analysis of immunoblot data on PDI expression 
following chronic exposure (6 days) of vanadium 10µM (Panel A) and 100µM (panel B). 
There was a significant decrease in PDI expression (p<0.0001) following treatment with a sub-
toxic concentration of Vd (10µM – panel A) and non-significant increase (p>0.05) with 100 
µM of Vd (panel B). Blots were quantified by image J. Inserts show representative of western 
blots for 10µM & 100µM Vd (panel C & D respectively). All values are means ± SD, from at 
least 4 separate experiments and n=3 for each experiment. Student’s unpaired T-test with 
Welch’s correction was performed. ***p<0.0001; ns= not significant. 
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MAP2 Immunofluorescence of CAD cells following treatment with vanadium (10µM 
and 100µM) at different stages of development  
Using immunofluorescence, we investigated the possible effect of Vd treatment on 
differentiation. Exploring the effect of treatment on maturing and matured cells using 
differentiation marker as the primary antibody (MAP2) and Alexa fluorophore as secondary 
antibody CAD cells were exposed to sub-toxic (10µM and 100µM doses) to elucidate the 
chronic effect following 6 days of chronic exposure of cells to Vd (differentiating cells) and 
acute 24 hours exposure (differentiated cells).  
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4.12.2 MAP2- Immunofluorescence of CAD cells, chronic exposure (6 days) -
differentiating cells; Sham vs Treated (100µM). 
Protein misfolding (an indication of ER stress) is associated with dendritic spine loss. 
Immunofluorescence (of MAP2) following chronic exposure of Vd to oxidative stress dose 
(100µM) shows significant loss of processes in differentiating cells. 
 
Figure 4.17: MAP2 localised to neuronal processes in Differentiating (chronic exposure-
6 days) CAD cells. Immunofluorescence shows that MAP2 expression was localised to 
neuronal processes of differentiating CAD cells (Sham treated cells- upper panel) and a 
significant reduction in the expression of MAP2 in treated cells following chronic exposure 
to Vd (100μM- bottom panel). DAPI was used as a nuclear stain (DAPI: 1:1000; incubated 
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for 10mins). While MAP2 was stained with Alexa-Fluor 594 (1:500; incubated for 25mins). 
Images were obtained on a widefield fluorescence microscope (Zeiss Axiovert 200M 
Apotome) using the 20X objective lens. Scale bars = 100μm). 
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4.12.3 MAP2- Immunofluorescence of CAD cells, acute exposure (24 hours) - to 
differentiated cells; Sham vs Treated (100µM) 
Immunofluorescence CAD cells (MAP2) to acute exposure of oxidative stress dose (100µM) 
shows far significant loss of processes in differentiated cells, however, not as profound as 
chronic exposure. 
 
Fig.3.4.18: MAP2 localised to neuronal processes in Differentiated (acute - 24 hours 
exposure) CAD cells. Immunofluorescence shows that MAP2 expression was localised to 
neuronal processes of differentiated CAD cells (and very markedly expressed in Sham treated 
cells- left panel) but a significant reduction in the expression of MAP2 in treated cells 
(100μM- lower panel). DAPI was used as a nuclear stain (DAPI: 1:1000; incubated for 
10mins). While MAP2 was stained with Alexa-Fluor 594 (1:500; incubated for 25mins). 
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Images were obtained on a widefield fluorescence microscope (Zeiss Axiovert 200M 
Apotome) using the 20X objective lens. Scale bars = 100μm) 
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4.12.4 MAP2- Immunofluorescence of CAD cells- at different stages of development 
Sham vs Treated (10µM & 100 µM). 
Immunofluorescence (MAP2) of acute exposure of low dose Vd  to mature, maturing and 
matured cells  
 
Figure 4.19: Immunofluorescence (IF) labelling of three stages of development of CAD 
cells.  
showing processes in maturing (differentiating) and matured (differentiated) CAD cells, 
using MAP2 differentiation marker as primary antibody and Alexa fluorophore, as secondary. 
A clear absence of processes in undifferentiated CAD cells is evident- this was used as a 
negative control (following sham treatment). There was a marked loss of processes following 
chronic treatment (differentiating cells-100µM) and moderate loss in acute exposures 
(differentiated cells-100µM) when compared with sham acute treatments. This marked loss is 
not seen in differentiating & differentiated cells exposed to sub-toxic dose (10µM). Images 
were obtained on a widefield fluorescence microscope (Zeiss Axiovert 200M Apotome) 
using the 20X objective lens. Scale bars = 100μm). 
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4.13 Effect of vanadium on the nuclear shape (DAPI-staining) 
ER stress has been reported in several neurodegenerative diseases. Chronic ER stress leads to 
over activation of unfolded protein response (UPR) and thereby triggering apoptosis.  UPR 
activation is a common feature observed in most neurodegenerative diseases. Perri, et al 
(2016) reported a strong association between ER stress and UPR in most neurodegenerative 
disorders. The effect of Vd (acute and chronic exposures) on different stages of development on 
dopaminergic neurons was investigated. A strong functional indicator of ER stress is nuclear shape 
change. A round-shaped nucleus is an index of a healthy cell, while a stressed cell nucleus is bean-
shaped (unpublished observation).  
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4.13.1 DAPI- Immunofluorescence of CAD cells- on the nuclear shape, chronic exposure 
(differentiating cells); Sham vs Treated (100µM vanadium) 
Nuclear shape morphology is an index to establish ER stress spherical nuclear is indicative of 
a healthy morphology whilst, crescent shape is indicative of stress cells.   
 
Figure 4.20: Immunofluorescence labelling of nuclear shape in differentiating (chronic 
exposure to vanadium-100μM) CAD cells; sham vs treated.  
Results show mostly circular nuclear shape in sham-treated (differentiating) cells (A). In contrast, most 
of the treated cells (B) showed alterations in nuclear shapes in most cells. DAPI was used as a nuclear 
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stain (DAPI: 1:1000; incubated for 10mins). Images were obtained on a widefield fluorescence 
microscope (Zeiss Axiovert 200M Apotome) using the 20X objective lens. Scale bars = 100μm). 
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4.13.2 DAPI- Immunofluorescence of CAD cells- on the nuclear shape, acute exposure 
(differentiated cells); Sham vs Treated (100µM) 
Acute treatment of matured cells with oxidative stress dose (100µM)  shows a higher number 
of crescent-shaped nuclear in relation to sham-treated cells. 
 
 
Figure 4.21: Immunofluorescence labelling of nuclear shape in differentiated (acute-
24h, exposure to vanadium;100μM) CAD cells; sham vs treated.  
Results show mostly circular nuclear shape in sham-treated (differentiated cells (A). In contrast, most of 
the treated cells (B) showed alterations in nuclear shapes. DAPI was used as a nuclear stain (DAPI: 
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1:1000; incubated for 10mins). Images were obtained on a widefield fluorescence microscope (Zeiss 
Axiovert 200M Apotome) using the 20X objective lens. Scale bars = 100μm). 
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4.13.3 DAPI- Immunofluorescence of CAD cells- on the nuclear shape, acute exposure 
(differentiated cells); at different stages of development Sham vs Treated (10 µM & 100 
µM) 
 
Figure 4.22:  Effects of vanadium on the nuclear shape of three stages of development of 
CAD cells. 
Results show the effect of acute exposure of Vd (10μM & 100μM) in immature 
(undifferentiated), maturing (differentiating) and matured (differentiated) CAD cells; sham vs 
treated. Oxidative stress dose had a significant effect on nuclear shapes (clearly shown in 
Fig.3.19 and Fig.3.20). DAPI was used as a nuclear stain (1:1000; incubated for 10mins). 
Images were obtained on a widefield fluorescence microscope (Zeiss Axiovert 200M Apotome) using 
the 10X objective lens. Scale bars = 100μm) 
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4.14 PDI  
The biochemical function of the enzyme, Protein Disulphide Isomerase (PDI) is adapted to 
form, breakdown and rearrange disulphide bonds that support in promoting the formation of 
native conformation in a misfolded or unfolded protein. Protein misfolding within the ER 
triggers ER stress. thus, the upregulation of PDI. PDI is upregulated in various tissues during 
disease and interestingly, its protective and detrimental effects have been described (Hertz 
and Mollereau, 2014). PDI is upregulated in dopaminergic neurons and Lewy bodies of 
patients with PD (Con, et al., 2004; Uehara, et al., 2006; Varma and Sen, 2015; Fernandes, et 
al., 2016).  The effect of low and oxidative stress doses of Vd of PDI expression will help 
elucidate the molecular mechanism underpinning disease pathology associated with sporadic 
PD associated with this heavy metal. 
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4.14.1 PDI Immunofluorescence: Effect of chronic exposure vanadium on 
differentiating cells Sham vs Treated (100µM)  
The protein disulphide isomerase (PDI) is located around the nucleus. Chronic exposure of 
differentiating CAD cells to oxidative stress dose of Vd (100µM) shows morphological 
differences in shapes between the treated and sham group  Figs 4.23 and 4.24 below.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.23: Immunofluorescence labelling of PDI expression in differentiating (chronic 
exposure) CAD cells; sham vs treated (100μM Vd). 
Results show the perinuclear localisation of PDI expression in sham-treated differentiating 
cells (upper panel) which are mostly round- shape compared to the treated cells. In contrast, 
most of the treated cells (chronic treatment-100μM Vd; lower panel) are bean-shaped; an 
indication of stressed-cells. The immunofluorescent signal labels PDI in differentiated CAD 
cells. Polyclonal PDI was stained with Alexa Fluor 488 (1:500; incubated for 25mins); 
Primary AB PDI: 1:200 (incubated for 2 hours). Images were obtained on a widefield 
fluorescence microscope (Zeiss Axiovert 200M Apotome) using the 20X objective lens. 
Scale bars = 100μm). 
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4.14.1.1 PDI Immunofluorescence: Effect of chronic exposure vanadium on differentiated cells 
Sham vs Treated (100µM).  
Results of acute treatment of differentiated CAD cells to oxidative stress dose Vd (100µM) 
shows a distinct morphological difference of the perinuclear location of PDI in the treated vs 
the sham group. 
 
Figure 4.24: Immunofluorescence labelling of PDI expression in differentiated (acute 24 
hours exposure) CAD cells; sham vs treated (100μM).  
Results show the perinuclear localisation of PDI expression with more rounded shaped cells 
in sham-treated differentiated cells (upper panel). In contrast, most of the treated cells (lower 
panel) are bean-shaped; an indication of stress-cells. The immunofluorescent signal labels 
PDI in differentiated CAD cells. Polyclonal PDI was stained with Alexa Fluor 488 (1:500; 
incubated for 25mins); Primary AB PDI: 1:200 (incubated for 2 hours). Images were obtained 
on a widefield fluorescence microscope (Zeiss Axiovert 200M Apotome) using the 20X 
objective lens. Scale bars = 100μm). 
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4.14.1.2 PDI Immunofluorescence: Effect of vanadium on the nuclear shape at different stages of 
development Sham vs Treated   
Cross-sectional representation of PDI expression at different stages of development for both 
low dose and oxidative stress doses of Vd. 
 
Figure 4.25: Effects of vanadium upon PDI expression in different stages of 
development of CAD cells exposed to vanadium (10μM & 100μM) -undifferentiated, 
differentiating, and differentiated CAD cells.  
The immunofluorescence signal indicating PDI signal (green), shows a circular pattern 
around the nucleus in the control group (clearly shown in Figs. 3.22 and 3.23 above) as 
compared with sham vs treated (10μM & 100μM. Polyclonal PDI was stained with Alexa 
Fluor 488 (1:500; incubated for 25mins); Primary AB PDI: 1:200 (incubated for 2 hours). 
Images were obtained on a widefield fluorescence microscope (Zeiss Axiovert 200M 
Apotome) using the 20X objective lens. Scale bars = 100μm). 
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4.15 Discussion 
This chapter was devoted to investigating the effect of sub-toxic Vd (an exogenous metal) 
which has been proposed as a potential causal agent of  PD. The aetiology of PD has been 
broadly categorised into familial (genetic) or sporadic (xenobiotics) (Dauer, et al., 2003). 
Familial causation of PD occurs through the recessively inherited loss-of-function mutations 
in parkin, DJ-1, and PINK1 which leads to mitochondria dysfunction and accumulation of 
reactive oxygen species (ROS) (Springer, et al., 2011). However, the dominantly inherited 
missense mutations in α - synuclein and LRRK2 affects protein degradation pathways.  
 
This leads to the aggregation of protein (proteinopathies) and accumulation of Lewy bodies. 
PD can also potentially arise as a result of exposure to environmental neurotoxins. These results 
functional impairment of the mitochondrial (Corti, et al., 2005; Rossignol and Bradstreet, 2008; 
Ekstrand and Galter, 2009)  and release of ROS (Patten, et al., 2010) leading to a plethora of 
cellular responses including apoptosis and disruption of protein degradation pathway and 
misfolding of proteins. 
 
As a first step towards determining suitable concentrations for Vd for subsequent experiments 
on neuronal functionality and differentiation, a dose-response effect of Vd on CAD cells was 
performed using acute (24 hours) and chronic (6 days) exposure times on metabolic activity 
(MTT) and cytotoxicity (LDH). From the experiments, neuronal metabolic status was resistant 
to applied Vd in undifferentiated, differentiating, and differentiated CAD cells, with IC50 
values >1000µM. However, on chronic exposure, undifferentiated cells were relatively more 
sensitive to Vd (6 days exposures) with IC50 values of ca.30µM (from day 3 of exposure) in 
contrast to differentiated CAD cells with IC50 values of 500µM.  
 
Based on these results, 10µM of Vd was shown to have no significant effect upon metabolic 
rate or cytotoxicity, while 100µM of Vd only reduce metabolic rate for undifferentiated CAD 
cells (from day 3 of chronic exposure) and no significant effect on differentiating and 
differentiated CAD cells (6 days of exposure) – but remained non-cytotoxic for differentiated 
CAD cells as shown in the LDH result in Fig 3.6.  
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Vd-induced oligodendrocyte cytotoxicity is modulated by iron content (Todorich, et al., 2011). 
Therefore, the metal content in undifferentiated and differentiated CAD neurons was 
investigated. A significant difference was observed in metal content with a  significant 
variation in the concentration of metals in undifferentiated and differentiated CAD cells 
(Fig.4.4). The concentrations of Fe, Mg and Mn were significantly higher in undifferentiated 
CAD cells compared to differentiated cells. However, Ca2+ levels were significantly higher in 
differentiated CAD cells with over 300% difference in Ca2+ content compared with that in 
undifferentiated cells. Mg (226.85 ppb) was about 350% higher in undifferentiated cells 
compared to differentiated cells (66.31 ppb). The concentration of Fe2+ in undifferentiated cells 
(14.79 ppb) was over 3-fold higher than differentiated cells (4.8 ppb).  
 
There is a growing concern on the role of redox-active transition metals in the etiopathology 
of neurodegenerative disorders, such as PD, AD and Amyotrophic Lateral Sclerosis (ALS). 
These metals are crucial in most biological reactions, notably Fe. However, excessive tissue 
accumulation of Fe can be cytotoxic, particularly due to the fact that perturbation in metal 
homeostasis leads to a plethora of cellular disturbances characterised by oxidative stress and 
an increase in the production of free radicals. The resultant oxidative stress leads to the 
production of reactive oxygen species (ROS) and concomitant molecular damage, resulting in 
critical failure of biological functions and ultimately cell death. It is noted that Vd capacity to 
disrupt iron homeostasis and resultant depletion of iron from intracellular iron store underpins 
its role in ROS generation and subsequent cytotoxicity (Ghio, et al.,2015). Ghio and his 
colleagues (2015) reported that Vd can reduce the non-heme iron in the mitochondria and 
nuclear fraction in the bronchial epithelial cells with a resultant increase in the non-heme iron 
of the supernatant.  
 
The associated iron deficiency created by Vd results in the increase expression of DMT-1 and 
triggers the production of oxidants such as superoxide (Ghio, et al.,2015). There is a strong 
indication that a strong relationship exists between Vd and Fe. For example, Vd toxicity is 
markedly reported in cells known to utilize a great deal of iron, such as the Oligodendrocytes 
Progenitor Cells (OPC) (Todorich, et al., 2011). Though essential for cellular respiration as a 
component of cytochromes protein in the mitochondria-electron transport chain and 
metabolism, Fe can undergo univalent redox reactions. Its oxidized and reduced forms - ferric 
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and ferrous iron respectively in aberrant levels has been implicated in most cases of 
neurodegenerative diseases – hence, its level is tightly regulated. 
 
Fe chelation, therefore, as a possible therapy to mitigate against these effects has been 
proposed. As highlighted above, Vd-induced toxicity is exacerbated in the presence of Fe in 
oligodendrocyte progenitor cells (Todorich, et al., 2011). The effect of iron chelation (DFO) 
on Vd insults in cells was, therefore, explored. To select the appropriate concentration of DFO 
to use for the experiments and to ensure that DFO had no significant effect on CAD cells 
viability, an acute (24 hours) treatment of CAD cells with a wide range of concentrations was 
performed. DFO does not elicit any apparent neurotoxic effect (up to 250µM). Based on the 
dose-response curves, 10µM Vd was selected as a non-toxic, non-stress dose and 100 µM as 
non-toxic, mild-stress dose, respectively, for the subsequent molecular, cellular, and functional 
analyses. Both the synthetic (DFO) and natural Fe chelator (Aloysia citrodora Palau)  
significantly and efficiently protected against chronic (6 days) exposure to Vd (200μM) and 
induced significant mitochondrial stress (approx. 50%), which favours the case for iron 
chelation therapy (Fig. 4.6). 
 
Functional effects of sub-toxic concentrations of Vd (10μM) have a neuroprotective effect 
against Vd-induced toxicity following chronic exposure. Oxidative stress dose (100 μM) had 
no apparent effect on mitochondrial stress and is non-cytotoxic confirmed by LDH release 
assay (Fig. 3.6) in immature cells (undifferentiated). These findings correlate with that reported 
by Fatola, et al (2019) where they noted that at concentrations commonly used as a 
nutraceutical, Vd is non-toxic; due to the low absorption rate of dietary Vd. However, Rehder 
(2015) adduced the metabolic regulatory functions of Vd to its resemblance to phosphate in 
structure - which mirrors the functional crosslink between vanadate and phosphate-dependent 
enzymes, in which the protein binding domains for phosphate is blocked by vanadate. This 
interaction (vanadate-phosphate antagonism) couple with the influence of Vd on DNA as well 
as its involvement on ROS generation has been identified as Vd’s mode of action in therapeutic 
application.  
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Intracellular calcium mobilisation is a useful method to assess the functional effects of Vd. 
Calcium changes can reflect effects upon voltage-gated calcium channels, intracellular calcium 
stores in the ER and mitochondria organelles. The non-toxic dose of Vd (10µM) had no clear 
effect on the cell body intracellular calcium levels or elevation due to KCl–induced 
depolarisation in undifferentiated CAD cells (See Fig 3.7). However, a sub-toxic, yet oxidative 
stress dose of Vd (100µM) caused a modest rapid inhibitory spike followed by a protracted 
inhibition, with limited effects upon depolarisation response. In differentiated CAD cells, a 
contrasting effect was observed between the cell body and cell process (Fig 3.9). Vd (10µM) 
again showed no effect alone or KCl-induced depolarisation on the cell body. In contrast, a 
sharp but transient large increase in intracellular calcium in the process upon depolarisation 
was attenuated by 100µM Vd.  
 
As noted above, 10μM of Vd has no apparent effect on mitochondrial stress and is non-
cytotoxic while 100μM does elicit mild mitochondrial stress in undifferentiated but is non-
cytotoxic. Differential levels of Fe in undifferentiated cells (14.79 ppb) and differentiated cells 
(4.8 ppb) correlate with sensitivity to Vd. As earlier mentioned, a strong relationship exists 
between Vd and Fe which explains the susceptibility of undifferentiated CAD cells to Vd.  
 
Fe has been shown to aggravate the cytotoxic effect of cells in culture (Todorich, et al., 2011). 
This is made possible by the capacity of Vd to disrupt Fe homeostasis and further depletion of 
Fe from intracellular store - which is the mechanism that underlies its role in the generation of 
reactive oxygen species and eventual cytotoxicity (Ghio, et al., 2015). Fe deprivation in culture 
has been shown to result in growth arrest (Pittelkow, et al.,1986) which can be reversed by 
exogenous addition of Fe. Also as previously explained, the capacity of univalent iron to 
undergo redox reactions when reduced (ferrous) makes it deleterious to cells.  
 
The possible depletion of intracellular Fe store by Vd and the higher Fe content (in situ) in 
undifferentiated cells may cause the readily available Fe, (in the ferrous oxidative state) free to 
participate in Fenton chemistry. This constitutes a significant source of oxidative stress. The 
ferrous iron subsequently catalysed conversion of hydrogen peroxide into a hydroxide ion and 
a hydroxyl free radical with the concurrent oxidation of ferrous iron to ferric iron (Dunford, 
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1987). As noted, (Fig 4.6) above, Iron chelation protects against toxic Vd concentration this in 
contrast to Cu (previous chapter) where iron chelation exacerbates toxicity.  
 
In contrast to sub-toxic doses, spiking with a toxic dose (500µM) elicited a modest increase in 
calcium signal in both the cell body and processes but did not suppress the depolarisation 
response in the cell body or process. However, whilst the signalling response in the cell body 
was restored to the baseline, at this dose, it was further repressed in the processes (post- 
depolarisation) - an indication that this may have a serious implication of synaptic plasticity 
and transmission. 
 
Whilst 10μM of Vd had no apparent effect on mitochondrial stress and is non-cytotoxic and 
100 μM does elicit mild mitochondrial stress in undifferentiated but is non-cytotoxic. These 
(concentrations 10μM and 100μM) have effects on differentiation and ER stress. The effect of 
Vd on differentiation was elucidated with the differentiation marker (MAP2). Microtubule 
associate protein, MAP2 is a protein that belongs to the MAP family, involved in microtubule 
assembly, an essential step in neuritogenesis. It serves to stabilize microtubule (MT) growth 
by cross-linking with intermediate filaments and other MTs. Its equivalent in mouse and rats 
are the neuron-specific cytoskeleton that is enriched in dendrites, implicating a role in 
determining, as well as stabilising, dendrite shape during neuron development. As previously 
stated (in Section 3.10), four isoforms of MAP-2 had been delineated which are restricted to 
the somatodendritic compartment, viz; high molecular weight MAP2a (~280 KD) and MAP2b 
(~270 KD) and the low molecular weight MAP2c (~70 KD) and 2d (~68 KD) have been 
identified in the neurons (Dehmelt, et al., 2005).  
 
MAP2a which are often localised in the dendrites appears at the end of the differentiation 
process and it is absent in axons. Whereas MAP2b is found early in the differentiation process, 
therefore, any xenobiotics that interferes with embryogenesis may adversely affect the 
expression of MAP2b, hence, the differentiation process. MAP2b is often located in the 
dendrites (Doll, et al., 1993). There is a marked increase concentration of MAP2b during the 
maturation process but is absent in the axons. MAP2b are found in early development but are 
replaced. 
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The only two detectable isoforms in differentiated CAD cells were MAP2c and 2d (latter most 
prominent) which is surprising. In differentiated CAD cells, following acute exposure (24 
hours) (10µM) of Vd, caused an up-regulation of MAP2c and 2d, which, however, was not 
statistically significant. In contrast, 100µM Vd caused a marked decrease in MAP2c 
expression, while chronic exposure of differentiating CAD cells to a toxic dose (1000µM) 
showed some expression of MAP2d but completely lacked the expression of 2c, 2b and 2a (not 
shown). MAP2c are juvenile forms of MAP2 and are found in both dendrites and axons. Their 
levels diminish during neuronal development. Besides, their presence during embryogenesis 
are transitional, and it is eventually replaced by MAP2a in the matured neurons (Banker and 
Goslin, 1990). The significant decrease in the expression of MAP2c and the absence of MAP2a 
and MAP2b suggest that acute exposure of matured CAD cells to Vd affected the further 
development of neurites in these matured CAD cells.  
 
Low molecular MAPs (2C and 2D) are expressed in developing neurons, mostly prenatally 
(Melkova, et al., 2019). The downregulation of MAP2D and absence of 2C, 2B and 2A 
following chronic exposure of CAD cells to Vd to oxidative stress dose (100uM) suggest that 
this concentration of Vd interferes with microtubules dynamics (which is crucial in intracellular 
cargo trafficking along the axons and dendrites (Pellegrini, et al., 2017).  
 
Goslin and Banker (1990) posited that MAPs and tau that are specifically expressed in the 
neurons are pivotal molecules to produce dendrites and axonal processes. Caceres and Kiosk 
(1990) further pointed out that if the expression of MAP2 is suppressed, it inhibits the 
development of exploratory neurites, but suppression of tau prevents the differentiation and 
maintenance of the axonal process. This was further confirmed in a related study by Caceres, 
et al (1991; 1992). However, upregulation of MAP2c and 2 days by sub-toxic dose (10µM) of 
Vd, may be associated with a possible neuroprotective effect. This correlates with findings on 
metabolic function, where oxidative stress dose (10µM) had no apparent effect on 
mitochondrial stress and is non-cytotoxic. Findings from immunofluorescence investigations 
on MAP2 - result (Fig.4.12 cf  Fig. 4.13 and Fig. 4.13) also confirms that this concentration 
does not affect the neuronal processes in both chronic and acute exposures. 
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4.15.1 PDI expression and ER stress response 
Protein disulphide isomerase (PDI) is a versatile redox chaperone of the endoplasmic reticulum 
(ER). It is detected as a signal around the nucleus because of the proximity of the ER to the 
nucleus, and both organelles are closely associated/interact in the process of protein expression 
and maturation. Immunofluorescence result obtained provides qualitative information on the 
effect of 10μM and 100μM exposure on CAD cells to establish the presence or otherwise of 
possible Vd-evoke stress. In our investigation, we seek to explore the effect of sub-toxic dose 
(10uM) and oxidative stress dose (100uM) of Vd on the Redox regulation of PDI.  
In reducing condition, treatment of differentiating cells (chronic – Fig. 3.13) and differentiated 
cells (acute – Fig. 3.14) with sub-toxic dose Vd (10μM) resulted in a downregulation in the 
expression of PDI (signal). Reduced condition (in the presence of DTT) affect the conformation 
of PDI, restricting it to exist only reduced configuration. As PDI catalyses redox reaction, it 
gets reduced and oxidized respectively. This forces the protein to change conformation 
(Galligan and Petersen, 2012). Evidence implicates PDI in increasing the levels of ROS, hence 
inducing oxidative stress and apoptosis (through its chaperone activity) rather than the 
disulphide interchange activity (Fernandes, et al., 2009; Wantabe, et al., 2014). Paes and his 
colleague (2011) noted that only oxidized PDI triggers the production of ROS. Reduced PDI 
inhibits the production of ROS (Paes, et al., 2011). 
Similarly, in non-reducing condition, there was down-regulation of PDI protein expression 
following acute exposure of differentiating cells (chronic exposure- 6 days) to the sub-toxic 
dose of Vd (10μM - Fig. 3.15). This implies, that the expression of PDI in both reducing and 
non-reducing condition remains unchanged (compare to the control). This suggests that the 
sub-toxic dose, in both acute and chronic exposure, did not induce ER stress.  
In contrast, oxidative stress dose of Vd (100μM) resulted in an up-regulation of PDI protein 
expression in both acute (differentiated cells – 24 hours) and chronic exposure to Vd reducing 
and non-reducing conditions (Figs 3.13; 3.14 and 3.15). In moderate ER stress, there is an 
upregulation in PDI protein and concurrently/ concomitant modification of PDI. However, in 
severe stress, a notable increase in PDI expression was evident with oxidative dose (100uM) 
in differentiating cells. There was a significant increase in PDI protein expression. In addition 
to the increase, PDI expression observed in both differentiating and differentiated cells (under 
reducing and non-reducing conditions).  Furthermore, exposure to acute and chronic oxidative 
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stress dose resulted in a double band (upper and lower) PDI signal expression (under both 
conditions) (Figs 3.13; 3.14 and 3.15).  
PDI has been implicated in both the physiology and pathophysiology of neurodegenerative 
conditions (Andreu, et al., 2012). It is upregulated in various tissues in disease conditions 
(Andreu, et al.,  2012), in response to hypoxia in the brain (Tanaka, et al., 2000), in 
dopaminergic neurons and Lewy bodies of patients with Parkinson disease (Uehara, et al., 
2006);  to prevent neuronal apoptosis (Tanaka, et al., 2000). Most studies suggest that the 
stimulation of PDI during ER stress in neurodegenerative diseases reduce the load of misfolded 
proteins and therefore, protective. This protective effect restores proteostasis and increases 
neuronal viability. A metabolic disorder that underlies most neurodegenerative diseases is 
protein misfolding. Since protein misfolding within the ER triggers ER stress and the 
associated up-regulation of PDI. Thus, ER stress is being connected to these diseases (Hetz and 
Mollereau, 2014). From the foregoing, the upregulation of PDI expression (in both acute and 
chronic exposure to Vd) is suggestive that this dose/concentration causes ER stress. This is 
reflected in the immunofluorescence result with PDI and nuclear shape (Figs 3.19 and 3.20 
respectively) where the nuclei displayed an aberrant crescent-formed shape. The nuclear shape 
serves as an indicator for the health of the cells (Chazot and Karakesisoglou - unpublished). 
Furthermore, double bands can be seen in the PDI protein expression in cells (differentiating 
and differentiated cells) (Figs 3.13; 3.14 and 3.15). The presence of reducing agents like DTT 
can alter the conformation of PDI and can influence the running of the protein in a gel. The 
Western blots undertaken in both reducing and non-reducing conditions showed the that the 
different PDI conformations were still present but altered - which was depicted in the double-
band signal seen for PDI on the membrane (Figs 3.13; 3.14 and 3.15).  This presence of double 
band is an indication of post-translational modifications of PDI. 
Aberrant post-translational modification of PDI associated with the state of the disease has 
been reported. Examples of this redox post-translation include S-nitrosylation, carbonylation 
and S-glutathionylation. Various publications have shown that PDI shows S-nitrosylation as 
post-translational modifications in patients suffering from neurodegenerative diseases 
(Forrester, et al., 2006; Uehara, et al.,2006; Nakamura and Lipton, 2019). Several events can 
lead to post translation (modification) of PDI. First, is as a result of metabolic activity at the 
cellular level which could result in accumulation of high levels of reactive nitrogen species 
(RNS), hydrogen peroxide and reactive oxygen species (ROS) in cells. These events provoke 
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nitrosative or oxidative stress. Secondly, nitrosative stress can. This leads to post-translation 
modification of PDI by the addition of NO to active site cysteine residues, resulting in S-
nitrosylation. S-nitrosylation of proteins under pathological conditions is an abnormal, 
irreversible process that is linked to protein misfolding, ER stress and apoptosis. Thirdly, 
proteins resident in the ER is particularly vulnerable to post-translation modification due to the 
presence of critical redox-regulated cysteines.  
Since PDI is the major enzyme responsible for modification of protein disulphide bonds, the 
loss of function of PDI could result in increased cellular protein misfolding and thus increase 
ER stress (Nakamura and Lipton, 2011; Wang et al., 2012) 
S-nitrosylated PDI has been detected in several neurodegenerative diseases (Nakamura and 
Lipton, 2011; Wang, et al., 2012). S-nitrosylation of PDI has been detected in postmortem brain 
tissues of patients with Alzheimer's disease, PD (Uehara, et al., 2006) and lumbar spinal cord 
tissues of ALS patients (Honjo, et al., 2010; Walker, et al., 2010). In essence, S-nitrosylation 
reduces both its chaperone and isomerase activity (Uehara, et al., 2006).  
These unfolded (Vitale and Boston, 2018; Cola Emanuela, 2019), However, in a persistent 
chronic state, it can further attenuate UPR and cause neuronal cell death. Hence, aberrant 
modifications of PDI lead directly to harmful effects as well as a loss of the normally protective 
properties of PDI.  
Overall, low sub-toxic levels of Vd have a range of morphological, cellular, functional, and 
molecular effects, which dose-dependently range in severity (between 10µM and 100µM), 
including morphological changes, cellular stress, reduced process excitability. The next chapter 
is designed to explore the behavioural (motor activity), and biochemical effects as well as 
ageing (lifespan) of a sub-toxic low dose (1µM) Vd upon wild-type and PD Drosophila fly 
models. 
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Chapter 5:  Interplay between iron and vanadium in PD in an in 
vivo model 
In the preceding chapter, we explored the interplay between Vd and iron in an in vitro model 
- Catecholaminergic a-differentiated (CAD) cells. This chapter is devoted to investigating the 
effect of Vd in an in vivo model (Drosophila melanogaster). We investigated the effect of 
chronic exposure of Drosophila melanogaster (WT and mutant) to low dose Vd, particularly 
the effect on iron-induced oxidative stress, motor activity and life span in both wild-type and 
the Pink-1 mutant Drosophila PD model. 
 
5.1 Introduction 
The PD pathology is characterised by distinct cellular defects, notably abnormal protein 
aggregation, oxidative damage, mitochondrial dysfunction, and a selective loss of 
dopaminergic neurons in the substantia nigra pars compacta (SNpc). The PD brain SNpc has 
also been found to have higher levels of iron than age-matched controls, which has been 
associated with mitochondrial dysfunction (Dexter, et al., 1991; Bharath, et al., 2002; Dauer 
and Przedborski, 200; Kaur and Andersen, 2004; Salazar, et al., 2008). Familial (genetic) 
inheritance accounts for 5 to 10 % of cases of PD while up to 90% are sporadic.  
 
Recent studies have linked environmental factors interacting with a genetic predisposition in 
the causality of PD (Bjorklund, et al., 2018; Draoui, et al., 2020). Several studies have 
reported several PD genes that are activated by xenobiotic as evidence of a link between 
environmental toxicants and PD (Rybicki, et al., 1993; Shiba-Fukushima, et al., 2014; 
Kumudini, et al., 2014). Several epidemiological studies have particularly reported an 
association between PD and exposure to metals (Zayed, et al., 1990; Winkel, et al., 1995; 
Gorrel, et al., 1997; Kuhn, et al.,1998; Gorrel, et al., 1999; Miller, et al., 2009; Coon, et al., 
2006; Taba, 2017).  The cellular toxicity of exogenous heavy metals such as Vd has 
previously been shown to be exacerbated in the presence of iron in oligodendrocyte 
progenitor cells (Todorich, et al., 2011; Olopade and Conor, 2011; Fatola, et al., 2019). As a 
heavy metal nutraceutical, Vd has some therapeutic functions. It has been used at, low doses, 
in different health supplement formulations (Rehder, 2015). Environmental exposures to low 
dose Vd can have deleterious effects on the population over extended periods. 
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5.1.1 ROS/RNS, Oxidative Stress and Neurodegenerative Diseases 
Reactive Oxygen Species (ROS) is a group of reactive molecules derived from oxygen 
(Bolisetty, et al., 2013). They are labile and highly reactive due to their unpaired valence 
electrons (Patten, et al., 2010). These include free radicals (superoxide, O2), hydroxyl radical 
(-OH), or non-radical (hydrogen peroxide, H2O2). Due to its short-lived nature in the cell, O2 
- plays a key role in ROS production. It can be transformed into a more stable H2O2  form (by 
superoxide dismutase) or protonated to form H2O2. The resulting H2O2 can form a highly 
reactive hydroxyl radical –OH (Patten, et al., 2010). This can further be broken down into 
H2O and O2 by catalase, glutathione peroxidase, and other peroxidases (Song, et al., 2015).  
 
The most reactive ROS that is mainly responsible for the cytotoxic effects in cells is –OH 
(Bolisetty, et al., 2013). Through a process of Fe2+-mediated decomposition, -OH can be 
generated from H2O2 and O2, which is catalysed by Fe ions by Fenton reaction (Zorov, et al., 
2014). Reactive Oxygen Species (ROS) in cells have an endogenous and exogenous origin 
(Mani, 2015). Endogenous production of ROS is mediated enzymatically by mitochondrial 
and non-mitochondrial derived enzymes. Thus, comprising nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase, (NOx), xanthine oxidase (XO), cytochrome p450 
(from ER) and Flavin oxidase-from peroxisomes (Song, et al., 2015; Mani, 2015). ROS are 
predominantly produced from the mitochondrial respiratory chain and NOx system.  
 
A significant driver of the pathogenesis of PD is oxidative stress (Jiang, et al., 2016). 
Oxidative stress results in mitochondrial dysfunction (Bonnard, et al., 2008; Hsu, et al., 2000; 
Hastings, 2009). There is an upregulation of ROS production and oxidative stress in patients 
with PD. Besides, the impairment of mitochondrial functionality has been reported in PD 
patients (Hald and Lotharius, 2005; Zhou, et al., 2008; Gan, et al., 2014). The increased 
oxidative stress is underscored by elevated iron levels (Gotz, et al., 1990; Hartley, et al., 
1993), elevated lipid peroxidation (Boll, et al., 2008; Agil, et al., 2006; Sanyal, et al., 2009), 
nuclei acid oxidation (Zhang, et al., 1999; Kikuchi, et al., 2002; Moreira, et al., 2008; Sanders 
and Greenamyre, 2013), and low levels of the antioxidant, glutathione (GSH) in the 
dopaminergic areas. 
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5.2 List of Materials & Chemicals  
Table 5.1: Materials and corresponding suppliers 
Product  Supplier 
WT (WT) flies 
- Dahomey; Drosophila melanogaster 
Dr Ed Okello’s lab- Institute of Cellular 
Medicine, Medical School, Newcastle 
University 
PINK1  mutant flies – 
(w- PINK1 B9/FM7. GFP w+ )  
-Drosophila melanogaster PINK1 
Dr Ed Okello’s lab- Institute of Cellular 
Medicine, Medical School, Newcastle 
University 
250ml flies’ bottles Scientific Laboratory Supplies 
Applied Scientific Jazz-Mix Drosophila Food Fisher Scientific (Loughborough, UK) 
Carbon dioxide Sigma Aldrich (Dorset, UK) 
Fly pad Blades Biological (Kent, UK) 
Controlled room (12 hourly day-night cycle 
@25oC) 
Lab 
Brush Blades Biological (Kent, UK) 
Filter using Whatman #1 paper Fisher Scientific (Loughborough, UK) 
Microplate reader - Thermo scientific 
multiskan FC. 
Thermo Fisher Scientific Oy 
 P.O Box 100, FI-01621 Vantaa, Finland 
 
Refrigerated centrifuge (4oC)-  
Eppendorf Centrifuge 5415R.  
Spec:CF3CH2F. 
Eppendorf AG 22331 Hamburg, Germany 
Liquid nitrogen Biosciences Nitrogen Tank 
Synergy H4 hybrid multi-mode microplate 
reader 
 BioTek Instruments, Inc., P.O. Box 998, 
Highland Park, Winooski, Vermont 05404-
0998 USA. 
Vortex (machine) Genie-2; Model:G-560E Scientific Industries Inc. Bohemia, NY, 11716, 
USA 
Plugs  Blades Biological (Kent, UK) 
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Table 5.2: Chemicals and corresponding suppliers 
Product Supplier 
Absolute Ethanol Fisher Scientific, UK 
Ascorbic acid (vitamin C powder) Sigma Aldrich (Dorset, UK) 
Bovine Serum Albumin (BSA) Sigma Aldrich (Dorset, UK) 
Bradford Reagent Sigma Aldrich (Dorset, UK) 
Coomassie Brilliant Blue G-250 Sigma Aldrich (Dorset, UK) 
DCFH-DA (2,7-Dichloroflouresceine 
diacetate) 
Sigma Aldrich (Dorset, UK) 
Deferoxamine (DFO) Mesylate salt Sigma Aldrich (Dorset, UK) 
Dibasic Phosphate buffer (K2HPO4) Sigma Aldrich (Dorset, UK) 
DTNB (Ellman's Reagent) (5,5-dithiobis-(2-
nitrobenzoic acid) 
ThermoFischer Scientific 
Ethanol Sigma Aldrich (Dorset, UK) 
L-DOPA (3,4-Dihydroxy-L-phenylalanine) Sigma Aldrich (Dorset, UK) 
Methanol Fisher Scientific, UK 
Monobasic Phosphate buffer (KH2PO4) Sigma Aldrich (Dorset, UK) 
Phosphoric acid (H3PO4) Sigma Aldrich (Dorset, UK) 
Potassium Phosphate Buffer Fisher Scientific, UK 
Reduced Glutathione- GSH Abcam 
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5.3 Method  
5.3.1 Drosophila melanogaster stocks and culture conditions. 
Drosophila melanogaster PINK1 (w- PINK1B9/FM7.GFPw+) mutant and - Dahomey WT (WT) 
were used for this experiment. Flies were kept in an incubator with a 12 hour day-night cycle 
at 25oC. Fly food was prepared by mixing 15.025g of instant medium (Applied Scientific 
Jazz-Mix Drosophila Food) with 46ml of deionized water (formula with this food: water ratio 
was found to have the best consistency) per bottle; 250mL. Following this, each bottle was 
slightly shaken to ensure even distribution of water. Each bottle was plugged with a foam 
plug and left to set for at least an hour at room temperature before transferring the flies 
(progenies) into them. Fresh food was prepared every two weeks and flies were flipped into 
new bottles.  
5.3.2 Dosage and treatment 
A low dose (oxidative stress dose) of Vd (1µM) was used. This concentration of Vd was 
calculated using the equation by Hong, et al (2011) to convert dosages used in human studies 
to effective and non-toxic doses that could be used in the Drosophila melanogaster 
experiments. To investigate the effect of chronic exposure of Vd on motor activities, lifespan, 
iron chelation and oxidative stress markers, 3 or 4 groups (depending on the experimental 
design) were used. These consisted of a control group (with no treatment), positive control 
(treated with L-dopa; 1.6mg) and a treatment group (Vd-1µM). Each group comprised of five 
replicates and each bottle had 10 flies. To prevent oxidation of L-Dopa, 20.8mg of ascorbic 
acid (equivalent to, 1.6µM) was added to each bottle containing L-Dopa (like the amount 
used in a study by Pendleton, et al. 2002).  
 
At the start of each experiment, flies were allowed to lay eggs on food once the larvae 
appeared, the adult flies were released from the bottles, after 6 days the progenies were 
transferred to fresh food and redistributed onto treatments the next day (which is counted as 
test day zero). To establish the effect of synthetic iron chelation on motor activity and 
lifespan, a dose-dependent effect of DFO (0µM, 5µM, 10µM, and 20µM) was tested –in both 
WT and mutant flies. From the result of this experiment, we established an optimal 
concentration of synthetic iron chelator Deferoxamine (DFO) Mesylate salt required for the 
subsequent experiment as 5µM; WT & 20µM; PINK1. 
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5.3.3 Climbing assay and lifespan 
The motor functions were tested against different treatment regimen with respect to the 
symptoms in PINK1 vs WT flies. This was measured by testing their climbing ability. Adult 
flies were placed in vials with treated foods. These could lay eggs in these vials. After 
eclosion, the adult flies were released, and male flies were selected from their progenies and 
transferred into new vials. These  (selected male) were used for the various chronicity 
investigations - motor activity using a climbing test adapted from Pendleton, et al (2002), 
Nichols, et al (2012) and Cha, et al (2005), conducted with moderate modifications, survival 
test and biochemical assays. Days of the climbing assay (i.e. day zero) is taken as the day the 
progenies were transferred into the new vials.  
 
For the motor activity, all groups were tested at random. Groups of 10-15 flies (depending on 
the experiments) were transferred into empty 100mL Pyrex graduated cylinder with a foam 
plug, and a height of 8cm horizontal line above the bottom of the cylinder was drawn on a 
paper as criteria. The flies were allowed 10 minutes to acclimatise. The flies were then gently 
tapped down and allowed to climb up past the 8cm mark (in 8 seconds) on the chart, and 
afterwards tapped down again. A digital camera was used to record the flies, at 30cm from 
the paper, and a timer was used to record the time. The total number of flies that crossed the  
8cm mark was recorded as the “Escaped flies”. This was repeated twice more.  
 
The climbing assay was performed at 10am, every two to three days. An average of the total 
number of flies that escaped was noted. The ability of surviving flies per day (%) was 
calculated by dividing the number of flies that climbed over the 8 cm mark by the total 
number of surviving flies multiply by a hundred. The survival rate per day was calculated by 
dividing the number of surviving flies by the number of flies on Day Zero (multiply by a 
hundred). Experiment duration was for two weeks (from the start of the experiment). The 
mean of each group was calculated using the data from the three replicates tests. An adjusted 
two-way multiple measure analysis of variance (ANOVA) with post-test Bonferroni 
correction was performed using GraphPad Prism, Version 7 (GraphPad Software, San Diego 
California USA).  
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5.3.4 Sample preparation for biochemical assays 
At the end of exposure (14 days), the flies from each group of control and treated (Vd only; 
Vd + DFO) groups were anaesthetised in ice. The flies were then snapped frozen in liquid 
nitrogen and vortexed at high speed to separate the fly head from the body (since we are only 
interested in measuring the RONS in the head). The detached fly heads were transferred into 
pre-weighed Eppendorf tubes and weighed. It was then homogenised in 0.1M phosphate 
buffer, pH 7.0 (1mg: 10µL), centrifuged for 10 minutes at 4000g (temperature, 4oC). The 
supernatants obtained were stored at -20o C and used to determine the RON’s level, protein, 
and total thiol content. The assays were performed in duplicates for each of the three 
replicates of the treatment groups (Vd only; Vd + DFO) treatment groups. 
  
5.3.5 Measurement of DCFH oxidation for RONS – Kinetic assay  
To determine the RONS level following chronic exposure to Vd and influence of Fe 
chelation, 2’, and 7’-Dichlorofluorescein (DCFH) oxidation was measured as an index of 
oxidative stress according to the method of Perez-Severiano, et al (2004). From the frozen 
supernatant, five microliters (5µL, 1:10 dilution) of each supernatant from Vd only- and Vd + 
DFO- treated and control flies (for both WT and mutant) were transferred into a 96-well 
plate.  
 
Subsequently, 5µL of 200 µM DCFH-DA (final concentration of 5µM) was added to the 
samples and the fluorescence product of DFH oxidation (that is, DCF) was measured for 10 
minutes (at 30-secs intervals), using Synergy H4 hybrid multi-mode microplate reader (See 
Table 5.1) with excitation 488 and 525nm emission. All the experiments were conducted in 
duplicates for each of the three replicates of Vd ±DFO – treated and control flies (for both 
WT and mutant). The rate of DCF formation was expressed in percentage of the control 
group. 
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5.3.6 Total Thiol (T-SH) assay – WT and Mutant. 
The total thiol content for both WT and mutant flies was determined using the method of 
Ellman (1959). The reacting mixture contained 170µL of 0.1 M potassium phosphate buffer 
(pH 7.4), 20µL of the sample as well as 10µL of 10mM DTNB. It was incubated for 30 
minutes at room temperature, the absorbance was measured at 412nm and used to calculate 
the sample total thiol levels (in µmol/mg protein) using GSH as standard. 
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5.4 Results  
These sets of experiments were designed to explore the effect of Vd on an in vivo PD model, 
Drosophila melanogaster- (PINK1 mutant) and WT. The aim was to determine the effects of 
low dose Vd on a mutant PD Drosophila melanogaster model as well as the interaction 
between Vd and iron in neurons. Furthermore, we investigated the ameliorating effect of an 
iron chelator and the effect of chronic exposure to low dose Vd on oxidative stress markers in 
the model. 
5.4.1 Effect of chronic exposure of vanadium (1µM) to motor activity and lifespan in 
Drosophila melanogaster: WT and PINK1 Mutant 
 
5.4.1.1 Time-dependent effect of chronic exposure of sub-toxic vanadium on the motor activity 
and survival of WT. 
A progressive decrease in the motor activity of the WT types of flies with increasing age was 
observed. Besides, in the WT flies, chronic exposure to sub-toxic doses of Vd revealed no 
significant effect. A modest increase in motor activity was seen in flies treated with L-dopa 
(p<0.05) compared to the control group. 
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Figure 5.1: Effect of chronic exposure of vanadium (1µM) on the percentage of flies that 
escaped in the climbing ability test for WT flies.  
A progressive decrease in the motor activity of the flies over time was observed across the 
three groups tested: saline (control blue line), L-dopa (black line) and Vd (1 µM) treatment 
groups. A modest increase in motor activity can be seen with flies treated with L-dopa 
(p<0.0001) as well as the group treated with Vd (p< 0.01) compared with the control group. 
There is no significant difference between the L-dopa and Vd treated group (p<0.1). A 
repeated measure one-way ANOVA (with Tukey’s Multiple Comparisons Test) was 
performed. Panels B show significant contrasting effects on climbing ability after two weeks 
(day 16 for WT and Mutant, respectively), analysed with a one-way ANOVA (with Dunnett’s 
Multiple Comparisons Test) was performed. (ns= p>0.05; *p<0.05; **p<0.01; 
****p<0.0001) 
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5.4.1.2 Time-dependent effect of chronic exposure of sub-toxic vanadium on the motor activity 
and survival of PINK-1 mutant flies  
Vd significantly exacerbated the existing locomotor deficits in mutant PINK-189 flies 
(p<0.01) while L-dopa ameliorated this effect. 
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Figure 5.2: Effect of chronic exposure of vanadium (1 µM) on the percentage of flies 
that escaped in the climbing ability test for PINK1 flies.  
A progressive decrease in the motor activity of the PINK1 flies over time was observed 
across the three groups tested: saline (control blue line), L-dopa (black line) and Vd (1µM) 
treatment groups. Whilst exposure of PINK1 mutant to Vd exacerbated the existing 
locomotor deficits (p<0.001), a significant increase in motor activity was observed with flies 
treated with L-dopa (p<0.0001) relative to the control group. There was no significant 
difference between the L-dopa and Vd treated group (p<0.1 A repeated measure one-way 
ANOVA (with Tukey’s Multiple Comparisons Test) was performed. Panels B show 
significant contrasting effects on climbing ability after two weeks (day 16 for WT and 
Mutant, respectively), analysed with a one-way ANOVA (with Dunnett’s Multiple 
Comparisons Test) was performed. (ns= p>0.05; *p<0.05; **p<0.01; ****p<0.0001).  
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5.4.1.3 Effect of chronic exposure to vanadium (1µM) on survival in WT flies 
Similar to the effect on motor activity, chronic vanadium had no general effect on the 
survival of WT flies apart from a modest effect seen in the first week (Day 5).  However, a 
significant increase in survival of flies treated with L-dopa (p = 0.0016) was observed (Fig. 
4A). 
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Figure 5.3: Effect of chronic exposure of vanadium (1µM) on the percentage of fly’s 
survival in lifespan studies in WT flies.  
A progressive decrease in the lifespan over time was observed across the three groups tested. 
Saline (control blue line), L-dopa (black line) and Vd (1µM) treatment groups. Results show 
a significant increase (and clear effect in the first week) in the lifespan of flies treated with L-
dopa (p<0.01) and a slight, but insignificant, increase in lifespan in the group exposed to Vd 
(1µM) p>0.05, relative to the control.  
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5.4.1.4 Effect of chronic exposure to vanadium (1µM) on survival in PINK1 flies 
In PINK1 mutant flies, a reduction in survival in the Vd treated group (p= 0.0349) relative to 
the control group was observed with the median survival for Vd treated group being 5 days 
compared to 8 days for control flies. There was no significant effect on survival in the L-dopa 
treated group relative to control, with median survival for both groups (WT and PINK1) 
being 8 days. 
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Figure 5.4: Effect of chronic exposure of vanadium (1µM) on the percentage of fly’s 
survival in lifespan studies in PINK1 flies.  
A progressive decrease in the life span over time was observed across the three groups tested. 
Saline (control, blue line), L-dopa (black line) and Vd treatment groups. Results show an 
increase in lifespan in flies treated with L-dopa, though not statistically significant (p>0.05) 
and a reduction in the life span in the Vd treated group (p>0.05) relative to the control. Data 
are presented as mean of SEM of three independent replicates carried out in duplicates: ns 
p>0.05 
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5.4.2 Dose Dependent effect of DFO- Motor Activity and lifespan in – WT and PINK1 
mutant Drosophila melanogaster 
The effect of iron chelation in an in vivo model was investigated to establish the effect of iron 
chelation on motor activity and lifespan (in both WT and mutant flies). The next sets of 
experiments were designed to establish the effect and optimum concentration of synthetic 
iron chelation (DFO) on motor activity and lifespan (in both WT and mutant flies). This is 
aimed at both establishing a possible beneficial or deleterious effect of DFO on DM and the 
optimal concentration useful for further in vivo assays.  
 
5.4.2.1 Motor effect of different concentration of DFO in WT flies (DM) 
PDF optimisation result shows that 5µM resulted in an improved and a significant increase in 
motor activity with WTs flies. 
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Figure 5.5: Dose-dependent effect of Iron Chelator (Deferoxamine Mesylate-DFO) 
following chronic exposure on Drosophila melanogaster WT.  
Result of dose-dependent concentrations of DFO (0µM, 5µM, 10µM, and 20µM) on motor 
activity in WT DM shows a decrease in motor activity with time, but a relative increase in 
motor activity following treatment with DFO can be seen when compared with the control 
group. An improved (and significant) motor activity with DFO can be seen with the group 
treated with 5µM (p<0.1) when compared with control; as against 10µM (p>0.05); second 
week of treatment. However, the optimal effect of DFO is seen in the group treated with 
20µM (p>0.05). All values are means (± SEM) from 5 separate experiments and n=10 for 
each experiment: with a Tukey’s Multiple Comparisons Test (repeated measures two-way 
ANOVA). 
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5.4.2.2 Motor effect of different concentration of DFO in PINK1 flies (DM) 
In contrast to WT flies, DFO optimisation in mutant shows that 20µM of DFO resulted in an 
optimum improvement in motor activity in the mutant. 
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Figure 5.6: Dose-dependent effect of Iron Chelator (Deferoxamine Mesylate-DFO) 
following chronic exposure on Drosophila melanogaster PINK1.  
Result of dose-dependent concentrations of DFO (0µM, 5µM, 10µM, and 20µM) on motor 
activity in PINK1 flies shows a decrease in motor activity with time. Improved motor activity 
(though not significant) can be seen with lower concentrations 5µM (p>0.05) and 10µM 
(p>0.05) in the first week when compared with the control group. The optimal (but not 
significant) effect of DFO was seen with the group treated with 20µM (p> 0.05) when 
compared with control. All values are means (± SEM) from 5 separate experiments and n=10 
for each experiment: with a Tukey’s Multiple Comparisons Test (repeated measures two-way 
ANOVA). 
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5.5 Effects of iron chelation on survival in both WT and mutant flies were 
investigated. 
 
5.5.1 Effect of dose-dependent concentration of DFO on the survival of WT flies (DM) 
There was an increased survival rate in flies exposed to a higher concentration of DFO (20 
µM). This contrasted with the response from the motor activity where a low dose of DFO 
(5µM) improved motor activity.  
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Figure 5.7: Dose-dependent effect of Iron Chelator (Deferoxamine Mesylate-DFO) 
following chronic exposure on Drosophila melanogaster PINK1.  
Result of dose-dependent concentrations of DFO (0µM, 5µM, 10µM, and 20µM) on lifespan 
in PINK1 flies shows decrease lifespan with age. An enhanced lifespan effect can be seen in 
the group treated with 20µM (p<0.1) and 10µM, not significant, (p>0.05) when compared 
with the control group. The group treated with 5µM did not enhance lifespan (p>0.05) when 
compared with control. All values are means (± SEM) from 5 separate experiments and n=10 
for each experiment: with a Tukey’s Multiple Comparisons Test (repeated measures two-way 
ANOVA). 
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5.5.2 Effect of dose-dependent concentration of DFO on the survival of PINK 1 flies 
(DM) 
There was an increased survival rate in flies exposed to a lower concentration of DFO (5µM). 
This contrasted with the response from the motor activity where a high dose of DFO (20µM) 
improved motor activity.  
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Figure 5.8: Dose-dependent effect of Iron Chelator (Deferoxamine Mesylate-DFO) 
following chronic exposure on Drosophila melanogaster PINK1.  
Result of dose-dependent concentrations of DFO (0µM, 5µM, 10µM, and 20µM) on lifespan 
in PINK1 flies shows a decrease in lifespan with time. Significant enhancement of lifespan 
can be seen with flies treated with 5µM (p<0.01) DFO when compared with the control 
group. Also, 10µM DFO improved lifespan but not significant (p>0.05) when compared with 
the control, while 20µM DFO had a marked reduction in lifespan, though not significant 
(p>0.05) when compared with control. All values are means (± SEM) from 5 separate 
experiments and n=10 for each experiment: with a Tukey’s Multiple Comparisons Test 
(repeated measures two-way ANOVA).  
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Having established the effect of Fe chelation on both the mutant and WT flies, an effective 
optimum concentration was selected. This concentration was used in exploring the effect of 
Fe chelation on motor functions and lifespan in chronic exposure to Vd in the presence and 
absence of Fe with 20µM and 5µM of DFO in WT respectively, as the optimum 
concentration with improved motor activity. 
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5.6 Effect of iron chelation on Drosophila Melanogaster on motor activity 
and Life span: In the presence of vanadium  
 
5.6.1.1 Motor response to iron chelation following exposure to vanadium (1µM) in WT flies 
To determine the effect of iron chelation on the VD - exacerbated motor deficits in PINK1 
mutant flies, DFO was given to a sub-set of mutant flies (Vd +DFO). A significant 
improvement was observed in the motor activity in the presence of the iron chelator (DFO) + 
Vd on Day 10. 
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Figure 5.9: Effect of iron chelation on motor activity in WT (DM) following chronic 
exposure to Vd (1µM).  
Result of iron chelation with DFO (20µM) on motor activity in WT flies shows a decrease in 
motor activity with time. In the first couple of days post-treatment, there was a modest (but 
insignificant) increase in motor activity followed by a continuous decrease in motor activity 
with Vd (p>0.05) and Vd + DFO (p>0.05) as compared with control and Vd + DFO treatment 
group (p>0.05). All values are means (± SEM) from 5 separate experiments and n=10 for 
each experiment: with a Tukey’s Multiple Comparisons Test (repeated measures two-way 
ANOVA).  
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5.6.1.2 Chronic exposure of Drosophila melanogaster (PINK1 mutant) to low dose vanadium: 
influence of iron  
Iron is an essential transition metal which is critical in many physiological functions in the 
cell and it is tightly regulated. As an enzyme co-factor, it protects the cell from oxidative 
damage. However, in the aberrant state, it is toxic and implicated in iron-mediated oxidative 
and carbonyl stress resulting in the alteration of internal homeostasis milieu. Vd toxicity is 
exacerbated in the presence of Fe (Todorich, et al., 2011).  
 
This study was designed to investigate the possible benefits or otherwise of Fe chelation in 
an in vivo model- DM. A synthetic Fe chelator (DFO) was used is an iron-chelating agent. 
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Figure 5.10: Chronic exposure of Drosophila melanogaster (PINK mutant) to low dose 
vanadium: influence of iron chelation.  
Exposure of PINK1 mutant to Vd exacerbated the existing locomotor deficits in PINK1 flies 
(p<0.01) compare to the control. However, a moderate (but non-significant) improvement 
was observed in the motor activity in the presence of the iron chelator (DFO) + Vd (p>0.05) 
and DFO only (p>0.05) treated group (p>0.05) when compared with Vd only treated group. 
All values are means (± SEM) from 5 separate experiments and n=10 for each experiment: 
with a Tukey’s Multiple Comparisons Test (repeated measures two-way ANOVA). 
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5.6.2 Effect of Fe iron chelation on life span in PINK1 mutant and WT. 
 
5.6.2.1 Survival response to iron chelation following exposure to vanadium (1µM) in WT flies 
Iron chelation did not enhance survival rate in WT flies following chronic exposure to Vd 
(1µM) in relation to Vd only group. However, a slight increase in survival rate was observed 
about the control group. 
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Figure 5.11: Effect of iron chelation on lifespan in WT flies (DM) following chronic 
exposure to vanadium (1µM).  
Result of iron chelation using DFO (20µM) on lifespan in PINK1 flies shows a decrease in 
lifespan with time. A slight enhancement in lifespan was observed in Vd treated group in WT 
flies, but non-significant (p>0.05), when compared with control or in the presence of DFO 
(p>0.05). There was no significant difference in lifespan between the control group and the 
Vd + DFO treated group (p>0.05). All values are means (± SEM) from 5 separate 
experiments and n=10 for each experiment: with a Tukey’s Multiple Comparisons Test 
(repeated measures two-way ANOVA).  
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5.7 Effect of vanadium and iron chelation on D. Melanogaster Brain oxidative stress 
markers (ROS, RONS and T-SH) - WT versus Mutant (PINK1) 
 
Oxidative Stress (OS) plays a central role in the common pathophysiology of 
neurodegenerative diseases, such as PD. The brain is particularly vulnerable to the effects of 
ROS due to its high oxygen demand and owing to the presence of peroxidation-susceptible 
lipids cells. Oxidative stress predisposes to the degeneration of vulnerable neurons. The cause 
of this oxidative stress is multifactorial: mitochondria dysfunction, increased dopamine 
metabolism. Thus, leading to excess production of hydrogen peroxide and other ROS, 
increased reactive iron and a breakdown of the antioxidant defence pathways as well as a 
high oxidative intracellular environment in the dopaminergic neurons.  
 
Mitochondrial dysfunction, alterations of the Ubiquitin Proteasomal System (UPS) and 
oxidative stress may lead to a cascade of events which act synergistically in the etiopathology 
of PD. The effect of chronic exposure of WT and PINK1 mutant flies to low dose (oxidative 
stress dose) Vd (1µM) was investigated. Oxidative stress markers (ROS/RONS) were 
measured. 
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5.7.1 Reactive Oxygen and Nitrogen Species (ROS) levels with Vanadium (1 µM): 
influence of iron chelation – WT 
Measurement of ROS production in the WT flies, with a low dose of Vd, significantly 
reduced ROS generation after 14 days compared to the controls and iron chelation (DFO) 
completely reverses this Vd-induced reduction of ROS. 
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Figure 5.12: Kinetic assay of ROS levels in WT flies’ brains after chronic exposure to 
vanadium.  
Results showed that treatment with a low dose of Vd (1µM) decreased ROS generation after 
10 days in WT flies when compared with the control (p<0.0001). In contrast, iron chelation 
enhances ROS generation (Vd + DFO), though not significant when compared with the 
control group (p>0.05). ROS level following iron chelation was markedly significant in 
comparison with the Vd only treated group (p<0.0001). All values are means (± SEM) from 2 
separate experiments and n=50 for each experiment: with a Tukey’s Multiple Comparisons 
Test (repeated measures two-way ANOVA). 
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5.7.2 Reactive Oxygen Species (ROS) levels with Vanadium (1µM): influence of iron 
chelation – PINK1  
Measurement of ROS production in PINK1 mutant fly brains revealed that treatment with a 
low dose of Vd enhanced ROS generation after 14 days, compared with the control group, 
and that iron chelation (DFO) significantly reverses this. 
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Figure 5.13: Kinetic assay of ROS levels in PINK1 flies’ brains after chronic exposure to 
vanadium.  
Results showed that treatment with a low dose of Vd (1µM) enhanced ROS generation after 
10 days in PINK1 flies when compared with the control group (p<0.01). In contrast, iron 
chelation (Vd + DFO; 20µM) seems to decrease ROS generation, though not significant 
when compared with the control group (p>0.05). However, comparing the enhanced ROS 
levels following treatment with Vd only with Vd + DFO was significant (p<000.1). All 
values are means (± SEM) from 2 separate experiments and n=50 for each experiment: with a 
Tukey’s Multiple Comparisons Test (repeated measures two-way ANOVA). 
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5.8 Reactive Oxygen and Nitrogen (RONS) levels in DM brains following treatment 
with low dose vanadium (1µM): Iron chelating effect (DFO: 5µM; WT and 20µM; 
PINK1). 
 
Dysfunction of the mitochondrial respiratory system is a major source of RONS in the cell. 
Excessive RONS may induce dysfunction of the UPS resulting in protein aggregation. This 
explains the aetiology of the two PD neuropathological hallmarks - Lewy bodies formation 
and neuronal death. The RONS level was measured by investigating the effect of chronic 
exposure WT and mutant flies to Vd and Fe chelator (DFO). Following this, 2’, 7’-
Dichlorofluorescein (DCFH) oxidation was measured as an index of oxidative stress. 
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5.8.1  RONS generation in DM brain: influence of iron chelation (with DFO: 5µM) in 
WT. 
Low dose Vd (1µM) had a beneficial effect on ROS/RONS generation after 14 days in WT 
flies as evident by the decrease in RONS level in reference to the control group. However, 
iron chelation, further increased ROS/RONS level. This contrasted with what was seen in the 
mutant flies. 
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Figure 5.14: RON’s generation % of control in WTs flies’ brains: iron-chelating effect.  
A significant decrease in RONS levels is seen following treatment with Vd after chronic 
exposure to Vd (1µM) when compared with the control group (p<0.1). In contrast, RONS 
level was not enhanced following iron chelation with DFO (20µM) when compared with the 
control group (p>0.05). All values are means (± SEM) from 2 separate experiments and n=50 
for each experiment: with a Tukey’s Multiple Comparisons Test (repeated measures two-way 
ANOVA). ns= p >0.05; *=p<0.1. 
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5.8.2 RONS generation in DM brains: influence of iron chelation (with DFO: 20µM) in 
PINK1  
Low dose Vd (1µM) enhanced ROS/RONS generation after 14 days in mutant flies, in 
reference to the control group. This effect was completely reversed with iron chelation 
(DFO). 
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Figure 5.15: RONS generation % of control in PINK1 flies’ brains: iron-chelating 
effect.  
A slight, but significant increase, increase in RONS levels is seen following chronic 
treatment with Vd (1µM); p<0.1 and a non-significant decrease in RONS level with iron 
chelation (DFO; 5µM); p>0.05. All values are means (± SEM) from 2 separate experiments 
and n=50 for each experiment: with a Tukey’s Multiple Comparisons Test (repeated 
measures two-way ANOVA). ns= p >0.05; *=p<0.1; **p<0.01 
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5.8.3 Total thiol levels 
Total thiol (T-SH) levels in fly brains of both the WT and mutant was measured. Thiol 
groups are highly reactive and susceptible to oxidation that could cause a significant loss of 
biological activity. In a biological system, the regulation of thiol redox balance is critical for 
several metabolic signalling and transcriptional process in mammalian cells. The oxidation of 
free thiol groups (in proteins) produces modification with a structural-functional implication - 
impact on the protein function (that is, its ability to engage in protein-protein interaction). In 
the cell, there is a thiol redox buffering system that is in place to protect thiol groups from 
oxidation and to repair those that have been oxidised due to physiological or aberrant cellular 
metabolism. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
209 
 
5.8.3.1 Chronic effect of low dose of vanadium (1µM) on total thiol (T-SH) levels in the brains 
of D. melanogaster- WTs and PINK1 mutant. 
 
5.8.3.2 Chronic effect of low dose of vanadium (1µM) on T-SH levels in the brains of WT flies: 
Influence of iron chelation 
Low Vd (1µM) Vd elicited a reduction in T-SH in WT flies. This result is indicative of the 
beneficial effect of Vd and was consistent with the positive effect on motor activity in WT 
flies. 
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Figure 5.16: T-SH levels in WT flies’ brains following chronic exposure to vanadium: 
iron chelating effect. 
A significant decrease in T-SH levels is seen following chronic treatment with Vd (1µM) 
when compared with the control; p<0.01. The decreased T-SH level may be indicative of the 
positive effect of Vd treatment with WT DM. This ties in with observed positive effects on 
motor activity following chronic exposures to WT flies. A, non-significant, decrease in T-SH 
levels following iron chelation (Vd + DFO; 20µM). All values are means (± SEM) from 2 
separate experiments and n=50 for each experiment: with a Tukey’s Multiple Comparisons 
Test (repeated measures two-way ANOVA). ns= p >0.05; *=p<0.1; **p<0.01. 
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5.8.3.3 Chronic Effect of low dose of vanadium (1µM) on T-SH levels in the brains of PINK1 
mutant flies: Influence of iron chelation 
Low Vd (1µM) increased T-SH levels in WT flies. This result is indicative of exacerbation of 
the existing motor deficit in the mutant. 
 
C
o
n
t r
o
l
V
a
n
a
d
i u
m
V
a
n
a
d
i u
m
 +
 D
F
O
0 . 0
0 . 5
1 . 0
1 . 5
T
o
ta
l 
T
h
io
ls

m
o
l/
m
g
 
p
r
o
te
in
C o n t r o l
V a n a d iu m
V a n a d i u m  +  D F O
n s
n s
*
A
 
Figure 5.17: T-SH levels in PINK1 flies’ brains following chronic exposure to 
vanadium: iron-chelating effect.  
A slight (but non-significant) increase in T-SH levels is seen following chronic treatment 
with Vd (1µM) when compared with the control; p>0.05. A significant increase in T-SH 
levels following Iron chelation (Vd + DFO; 20µM) can be seen compared with the control 
group; p>0.05. T-SH levels ±DFO & Vd shows some significant difference (p<0.01). All 
values are means (± SEM) from 2 separate experiments and n=50 for each experiment: with a 
Tukey’s Multiple Comparisons Test (repeated measures two-way ANOVA). ns= p >0.05; 
*=p<0.1.  
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5.8.3.4 Effect of low dose of vanadium (1 µM) on T-SH levels- WT vs Mutant: Effect of iron 
chelation. 
Comparing the total thiol (T-SH) levels in the WT and PINK-1 mutant control flies, we 
observed a surprisingly high T-SH baseline level in the mutant compared to the WT flies. 
Chronic low dose Vd (1μM) elicited a reduction in T-SH in WT flies, but no significant 
effect upon PINK-1 mutant flies. Iron chelation (DFO) reversed the effect of Vd on TS-H 
levels in the WT flies to control levels, but significantly reduced the T-SH levels in PINK-1 
mutant flies compared to control and Vd-treated PINK-1 mutant flies.  
 
 
Figure 5.18: The influence of iron chelation following chronic exposure of Drosophila 
melanogaster (WT and PINK mutant) to low dose vanadium upon T-SH levels (after 
day 14): Influence of iron chelator. 
T-SH levels in WT flies is lower than with those seen in PINK1 mutant flies. Vd elicited a 
reduction in T-SH in WT flies, but no significant effect upon PINK-1 flies. Iron chelation 
(DFO) reverses the effect of Vd on TSH levels in the WT fly to control levels (*p<0.05), and 
significantly reduced the T-SH levels in PINK-1 flies (*p <0.05) compared to control and 
Vd-treated PINK-1 flies. All values are from 5 separate experiments, n=10 flies for each 
experiment, analysed with a repeated measure two-way ANOVA. *p <0.05. 
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5.9 Discussion 
The in vivo effect of chronic exposure of low concentration of Vd to WT and PINK1 mutant 
flies was investigated. PINK1 mutation causes mitochondrial bioenergetics deficit resulting 
in energy depletion, shortened lifespan, and degeneration of select indirect flight muscles and 
dopaminergic neurons (Course, et al., 2018). These outcomes were consistent with results 
obtained in the control values with PINK1 mutant (See Figs: 5.6; 5.8; 5.10; 5.15; 5.17 and 
5.18) that showed that the mutant flies had a motor deficit; evident in the observed decrease 
in motor activity (Fig.5.2); shortened lifespan compared to WT (Fig.5.3), increase in ROS 
production (Figs 5.15 and 5.17) as well as an increase in total thiol levels compare to the WT 
(Fig. 5.12 and 5.16).  
 
Mitochondrial dysfunction, oxidative stress, and alterations in the ubiquitin-proteasomal 
system (UPS) have been implicated in the death of specific neurons in the etiopathogenesis of 
PD (Branco, et al., 2010). These three events work in synergy to cause the devastating 
symptoms associated with PD. Arduino and his colleagues (2010) reported that mitochondrial 
dysfunction, oxidative stress and/or proteasome system dysfunction potentiated alpha-
synuclein aggregation in sporadic models of PD.  
 
Gallacher and Schapira (2009) noted that oxidative stress and free radical generation are 
linked to PD pathogenesis. In addition to these factors, a plethora of mechanisms are 
involved, among which include mitochondrial dysfunction, glutamate-mediated 
excitotoxicity, inflammation, oligodendrocyte interaction, neurotrophic factors, UPS 
impairment, autophagy and apoptosis are contributive factors underpinning  PD pathology.  
 
Oxidative stress is critical because it compromises the integrity of vulnerable neurons. Hence, 
it is an important player in neuronal degeneration. The source of oxidative stress has been 
attributed to mitochondrial dysfunction, impairment of antioxidant defence pathways, a 
highly oxidative intracellular environment within dopaminergic neurons, increased dopamine 
metabolism which leads to an excessive increase in hydrogen peroxide and other ROS and 
increased reactive iron (Arduino, et al., 2009; Medeiros, et al., 2016). 
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Reactive iron has gained notoriety in its contribution to ROS generation (Bondy and Kirstein, 
1996; Bondy, et al., 1998; Wu, et al., 2012; Zhang, et al., 2018; Yang, et al., 2019). The 
presence of reactive iron has been shown to exacerbate Vd toxicity in oligodendrocyte 
progenitor cells (Todorich, et al., 2011). Thus, exposure of D. melanogaster mutant to 
chronic low dose Vd, exacerbated the motor deficits seen in the mutant (Fig.5.2) causing a 
further reduction in lifespan (Fig. 5.4) compared to the control values.  
 
Findings from this present study showed that low dose Vd significantly increased RONS 
generation in mutant cells, with a possible deleterious effect on neuronal cell functionality. 
Increased RONS level implies disruption in antioxidant balance and redox status, evidenced 
by an increase in DCFH oxidation and an increase in the total thiol content (See Fig.5.17) in 
the mutant flies exposed to low dose Vd. Total thiol (T-SH) is a composite (but major) part of 
the total body antioxidants and they play significant roles in the defence against ROS.  
 
Decreased levels of thiol have been reported in several disorders, such as chronic renal failure 
(Hultberg, et al., 1995; Himmelfarb, et al., 2000), cardiovascular disorders (Ashfaq, et al., 
2006), stroke and neurodegenerative diseases (Mungli, et al., 2009; Prakash, et al., 2009). 
The observed increased in thiol levels, in our investigations, in the mutant flies (Fig. 5.17) 
may be an adaptive response. In oxidative stress, T-SH level is increased, the physiological 
response will be to synthesize GSH (an antioxidant) to combat the thiols levels, which will 
invariably lead to further increase in thiol levels.  
 
In PD, oxidative stress has been associated with the activation of N-methyl-D-aspartate 
(NMDA)-type glutamate receptors, with increased production of reactive nitrogen species 
(RNS). The increased RNS is due to over activation of neuronal NO synthase (nNOS) 
(Garthwaite, et al., 1988; Bredt, et al., 1991). Mitochondrial defects generate ROS 
(superoxide anion (O2-). This rapidly reacts with free radical (NO) and in turn creates 
peroxynitrite radical (ONOO-) (Beckman, et al., 1990; Lipton, et al., 1993).  
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Nakamura and Lipton (2009) noted that the excess RONS formation by these two processes 
induce UPS impairment and/or misfolding of molecular chaperons. This interphase 
(mitochondrial-UPS) provides another point of intersection between the mitochondria and the 
UPS functioning as an underlying mechanism in PD pathology. It is reported that 
mitochondria dysfunction and production of excessive ROS, adversely affect UPS activity 
(Nakamura and Lipton, 2009). 
 
Whilst, chronic exposure of mutant flies to low dose Vd worsens the motor deficit and 
decreased lifespan, in contrast, chronic exposure of WT D. melanogaster mutant to low dose 
Vd improved motor activity (Fig.5.1), indicating a beneficial health effect. Besides, improved 
lifespan effect was noted when compared with the control (Fig. 5.3). Vd reduced RONS 
generation in WT. This beneficial effect on WT was consistent with the effect of Vd on 
motor activity and lifespan in WT.  
 
Furthermore, low dose Vd significantly reduced the total thiol level in WT flies. The 
observed beneficial motor effect was attenuated by DFO (Figs 5.1; .5.12). Besides, the 
decreased RONS generation in WT was reversed in the presence of DFO back to control 
level (Fig. 5.14) suggesting that iron chelation is preventing the beneficial effect of Vd or 
interacting with Vd to modulate the beneficial effects seen in WT flies. This finding is 
consistent with previous findings in culture with CAD cells (Chapter 3).  
 
We also evaluated the effects of chronic exposure of low dose Vd on total thiols content in 
the brains of flies. Total thiols (protein and non-protein thiols) are important targets of RONS 
and useful biochemical indicators of oxidative stress (LoPachin and Barber, 2006;  2007). 
Membranes are also susceptible to free radicals resulting in lipid peroxidation and decreased 
concentration of –SH groups in membrane proteins Staroń, et al (2012).  
In our investigation, the levels of T-SH groups were significantly reduced in WT flies, but 
slightly (but insignificant) increased in the mutant (Fig.5.17) flies, following chronic 
exposure to low dose Vd. The potential increase seen in mutant flies may be due to increased 
free radicals/RONS seen in the mutant. Comparing the levels of T-SH in both WT and mutant 
(Fig. 5.18). It is evident that the oxidative stress in the mutant is much higher compared with 
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the WT flies (Fig.5.18). The modest increase in total thiol level following chronic exposure to 
Vd was reversed by DFO in mutant flies. 
 
It has been established that Fe chelation has a protective effect against oxidative-induced 
neurodegeneration. Fe chelation blocks/reverses the motor deficit of Vd as seen in mutant 
flies (Fig. 5.10). Crichton and Ward (2006) noted that redox-active metals (such as Fe, Cu, 
and Mn) play key roles in the nervous system. As metalloenzymes, they are extremely 
important in key metabolic pathways within the nervous tissue. For instance, Fe is an integral 
part of the enzyme Tyrosine hydroxylase, and crucial in the formation of dopa from tyrosine. 
However, if it is present in excess within localised regions of the CNS, it is often dangerous 
and associated with neurodegeneration (Folarin, et al., 2019).  
 
Chelation therapy has been highlighted as a step to limit this deleterious effect. The reversal 
effect of DFO on the motor deficit seen in the mutant (following chronic exposure to Vd), 
therefore, may be an index of the probable benefit of iron chelation as a therapy in PD. Also, 
the mutant flies were protected against increased RONS production by DFO (Fig. 5.15). This 
is again suggestive of the probable beneficial effect of Fe chelation therapy in PD.  
 
As previously stated, exposure to environmental toxicants generate reactive oxygen and 
nitrogen species (RONS), which often results in oxidative damage to cellular components 
(Schulz, et al., 2014; Liguori, et al., 2018; Madkour, et al., 2020). The results from this 
investigation indicated that exposure to chronic low dose Vd induces RONS-mediated 
antioxidant imbalance in flies’ brains. Though ROS are vital in several biochemical 
processes, their overproduction can induce oxidative damage to cellular biomolecules such as 
DNA, carbohydrate and lipids leading to lipid peroxidation (Bennett, et al., 2001). 
It is suggested that Vd exerts its effects at the level of the mitochondrial by inducing the 
generation of oxidative stress, through the Fenton-like reaction (Fatola, et al., 2019).  The 
ROS data suggests that Fe and Vd are interacting at the level of the mitochondria. It has been 
reported that Vd can disrupt iron homeostasis and cause depletion of iron from intracellular 
stores, which underpins its role in the generation of reactive oxygen species and eventual 
cytotoxicity (Ghio, et al., 2015; Fatola, et al., 2019).  
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Ghio, et al (2015) reported that Vd is capable of inducing iron deficiency and increasing the 
expression of DMT-1 thereby precipitating the production of oxidants such as superoxide. 
They noted that the resultant superoxide is the attempt of the cell to restore the intracellular 
level of functional iron via ferri-reductase activity (Ghio, et al., 2003).  
Liu, et al (2009) demonstrated in cell culture systems, where they induced loss of PINK1, that 
there is an existing relationship between mitochondrial dysfunction and proteasomal 
impairment. Furthermore, they noted that proteasomal function impairment is due to a 
reduction of mitochondrial-dependent ATP synthesis (Liu, et al., 2009), claiming that 
mitochondrial compromise is the primary event in mitochondria dysfunction. A consequence 
of this is alpha-synuclein aggregation. The resulting alpha-synuclein aggregates, in turn, can 
reduce significantly the proteasomal activity. Thus, resulting in a vicious cycle. Vd’s ability 
to exacerbate the existing deficits in PINK1 model of D. Melanogaster flies underscores the 
fact that Vd exerts its influence at the level of the mitochondria and its modulation of Fe 
homeostasis further highlights this.  
 
In conclusion, substantial evidence indicates that environmental toxicants can induce 
oxidative stress by altering cellular redox balance, and the activities of antioxidant enzymes 
such as GST, leading to excessive production of free radicals (Franco, et al., 2009). In turn, 
free radicals can damage lipids, proteins, carbohydrates, and nucleic acids, thereby, inhibiting 
their normal functions (Davies and Goldberg, 2000). It has been recently reported that the 
induction of lipid peroxidation in the brain following Vd administration underscores the role 
oxidative stress plays in the neurotoxicity of the metal (Folarin, et al., 2018; Igado, et al., 
2011; García, et al., 2004).  
Overall, strong evidence is provided that low dose Vd exacerbated the existing motor deficit 
in D. melanogaster mutant, reduced their lifespan, increased ROS generation total thiol 
levels. However, iron chelation reversed this motor deficit in mutant flies, which is indicative 
of a probable beneficial effect of iron chelation as a therapy in patients with familial PD. In 
contrast, chronic exposure of WT flies to low dose Vd caused an enhancement in motor 
activity that was attenuated by DFO, improved lifespan, and a reduction in the generation of 
RONS. The observed increase in total thiol levels was reversed by DFO.  
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Chapter 6:  Overall Summary and Conclusions 
 
This thesis was designed to address the following hypothesis: 
Sub-toxic doses of heavy metals (Cu and vanadium) will differentially modulate 
downstream signalling, cytoarchitecture, and neuroplastic events, through 
mitochondrial oxidative stress pathways in healthy and PD neurons. 
 
For many years, heavy metals have been implicated in the aetiology of brain diseases, 
including PD. Most studies to date have focussed on the toxicological effects of heavy 
metals. This study was designed to investigate the sub-toxic pharmacological effects of an 
endogenous (Cu, iron) and exogenous (Vd) upon neurons using an in vitro and in vivo 
approach. 
 
6.1 Chapter 3: In-vitro effect of sub-toxic concentration of Cu relevance to 
PD 
Evidence is provided in that sub-toxic Cu have a range of pharmacological effects upon 
monoaminergic neurons, including reduced mitochondrial functionality in both 
differentiating and differentiated dopaminergic neuronal cells, bi-directional modulation 
Ca2+ signalling in neurons and depolarisation-induced intracellular calcium levels, a 
significant reduction in the expression of MAP2, and an increased sensitivity of both 
immature and mature neurons in the presence of Fe chelators. 
 
6.1.1 Metabolic functions 
With respect to metabolic function, 10µM Cu had no effect on mitochondrial viability for 
both acute and chronic exposures. In contrast, whilst 40µM had no significant effect upon 
undifferentiated cells, it reduced mitochondrial viability for chronic differentiating and 
acutely treated differentiated cells. At both 10µM and 40µM, there was a suggestion of 
neuroprotection in undifferentiated CAD cells. The protective effect of this sub-toxic dose is 
suggestive of the physiological role of Cu (with this dose) in biological systems, a fine-tuned 
Cu homeostasis is essential in brain development. Cu deficiency or excess results in severe 
neuropathologies.  
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The mitochondria contain two notable Cu-dependent enzymes (cytochrome c oxidase and 
superoxide dismutase 1) that require adequate Cu supply (Zischka and Einer, 2018). The 
observed positive benefit is suggestive that this dose is within physiological and optimum 
required levels. Strong evidence is provided that the intracellular redox ability of Cu, as a co-
factor of mitochondrial cytochrome c oxidase as well as the detoxifying capacity of Cu/Zn 
superoxide dismutase (SOD1) against the reactive oxygen species (ROS) underpins the role 
of Cu in these enzymes to manage the biochemical challenge and a safe Cu-mediated 
reduction of oxygen and ROS respectively (Rae, et al., 1999). This function is made possible 
by Cu chaperones that enhances the activity of the Cu –dependent enzymes in the 
mitochondria. Although the dominant risk factor associated with neurodegenerative diseases 
is increasing age, several animal and human studies have reported a rise in the levels of brain 
Cu ( Barnham and Bush 2008). However, Barnham and Bush (2008) reported that from 
middle age onwards, Cu levels drop markedly, with a consequence loss of Cu-dependent 
enzyme activities- cytochrome c oxidase, superoxide dismutase I and ceruloplasmin. 
 
 
The critical metabolic functions of Cu probably explain why the sub-toxic dose did not affect 
mitochondrial viability. It sub-serves a key cellular function. It has, however, been noted that 
the mitochondria can accumulate high Cu amounts before they ultimately break down 
(Zischka, et al., 2011; Lichtmannegger, et al., 2016; Borchard, et al., 2018). This explains 
why acute exposure of Cu (10µM and 40µM) to undifferentiated cells were seen to be 
neuroprotective as against chronic exposure (differentiating cells).  
 
6.1.2 Signalling  
As a trace element, Cu is essential for neurotransmission (Zischka and Einer, 2018). 
On signalling, treatment with low dose Cu (40µM) showed a bidirectional modulation of 
calcium levels in neuronal processes (inhibitory effect) and cell body (an elevation of calcium 
signal) in differentiated cells. This has implications for synaptic plasticity and excitotoxicity. 
The inhibitory effect suggests that calcium ions which are vital in neurotransmitter release are 
blocked. These conclusions correlate well with studies that showed that Cu levels are 
distributed diffusely in neurons, but higher in the processes relative to other metal ions, such 
as zinc (Colvin, et al., 2015). Notably, Hatori, et al (2016) noted an increase in cellular 
demand for Cu during neuronal differentiation.  
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6.1.3 Cell Maturation 
In terms of neuronal cell maturation, Cu had a significant effect on MAP-2 expression in 
differentiated CAD cells. Sub-toxic Cu negatively modulates differentiation by selectively 
reducing MAP-2a isoform, with no significant effect upon MAP-2b isoform, for both 10µM 
and 40µM concentrations of Cu. Since MAP-2 is associated with microtubule assembly, 
cargo trafficking plays a vital role in determining as well as stabilising the shapes of dendrites 
during neuronal development. The observed differential decreased expression of MAP2a in 
differentiated cells in response to Cu (40µM) may relate to the observed differential 
modulation of overall metabolic activity and calcium signalling in the neuronal processes, as 
well as the apparent suppression of depolarisation induced calcium in the processes (but not 
in the cell body). This may again have implications for synaptic plasticity and neurotoxicity. 
Recent evidence suggests that PD pathogenesis might be underscored by early cytoskeleton 
dysfunction (Pellegrini, et al., 2017). 
 
6.1.4 Chapter 4: In-vitro effect of low and oxidative stress doses of Vanadium and the 
influence of iron with relevance to PD. 
In comparison to Cu, sub-toxic Vd (an exogenous heavy metal) also to have a range of 
pharmacological effects upon immature and mature neurons. There was resistance in terms of 
neuronal metabolic status to acute exposure to applied Vd at different stages of cell culture 
development, downregulation of differentiation markers with low dose Vd exposure (10µM), 
but an up-regulation with oxidative stress Vd dose (100µM), together with morphological 
changes, cellular stress indicators (nuclear shape) and reduced process excitability.  
 
Notably, in contrast to Cu, a neuroprotective effect against Vd-induced metabolic viability 
following chronic exposure in the presence of iron-chelators was observed. The levels of Fe 
in undifferentiated and differentiated cells correlated with sensitivity to Vd, with levels being 
significantly higher in undifferentiated cells in comparison to differentiated cells. Both 
natural and synthetic iron chelator significantly and efficiently protected against chronic Vd-
induced mitochondrial stress, which favours the case for iron chelation therapy. This was in 
sharp contrast to results obtained with Cu, where iron chelation exacerbates toxicity 
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6.1.5 Signalling 
In terms of cell signalling, sub-toxic Vd dose (10µM) had no clear effect on the intracellular 
calcium levels in cell bodies. However, an oxidative stress dose (100µM) caused a modest 
rapid inhibitory spike followed by a protracted inhibition.  
 
6.1.6 Cell Maturation and Differentiation 
Despite being sub-toxic doses, both 10µM, as well as 100µM Vd, had effects on 
differentiation. Acute exposure of differentiated CAD cells to 10µM resulted in up-regulation 
of MAP2c and 2d (though not statistically significant). However, an oxidative stress sub-
toxic dose (100µM) caused a marked decrease in MAP2c expression. Evidence suggests that 
the low molecular weight MAP2c are expressed prenatally, in developing neurons. While the 
high molecular weight isoforms (MAP2a & MAP2b) are specified in the cell bodies and 
dendrites of matured neurons (Melkova, et al., 2019).  
 
The expression of low molecular weight (MAP2c) is indicative of the non-toxic effect of this 
dose (10µM), whilst the absence of MAP2a and 2b is suggestive of a possible disruption of 
MAPs and development of the neuronal cytoskeleton. The expression of MAP2c in cells 
exposed to sub-toxic dose is suggestive that this dose did not affect the differentiation 
process/neurite formation. It was demonstrated in Chapter 3, that 10µM Vd did not affect 
neurite formation, in contrast to the oxidative stress dose (100µM), which showed a marked 
loss of processes following chronic treatment in differentiating cells, and a moderate loss in 
acute exposures to differentiated cells when compared with sham treatments.  
 
6.1.7 Cellular and ER Stress Response 
In terms of cellular ER stress responses, chronic exposure (differentiating cells) to 10µM Vd 
displayed a very moderate decrease in PDI expression, but an up-regulation of PDI signal 
with an oxidative stress dose (100µM). In ER stress, PDI is upregulated to attenuate the 
accumulation of misfolded proteins and decrease ER stress. However, S-nitrosylation 
compromises this stress response, due to post-translation modification. The presence of 
double protein bands in PDI expression in both acute and chronic exposures to oxidative 
stress dose is indicative of post-translational modifications of PDI.  
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It has been reported that PDI shows S-nitrosylation as post-translational modifications in 
patients suffering from neurodegenerative diseases (Benhar, Forrester, & Stamler, 2006; 
Uehara, et al., 2006; Wu, et al., 2014). Protein misfolding (an indication of ER stress) is 
associated with dendritic spine loss. There is evidence in our findings with 
immunofluorescence result of MAP2, where oxidative stress dose (100uM) caused a 
significant loss of processes in differentiating cells undergoing chronic exposure to Vd. 
Although PDI can be upregulated to attenuate the accumulation of misfolded proteins and 
decrease ER stress, S-nitrosylation post-translation modification compromises this stress 
response.  
 
6.2   Chapter 5: Interplay between iron and vanadium in PD in an in vivo 
model 
6.1.8 Behavioural and Biochemical effects- RONS and T-SH levels 
Sub-toxic Vd (1μM) exposure had a range of differential behavioural and biochemical effects 
on wild-type and PD PINK-1 Drosophila fly models. It exacerbated the existing motor deficit 
in PINK-1 flies, concomitantly increased RONS production, augmented total thiol levels and 
abrogated lifespan. This is in contrast to the wild-type flies. The observed significant increase 
in RONS levels in PINK-1 fly’s brains was, despite a slight increase in T-SH content, might 
be an adaptive response to a low dose of Vd. Indeed, the adaptive response is seen in 
organisms exposed to low to moderate stress levels (Santos, et al., 2018). Notably, iron 
chelation with DFO (Deferoxamine) hampered RONS production and reversed motor deficit 
in the mutant flies. 
6.1.9 Behavioural effects/Oxidative stress markers: influence of Iron chelation 
Chronic exposure of wild-type flies to low dose Vd caused an improvement in motor activity, 
reduction in RONS generation and extension of lifespan. Nonetheless, the observed 
beneficial motor effect (in wild-type) and increased T-SH content was attenuated by DFO, 
suggesting that chelation of iron ion interferes with the beneficial effect of Vd or possibly 
interacted with Vd, modulating the effects seen in wild-type flies.  
 
Iron regulation is crucial in the etiopathogenesis of PD. Early iron deficiency, in humans, has 
been shown to cause impairment of dopamine (DA) metabolism, as well as DA clearance, 
222 
 
transporter density, and dopamine receptor (D1 and D2) densities (Mohamed, 2015). Iron 
deficiency has been associated with delayed motor development (Lozoff, et al., 1991; Lozoff, 
et al., 2000) and impaired physical growth (Gambling, et al., 2004; Shahbazi, 2009). Iron 
chelation in the wild-type flies may have reduced the bioavailability of free iron required for 
optimum physiological functions. It has been posited that early life deficiency of iron results 
in impaired cognition, neurodegenerative diseases, and specific movement disorders such as 
PD (Powers, et al., 2003) and restless leg syndrome (Earley, et al., 2000).  
 
6.1.10 T-SH levels and Iron Chelation 
It was interesting to note that there was a significant differential in T-SH levels in both WT 
and mutant flies – and this was quite striking. This is adduced to the notable increase in 
oxidative stress observed in mutant compared to the wild-type flies. An important implication 
arising from this thesis is the case for iron chelation as a therapeutic strategy. This was 
indicated (by the outcome of our findings) in the reversal of the increase in total thiol level 
seen in the mutant flies in the presence of DFO. The Fe chelation blocks/reverses the motor 
deficit of Vd as seen in mutant flies - an indication that there may be high Fe content in 
mutant flies or deregulation of Fe homeostasis. Thus, the beneficial effect was seen with iron 
chelation.  
Further studies may be required to establish the basal Fe levels in both wild-type and PINK1 
mutant flies. Vd is capable of disrupting iron homeostasis and causing the depletion of iron 
from intracellular stores, which has been associated with Vd role in the generation of reactive 
oxygen species (Fatola, et al., 2019). 
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Chapter 7:  General Conclusions and Future Directions 
7.1 General Conclusions 
Strong evidence arising from this thesis is the neuroprotective effect of Cu on mitochondria 
functionality with low dose Cu (10µM) on undifferentiated CAD cells.  Same concentration 
did not affect mitochondrial functionality in both acute and chronic exposure to differentiated 
and differentiating CAD cells. In terms of neuronal cell maturation, low dose Cu caused a 
decrease in MAP2a protein expression. Also, there was no elevation in calcium signalling 
with a low dose of Cu. 
 
Overall, strong evidence is provided that low dose Vd exacerbated the existing motor deficit 
in D. melanogaster mutant, reduced their lifespan, increased ROS generation total thiol 
levels. However, iron chelation reversed this motor deficit in mutant flies. This is indicative 
of a beneficial effect of iron chelation - as a therapy in patients with familial PD. In contrast, 
chronic exposure of WT flies to low dose Vd caused an enhancement in motor activity 
(which was attenuated by DFO), improved lifespan, and a reduction in the generation of 
RONS. The observed increase in total thiol levels was reversed by DFO. 
  
7.2 Limitations  
The consequence of oxidative stress in the brain is neuronal cell death and thus, dopamine 
depletion. The research design was originally set out to establish dopamine levels in the fly 
brain. However, due to time constraint and funding limitation, these sets of the experiment 
could not be completed. The role of Cu and Vd on Tyrosine Hydroxylase activity would have 
been useful to explain the role of these metals on dopamine levels. For similar reasons, these 
were not done.  In addition to the qualitative investigations of the morphology of CAD cells 
from the IF data, it would have been useful to quantify the data from the IF experiment.   
  
7.3 Future Directions 
1. It has been noted that Vd is capable of disrupting iron homeostasis and cause the 
depletion of iron from intracellular stores. This has been associated with Vd role in 
the generation of reactive oxygen species (Fatola, et al., 2019). Further studies with 
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DM as a model may require a need to establish the basal Fe levels in both wild-type 
and PINK1 mutant flies.  
2. Accumulation of iron in the brain is an event related to PD. However, the proportion 
in which Cu or Cu proteins are responsible for iron dyshomeostasis in PD is 
unknown.  
a. It will be worthwhile to consider the role of Cu transporters in PD. It has been 
established that alpha-synuclein binds to Cu and acts as ferrireductase. This 
invariably increases the availability of iron for the generation of free radical, 
with deleterious implications in the brain, especially in the putamen and 
caudate regions, due to the presence oxidative labile dopamine (Dusek, et al., 
2015; Guiney, et al., 2017; Patel, 2018).  
b. The activity of ceruloplasmin (Cu-dependent ferroxidase) has been 
continuously reported to be reduced in samples from PD patients. 
Theoretically, the decreased function of ceruloplasmin would aggravate the 
above-mentioned situation of alpha-synuclein. Hence, the level of 
ceruloplasmin in the PD model fly versus WT as well as in animal models of 
PD should further be explored.  
c. Knowledge about Cu compartmentalisation in the brain will help to establish 
promising therapeutic strategies aimed at enhancing the positive role of this 
metal in Parkinson’s Disease. 
3. The outcome of oxidative stress in the brain is neuronal cell death and hence, 
dopamine depletion, with a consequence of dopaminergic neuronal degeneration. It 
would be useful to explore the effect of Vd on brain dopamine levels in 
a. Mutant and WT fly under acute and chronic states exposures to low dose (sub-
toxic), oxidative stress dose and toxic doses of Vd.  
4. Biochemical analysis of PD samples reveals a systemic defect of complex I. Exposure 
to complex I inhibitor (rotenone) results in pathological, biochemical, and behavioural 
idiosyncratic features of PD. This mechanistic pathway (rotenone-induced toxicity) is 
suggestive of oxidative stress pathway, due to the blocking of the respiratory chain 
and the selective destruction of dopaminergic neurons. It would be notable to explore 
the effect of low dose, oxidative stress, and high/toxic doses of Vd on complex I 
activity in the presence and absence of iron (using rotenone as a positive control). 
5. Besides, the disorder in Complex I causes aggregation of α-synuclein and this 
contributes to the demise of dopaminergic neurons. Other mitochondria complexes (II 
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and IV) are also implicated. For example, the production of Nitric oxide (NO) - either 
from the mitochondria or inducible NOS within the cell cytosol - inhibits components 
of the mitochondria respiratory chain, complexes I, II and IV (precisely in a reduced 
state of GSH), which cause a cellular energy-deficient state. It will be worthwhile to 
investigate the effect of sub-toxic, oxidative stress dose and toxic doses of Vd on 
Complexes II and IV as well α-synuclein expression. 
6. Future studies may seek to understand the beneficial effect of antioxidants and 
molecular chaperone (Heat shock proteins) that are induced in response to 
environmental, physical, and chemical stresses following exposure to sub-toxic, 
oxidative stress and toxic doses of Vd.
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Summary Fig and pathways of Vanadium and Cu mode of action 
 
 
  
Figure 7.0.1: Summary Fig and pathways of  Vanadium/ Cu mode of action 
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7.4 Summary Fig. 
KEY: ER – Endoplasmic Reticulum; PTM- Post Translational Modification; CE- Chronic 
Exposure; T-SH – Total thiol; PDI- Protein Disulphide Isomerase; RONS- Reactive Oxygen 
& Nitrogen Specie; ROS- Reactive Oxygen Species; WT- WT DM; PINK1 – Mutant DM; Fe 
– Iron; Ca2+ - Calcium ions; NO – Nitric Oxide; Cu – Cu, Van – Vanadium; MAP2; 
Microtubule Associated Protein; SAPK – Stress Activated Protein Kinase; GSH- Glutathione;    
Sub-toxic doses of Vd (10uM) and Cu (10uM) had a positive effect on mitochondrial 
functionality under acute exposure. 10µM Vd displayed a very moderate decrease in PDI 
expression and less sensitivity of differentiated cells to both acute and chronic exposure.  
In the condition of ER stress, the Apoptosis pathway is induced because PDI is unable to 
maintain cellular homeostasis  (A).  
(This evident in chronic exposure to oxidative stress dose of Vd (100uM), by the up-
regulation of the expression of PDI (under both reducing and non-reducing conditions). In 
sub-toxic dose, however, this was not apparent).  
Oxidative stress results in the accumulation of insoluble aggregates of misfolded protein in 
neurons (B). 
Ultimately leading to a decrease in neuronal cell viability and cell death (neurodegeneration) 
(C). 
Cumulative evidence supports oxidative stress “hypothesis” for initiation of nigral dopamine 
neuron loss - apoptosis. Cellular metabolism of dopamine generates H2O2 (D) which is 
reduced to hydroxyl radicals in the presence of Fe - which promotes neuronal damage (E). 
(It was reported in this thesis that Vd toxicity is exacerbated in the presence of iron, which 
was ameliorated in the presence of both synthetic and natural iron chelator. Also, a previous 
study (by our partner) reported that lipid peroxidation is induced by Vd in the presence of Vd. 
Stress Activated protein Kinase (SAPK) is activated by oxidative stress (F) and propagate 
stress signals to pathways. [JNK / SAPK & P38 / SAPK - Not Shown]  
This study argues that under chronic exposure (to low dose Vd 100uM), oxidative stress 
pathway way may be activated as evident in this thesis by the increase in PDI expression and 
post-translation modification of the PDI signal, as well as an increase in RONS, cellular 
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stress indicators (nuclear shape), reduced process excitability, and neuronal cells 
morphological changes. 
Post-translational Modification (PTM) (G) attenuate unfolded protein response (UPR) and 
cause neuronal cell death. Hence, aberrant modification of PDI leads directly to harmful 
effect and the loss of the usually protective properties of PDI.  
S-nitrosylation compromises this stress response due to post-translation modification. This 
was evident with low dose Vd in differentiating cells (chronic exposure). An increase RONS, 
T-SH and PDI expression was apparent in our in vivo studies with the mutant fly.  
Vd toxicity has been previously reported as a possible link in the pathogenesis of PD, yet a 
link between chronic low dose Vd and ER stress in PD has so far not yet been reported. 
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Positive Effects of sub-toxic concentration of heavy metals 
relevance to PD 
 
 
Low dose Cu (10µM) had no significant effect upon metabolic rate or cytotoxicity on 
differentiated and differentiating CAD cells. It had a neuroprotective effect on 
undifferentiated cells and decreased KCl-induced depolarisation. It positively enhanced the 
expression of MAP2 in differentiated cells. Low dose of Vd (20 µM) increased mitochondria 
viability in differentiating cells (following chronic exposure), decreased PDI expression, 
improved motor activity in, increased survival rate and reduces oxidative stress in WT flies. 
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Summary pathway of the interplay between iron and 
vanadium in PD in an in vivo model 
 
 
 
 
Summary pathway of the sub-toxic effects of Vd and its interplay with Fe on PD-like 
phenotypes in CAD cells, and Pink-1B9 Drosophila melanogaster models of PD, shows that 
that undifferentiated CAD cells were more susceptible to vanadium exposure than 
differentiated cells and this susceptibility was modulated by iron. In pink-1 flies, exposure to 
chronic low dose of vanadium exacerbated the existing motor deficits, reduced survival, and 
increased the production of reactive oxygen species (ROS), increase PDI expression, ER 
stress and T-SH; leading to post translational modification (PTM) and ultimately triggers 
neuronal cell death. Iron chelation ( with Aloysia citrodora L, a natural iron chelator, and 
Deferoxamine Mesylate a synthetic iron chelator)  significantly protected against the PD-like 
phenotypes in both WT and mutant flies: which favours the case for iron-chelation therapy as 
a viable option for the symptomatic treatment of PD. 
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